kidney

INTERNATIONAL

Volume 27, 1985

Editor Emeritus
Roscoe R. Robinson, Nashville

Editor
Thomas E. Andreoli, Houston

Associate Editors
Claude Amiel, Paris
James P. Knochel, Dallas

Consulting Editors
J. S. Cameron, London
Ramzi Cotran, Boston
William G. Couser, Seattle
Gerhard Giebisch, New Haven
Nishio Honda, Hamamatsu
Priscilla Kincaid-Smith, Melbourne
Wilhelm Kriz, Heidelberg
François Morel, Paris

Editorial Board
Vittorio E. Andreucci, Naples
A. W. Asscher, Cardiff
Robert C. Atkins, Melbourne
Knut Aukland, Bergen
Peter Bàlint, Budapest
Lindsay J. Barratt, Bedford Park
Jonas Bergstrom, Stockholm
Ori S. Better, Haifa
Roland C. Blantz, San Diego
Adalbert Bohle, Tubingen
Jean-Philippe Bonjour, Berne
Vittorio Bonomini, Bologna
Barry M. Brenner, Boston
Neal S. Bricker, Los Angeles
Hans R. Brunner, Lausanne
Ruth E. Bulger, Houston
Anthony R. Clarkson, Adelaide
Jack W. Coburn, Los Angeles
Guiseppe D'Amico, Milan
Hugh E. de Wardener, London
Vincent W. Dennis, Durham
Evert J. Dorhout Mees, Utrecht
Jean Dormont, Clamart
Ratislav Dzúrik, Bratislava
Laurence E. Earley, Philadelphia
Bryan T. Emmerson, Brisbane
Marilyn G. Farquhar, New Haven
Thomas F. Ferris, Minneapolis
Eli A. Friedman, Brooklyn
Carmelo Giordano, Naples
Richard J. Glassock, Los Angeles
Jared J. Grantham, Kansas City
J. P. Grünfeld, Paris
Robert A. Gutman, Durham
Renée Habib, Paris
Jean Hamburger, Paris
Lee W. Henderson, San Diego
Robert H. Heptinstall, Baltimore
Klaus Hierholzer, Berlin
Norman K. Hollenberg, Boston
Malcolm A. Holliday, San Francisco
Rex L. Jamison, Stanford
Colin I. Johnston, Melbourne
D. N. S. Kerr, Newcastle-upon-Tyne
Fredrik Kiil, Oslo
Saulo Klahr, St. Louis
Horst Klinkmann, Rostock
Franklyn G. Knox, Rochester
Juha P. Kokko, Dallas
Franciszek Kokot, Katowice
Kiyoshi Kurokawa, Tokyo
Neil A. Kurtzman, Lubbock
Paul H. Lambert, Geneva
Jacob Lemann, Jr., Milwaukee
David Z. Levine, Ottawa
Guy Lemieux, Montreal
Manuel Martinez-Maldonado, San Juan
Shaul G. Massry, Los Angeles
Joël Menard, Paris
Alfred F. Michael, Minneapolis
Paul Michielsen, Louvain
John F. Moorhead, London
L. Gabriel Navar, Birmingham
T. J. Neale, Wellington
Alphonse Nizet, Liege
Karl D. Nolph, Columbia
Jack Orloff, Bethesda
Tadeusz Orlowski, Warsaw
D. Keith Peters, London
Mordecai M. Popovtzer, Jerusalem
Jaime Borrero Ramirez, Medellin
Gabriel Richet, Paris
Jose L. Rodicio, Madrid
George E. Schreiner, Washington, D.C.
Robert W. Schrier, Denver
Donald W. Seldin, Dallas
Fred L. Shapiro, Minneapolis
David P. Simpson, Madison
Jay H. Stein, San Antonio
Liliane Striker, Seattle
Wadi N. Suki, Houston
Roger A. L. Sutton, Vancouver
Richard L. Tannen, Ann Arbor
Klaus Thurau, Munich
C. Craig Tisher, Gainesville
Bruno Truniger, Lucerne
Karl J. Ullrich, Frankfurt
Heinz Valtin, Hanover
Pierre Verroust, Paris
Herman Villarreal, Mexico, D.F.
Mackenzie Walser, Baltimore
Clark D. West, Cincinnati
Guillermo Whittembury, Caracas
Curtis B. Wilson, La Jolla
Douglas R. Wilson, Toronto

Manuscript Editor
Brenna Nichols, Houston

Editorial Assistants
Patricia Broussard, Houston
André Ulmann, Paris

Springer International

The exclusive copyright for all languages and for all countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Printed in the United States of America by The William Byrd Press Inc., Richmond, Virginia

© 1985 by International Society of Nephrology

Author Index For Volume 27

Abboud H (abst) 265
Abboud HE (abst) 222, 252
Abdel-Rahman RA (abst) 196
Abitbol C (abst) 130
Abraham J (abst) 345
Abraham PA (abst) 144, 146
Abrahamson DR (abst) 209
Abramson RG (abst) 315
Abreo K (abst) 114
Abu-Hamdan D (abst) 345
Abu-Romeh S (abst) 130, 152
Abuelo JG (abst) 156, 167
Acchiardo SR (abst) 178
Achenback V (abst) 235
Acosta G (abst) 270
Adafer E (abst) 208
Adair C (abst) 184
Adam WR (abst) 277, 313
Adams JS (abst) 103
Adams MB (abst) 342
Adams SP (abst) 104
Adamson O (abst) 350
Addison JF (abst) 108
Adedeji FA (abst) 157
Adelstein DJ (abst) 144
Adler AJ (abst) 108, 114, 115, 120
Adler AJ, Berlyne GM: Effect of chronic uremia in the rat on cerebral mitochondrial calcium concentrations ... 523
Adler S (abst) 134, 204
Adler SG (abst) 135, 253
Adler S: *see* Salant et al 938
Aframian D (abst) 259
Agrafiotis A (abst 352
Agrawal M (abst) 181
Agus D (abst) 240
Agus ZS (abst 130
Ahmad S (abst) 186
Akinsola A (abst) 130
Akmal M (abst) 226
Al-Awqati Q (abst) 288, 290, 313
Al-Mufti HI (abst) 156
Alatorre MC (abst) 262
Alavi N, Lianos E, Van Liew JB, Mookerjee BK, Bentzel CJ: Peritoneal permeability in the rat: Modulation by microfilament-active agents 411
Albini B (abst) 204
Alexopoulos J (abst) 352
Alfrey A (abst) 246
Alhaddad A (abst) 187
Alijani MR (abst) 257, 342
Allen AY (abst) 227
Allen GG, Barratt LJ: Effect of cisplatin on the transepithelial potential difference of rat distal tubule 842
Allen GG, Barratt LJ: Origin of positive transepithelial potential difference in early distal segments of rat kidney 622
Allen W (abst) 193
Alles WP (abst) 310
Allison TB (abst) 178
Alongi SV (abst) 346
Alperin L (abst) 168
Alpern RJ (abst) 302
Alpert H (abst) 286
Alpert HC (abst) 290
Alpert MA: *see* Ruder et al 768
Alvestrand A (abst) 240
Amair P (abst) 243
Amend W (abst) 337, 349
Amend WJC (abst) 339
Amsler K (abst) 279
Amsterdam D (abst) 159
Amsterdam J (abst) 141
Anagnostopoulos T (abst) 287
Anaizi NA (abst) 271
Andersen RC (abst) 347
Anderson D (abst) 146, 215
Anderson K (abst) 109
Anderson L (abst) 131
Anderson P (abst) 211
Anderson PS (abst 252
Anderson RJ (abst) 135, 252, 258, 325
Anderson S (abst) 247, 252, 258
Anderson S: *see* Brater et al 66
Andrassy K (abst) 225
Andreoli TE: About *Kidney International* (Editorial) 1
Andres G (abst) 207, 217, 248
Andress DL (abst) 148, 168
Andreucci VE: *see* Conte et al 792
Andrews PM (abst) 234, 292, 337
Andreyev VG (abst) 156
Ansari A (abst) 201
Antonovych TT (abst) 200
Appel G (abst) 131, 138, 224
Araki M (abst) 267
Aranda MR: *see* Lemieux et al 908
Araujo JL (abst) 347
Arbeit LA: *see* Carvounis et al 512
Arbes S (abst) 131, 147
Arbough J (abst) 142
Arbus GS (abst) 131
Ardaillou R (abst) 266
Ardaillou R: *see* Baud et al 855
Arend LJ (abst) 291
Arendshorst WJ (abst) 299
Arieff AI (abst) 115, 132, 139, 149, 156
Armbrecht A (abst) 338
Arnaout MA (abst) 204
Aronoff GR: *see* Kenner et al 739
Aronoff GR (abst) 132, 195
Aronson PS (abst) 282, 312, 316
Arruda JAL (abst) 280, 288, 289, 335
Asakura K: *see* Imai et al 756
Asano Y (abst) 267
Asano Y: *see* Terao et al 951
Ascher N (abst) 345
Ash SR (abst) 157, 158, 172

Ashida T (abst) 193
Atkins JL (abst) 227, 234, 258
Atkins RC (abst) 341
Atlas S (abst) 105
Atlas SA (abst) 202, 316
Atlas SA: *see* Maack et al 607
Attie M (abst) 129
Audet P (abst) 127
Aune TM (abst) 222
Ausiello DA (abst) 323, 336
Austin B (abst) 296
Austin H (abst) 204
Autenried P (abst) 212
Autio-Harmainen H, Karttunen T, Risteli L, Risteli J, Rapola J: Accumulation of laminin and type IV collagen in the kidney in congenital nephrosis 662
Avasthi PS (abst) 215, 291
Avison MJ (abst) 302
Avner ED (abst) 205
Avram MM (abst) 132
Aynedjian HS (abst) 241
Ayus JC (abst) 132, 223
Azar S (abst) 187, 249

Bach J-F: *see* Wolff et al 469
Bachelet M, Bourdeau A, Lair M, Bader C, Ben Nasr L, Thomas M, Ulmann A: Effect of plasma levels of parathyroid hormone on NADPH pathways in kidney and liver 401
Backman KA: *see* Stern et al 652
Baczynski R, Massry SG, Kohan R, Magott M, Saglikes Y, Brautbar N: Effects of parathyroid hormone on myocardial energy metabolism in the rat 718
Bader C: *see* Bachelet et al 401
Badertscher RR (abst) 143
Badie-Dezfooly B (abst) 241, 247, 254, 321
Badr KF (abst) 227
Bahoric A (abst) 175
Baines AD (abst) 307
Baines AD, Ho P, James H: Metabolic control of renal vascular resistance and glomerulotubular balance ... 848
Baird B: *see* Brater et al 66
Baird LG (abst) 213
Bakaletz AP (abst) 205
Bakris GL (abst) 227
Bakris GL, Burnett JC Jr: A role for calcium in radiocontrast-induced reductions in renal hemodynamics (Technical Note) 465
Balavoine F: *see* Baud et al 855
Baldamus CA (abst) 171
Baldwin DS (abst) 248
Bálint P, László K: Effect of imidazole and indomethacin on hemodynamics of the obstructed canine kidney .. 892
Ballermann BJ (abst) 253
Balletta M: *see* Conte et al 792
Balow JE (abst) 204
Balow JE: Renal vasculitis (Nephrology Forum) 954
Baluarte HJ (abst) 177
Baluarter J (abst) 181
Bander NH (abst) 151, 351
Bank N (abst) 241
Bannett A (abst) 339
Bannister KM (abst) 205
Bansal VK (abst) 119
Baquero A (abst) 339
Baranowski RL (abst) 158, 228, 236, 239, 253
Barbato AL (abst) 119
Barber J (abst) 187
Barbour GL (abst) 285
Barfuss D (abst) 303
Bargman JM (abst) 302
Baricso WH (abst) 205
Barker L (abst) 288
Barnes JL (abst) 206
Barnes LA (abst) 341
Barratt LJ: *see* Allen et al 622, 842
Barré P-E: *see* Kaye et al 574
Barry JM (abst) 346
Bartell CK (abst) 306
Barth RH (abst) 173
Bartholomew JR (abst) 175
Bartholomew WR (abst) 159
Barua MW (abst) 204
Bastl C (abst) 265
Basto P (abst) 322
Bates SB (abst) 234, 237, 292
Batlle DC (abst) 133, 152, 156, 202, 283
Batteiger BE (abst) 132
Baud L, Sraer J, Delarue F, Bens M, Balavoine F, Schlondorff D, Ardaillou R, Sraer J-D: Lipoxygenase products mediate the attachment of rat macrophages to glomeruli in vitro 855
Baudoin B (abst) 221
Baughman JA (abst) 144
Baum M (abst) 303
Baylis C (abst) 292, 294, 295
Bazin H: *see* de Heer et al 388
Bea CE (abst) 197
Beallo R (abst) 153
Beam TR (abst) 159
Beaudry-Lonergan M (abst) 323
Beaurain G: *see* Wolff et al 469
Beauwens R (abst) 286
Beck TR (abst) 283
Becker H (abst) 201
Beckwith D (abst) 300
Beeuwkes R (abst) 295
Behringer D (abst) 150
Beliveau R (abst) 303
Bell JD (abst) 337
Bell PD (abst) 303
Bellorin-Font E (abst) 109, 243
Bellucci A (abst) 133, 296
Benedetti RG (abst) 187
Ben Nasr L: *see* Bachelet et al 401
Bennett L (abst) 345
Bennett R (abst) 133
Bennett RR (abst) 182
Bennett SJ (abst) 150
Bennett WM (abst) 147, 155, 227, 231
Bens M (abst) 266
Bens M: *see* Baud et al 855
Bentley M (abst) 332
Bentzel CJ: *see* Alavi et al 411
Benya R (abst) 203
Benz RL (abst) 177
Berg JA (abst) 228
Berger J (abst) 218
Berger P (abst) 264
Bergeron M (abst) 323

Bergfeld M (abst) 116, 165
Bergrem H, Jervell J, Flatmark A: Prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients 459
Bergstrom J (abst) 157, 240
Berkowitz BA (abst) 197
Berkseth R (abst) 158
Berl T (abst) 242, 253, 335
Berland YF: *see* Charhon et al 426
Berlyne GM (abst) 108, 114, 115, 120, 166
Berlyne GM: *see* Adler et al 523
Bermudez FJ (abst) 136
Bernard A (abst) 221
Berndt TJ (abst) 109
Bernhardt JP (abst) 337
Bernier M (abst) 303
Bernstein J (abst) 142
Berry CA (abst) 303, 332
Berthelet F (abst) 323
Beschorner WE (abst) 206
Beyenbach KW (abst) 263, 306, 319
Beyer M (abst) 242
Beyer MM (abst) 109, 137
Bhakdi S: *see* de Heer et al 388
Bhan AK (abst) 224
Bia MJ (abst) 338
Biagi BA (abst) 277
Bialy GB (abst) 174, 188, 199
Bianchi G (abst) 292, 298
Bichara M (abst) 149, 278
Bichet D (abst) 133
Bidani A (abst) 134
Bielakoff J (abst) 159
Bielakoff J: *see* de Vernejoul et al 785
Biemesderfer D (abst) 303
Bierman L (abst) 125, 166
Bierman MH (abst) 178
Binder HJ (abst) 310
Bird JE (abst) 228
Birmingham DJ (abst) 212
Birnholz JC, Kasinath BS, Corwin HL: An improvised technique for ultrasound guided percutaneous renal biopsy (Technical Note) 80
Birzgalis A (abst) 330
Bishop J (abst) 226
Black AJ (abst) 271
Blackstock DG (abst) 293
Blake DE (abst) 158
Blake DL (abst) 157
Blantz RC (abst) 292, 298
Blaufox D (abst) 194
Blazer-Yost B (abst) 306
Blomgren P (abst) 231
Blomgren P: *see* Kenner et al 739
Bluestone P (abst) 178
Blum C (abst) 131
Blumenfrucht MJ (abst) 206
Boberg U (abst) 292, 298
Bock GH (abst) 220
Bodvarsson M (abst) 110
Bogusky RT (abst) 112, 113, 270
Bohannon LL (abst) 337
Bois E: *see* Feingold et al 672
Boles MA (abst) 203
Bolling G (abst) 175
Bolton K (abst) 208
Bolton WK (abst) 138, 141, 224
Bomalaski JS (abst) 179
Bomsztyk K (abst) 304
Bondar N (abst) 260
Bonduris DN (abst) 279, 308
Bonjour JP (abst) 111
Bonsib SM: Scanning electron microscopy of acellular glomeruli in nephrotic syndrome 678
Bonventre JV (abst) 135, 230, 323
Booker BB (abst) 316
Border WA (abst) 206, 212
Boring W (abst) 144
Borle AB (abst) 114
Boron WF (abst) 279, 286, 288
Borra S (abst) 320
Bosch JP (abst) 241, 245
Boulanger Y (abst) 276
Boulpaep EL (abst) 310
Bounerias F (abst) 118
Bourdeau A (abst) 118
Bourdeau A: *see* Bachelet et al 401
Bourgoignie JJ (abst) 241, 242
Bourke E (abst) 116
Bowden E (abst) 330
Bowen PA (abst) 233
Bower J (abst) 184
Bower JD (abst) 261
Bowlus CL (abst) 252
Boyd ND: *see* Masri et al 807
Boylan JW (abst) 188, 190
Braden G (abst) 161, 304
Bradley T (abst) 292
Brady-Smith M (abst) 163
Brand PH (abst) 335
Brandes L (abst) 182, 183
Brandon S (abst) 261
Brassfield M (abst) 153
Brater DC (abst) 295
Brater DC, Anderson S, Baird B, Campbell WB: Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men 66
Brautbar N (abst) 109
Brautbar N: *see* Baczynski et al 718
Brazy PC (abst) 253, 339
Breckon R (abst) 226, 252
Breillatt J (abst) 162
Brem A (abst) 324
Brem AS, Cashore WJ, Pacholski M, Tetreault J, Lawler RG: Effects of bilirubin on transepithlial transport of sodium, water, and urea 51
Bremer B (abst) 341
Brems R (abst) 228
Brennan P (abst) 201
Brennan S (abst) 270
Brenner BM (abst) 227, 247, 252, 253, 295, 311, 331, 337
Brensilver J (abst) 304
Brensilver JM, Daniels FH, Lefavour GS, Malseptic RM, Lorch JA, Ponte ML, Cortell S: Effect of variations in dietary sodium intake on sodium excretion in mature rats 497
Brentjens J (abst) 207, 217, 338
Brentjens JR (abst) 207, 248
Breyer J (abst) 131
Breyer MD (abst) 278

Brezin JH (abst) 157
Brezis M (abst) 107, 228, 238
Brianti E (abst) 276
Bricker NS (abst) 242, 246, 250
Briggs JP (abst) 261, 293
Brinker K (abst) 342
Broadus A (abst) 104
Broccoli AV (abst) 293
Brodsky WA (abst) 278
Brokl OH (abst) 325
Brolsch C (abst) 338
Brooks B (abst) 198
Brouhard BH (abst) 151
Brown BV (abst) 277
Brown DM: *see* Mauer et al 751
Brown G (abst) 254
Brown PS (abst) 198
Brown S (abst) 111
Brown T (abst) 114, 123
Browning M (abst) 229
Broyer M: *see* Feingold et al 672
Brukman J (abst) 226
Brunette MG (abst) 110
Brunisholz M (abst) 221
Brunkhorst R (abst) 338
Bruns FJ (abst) 134
Bucht H (abst) 240
Buckenheimer T (abst) 123, 124
Buerkert J (abst) 250, 278
Bulger RE (abst) 304, 319
Burakoff SJ (abst) 215
Burdick JF (abst) 206
Burg M (abst) 289
Burg MB (abst) 282
Burke C (abst) 325
Burke E (abst) 161
Burke JF (abst) 344
Burke T (abst) 237, 246
Burnatowska MA, Harris CA, Sutton RAL, Seely JF: Effects of vitamin D on renal handling of calcium, magnesium, and phosphate in the hamster 864
Burnatowska-Hledin M (abst) 128, 158, 238
Burnell JM (abst) 110
Burnett JC (abst) 227, 305, 308
Burnett JC Jr: *see* Bakris et al 465
Burstein AH (abst) 109
Bursten S (abst) 188
Burtis W (abst) 104
Bushinsky DA (abst) 110, 124
Butler N (abst) 153
Butt K (abst) 350
Butt KMH (abst) 138, 242

Cade R (abst) 134, 150
Cadnapaphornchai P (abst) 254, 260
Cajias J (abst) 243
Calalb MB (abst) 304
Calamia J (abst) 307
Caldwell J (abst) 282
Caldwell P (abst) 207, 217
Callahan MG (abst) 191
Camara DS (abst) 159
Camargo MJ (abst) 105, 202
Camargo MJF (abst) 316
Camargo MJF: *see* Maack et al 607
Cameron JS (abst) 345
Campbell WB (abst) 295
Campbell WB: *see* Brater et al 66
Campese VM (abst) 242
Campos H: *see* Wolff et al 469
Camussi G (abst) 206, 207
Canadian Society of Nephrology Abstracts, Montreal, Quebec, Canada, September 10–13, 1984 593
Cannon JK (abst) 331
Canobbio M (abst) 151
Cantiello HF (abst) 305
Cantley L (abst) 265
Canzanello VJ (abst) 110
Capasso G (abst) 279
Capdevila J (abst) 268
Caplan M (abst) 303
Capparell NJ: *see* Salant et al 938
Cardella CJ: *see* Cattran et al 436
Carlson JA (abst) 216
Carlson RW (abst) 113
Caro J (abst) 262
Carpenter CB (abst) 344, 347
Carpenter RJ (abst) 139
Carr DJ (abst) 157, 158
Carretero OA (abst) 317
Carretero OA: *see* Itoh et al 762
Carriere B (abst) 324
Carroll F (abst) 149
Carroll HJ (abst) 148
Carvounis CP (abst) 276, 324, 328
Carvounis CP: *see* Carvounis et al 512
Carvounis G (abst) 324
Carvounis G, Carvounis CP, Arbeit LA: Independent action of prostaglandins and kinins on vasopressin-stimulated water flow 512
Cashore WJ: *see* Brem et al 51
Castellino P (abst) 136, 243
Castro L (abst) 163
Catalano C (abst) 167
Cathey M (abst) 169, 170
Cato A (abst) 160
Cattell V (abst) 254
Cattran C (abst) 207
Cattran DC (abst) 181
Cattran DC, Cardella CJ, Roscoe JM, Charron RC, Rance PC, Ritchie SM, Corey PN: Results of a controlled drug trial in membranoproliferative glomerulonephritis 436
Cavallo T (abst) 207, 211, 223
Caverzasio J (abst) 111
Chaillet JR (abst) 279
Chaimovitz C: *see* Goligorsky et al 774
Chakrabartie (abst) 182
Chakravarthy A (abst) 312, 318, 326
Challoner-Hue L (abst) 200
Chamberlin ME (abst) 271
Champney K (abst) 238
Chan JCM (abst) 111
Chan L (abst) 229, 311, 348
Chan W (abst) 111, 122
Chan YL (abst) 156
Chandra M (abst) 179, 208
Chang BS (abst) 134
Chang CW (abst) 165
Chang PN (abst) 348

Charhon SA, Berland YF, Olmer MJ, Delawari E, Traeger J, Meunier PJ: Effects of parathyroidectomy on bone formation and mineralization in hemodialyzed patients ... 426
Charoenpanich R (abst) ... 170
Charron RC: *see* Cattran et al ... 436
Chase DH (abst) ... 312
Chase H (abst) ... 305
Chatelet F (abst) ... 276
Chatenoud L: *see* Wolff et al ... 469
Chaudhari A (abst) ... 254, 257, 259
Chavers BM (abst) ... 135
Chaves CC (abst) ... 305
Check IJ (abst) ... 225
Cheeks C (abst) ... 206
Cheema-Dhadli S (abst) ... 284
Cheigh J (abst) ... 350
Cheigh JS (abst) ... 188, 338, 347
Chen C (abst) ... 149, 242
Chen P (abst) ... 111
Chen T (abst) ... 123
Chen TC (abst) ... 112
Cherry J (abst) ... 259
Chesney RW (abst) ... 113, 324
Cheung AK (abst) ... 158
Cheung C (abst) ... 229, 311, 348
Cheung HS (abst) ... 121
Cheung JY (abst) ... 323
Chevalier RL (abst) ... 293
Chi Y (abst) ... 338
Child JS (abst) ... 151
Chinitz JL (abst) ... 157
Chiu L-Y (abst) ... 215
Choi SC: *see* Oken et al ... 871
Chompret A: *see* Feingold et al ... 672
Chou SY (abst) ... 293
Chretien P (abst) ... 150
Christensen EI: *see* Nielsen et al ... 39
Chrysant C (abst) ... 189
Chrysant SG (abst) ... 189
Chung HM (abst) ... 135, 156
Church HH: *see* Rapoport et al ... 726
Clair F (abst) ... 112
Claman P (abst) ... 139
Clark A (abst) ... 229
Clarke HS (abst) ... 196
Clarkson TW: *see* Hursh et al ... 898
Clausen C (abst) ... 280, 330
Clayman M (abst) ... 208, 217, 219, 240
Cleary MP (abst) ... 245, 297
Clemons G (abst) ... 178
Cliff WH (abst) ... 306, 319
Clifton G (abst) ... 255
Closkey G (abst) ... 213, 293
Cluzeaud F (abst) ... 276
Coachman D (abst) ... 280
Coburn J (abst) ... 116
Coburn JW (abst) ... 142, 147, 148, 168, 180, 185
Coda B (abst) ... 243
Codd T (abst) ... 155
Coe F (abst) ... 314
Coe FL (abst) ... 110, 120, 124, 251
Coffman TM (abst) ... 339
Cogan MG (abst) ... 102, 258, 279
Coggins CH (abst) ... 135
Cohen AH (abst) ... 135, 252
Cohen JJ (abst) ... 101, 271
Cohen JJ: *see* Madias et al ... 538
Cohen L (abst) ... 138
Cohen R (abst) ... 280
Cohen SM (abst) ... 239
Cohn D (abst) ... 240
Cohn R (abst) ... 261
Colao DJ (abst) ... 271
Colburn G (abst) ... 164
Cole BR (abst) ... 104, 294
Cole L (abst) ... 290
Cole LA (abst) ... 271
Collins A (abst) ... 158
Collins AB (abst) ... 213
Collins AJ (abst) ... 163
Collins J (abst) ... 242
Collins RC (abst) ... 294
Colombe BW (abst) ... 337
Colon PJ (abst) ... 306
Colpoys MC (abst) ... 294
Colvin RB (abst) ... 224
Comstock TJ (abst) ... 178
Conger JD (abst) ... 162
Conley ME: *see* Melvin et al ... 685
Conrad KP (abst) ... 294
Conte G, Dal Canton A, Fuiano G, Terribile M, Sabbatini M, Balletta M, Stanziale P, Andreucci VE: Mechanism of impaired urinary concentration in chronic primary glomerulonephritis ... 792
Contreras N (abst) ... 243
Cook HT (abst) ... 253
Cooney E (abst) ... 229
Cooper K (abst) ... 230
Coppin CML (abst) ... 127
Corey PN: *see* Cattran et al ... 436
Corry DB (abst) ... 243
Cortell S (abst) ... 304
Cortell S: *see* Brensilver et al ... 497
Cortes P (abst) ... 137, 274
Cortez S (abst) ... 205
Corwin HL (abst) ... 134, 135, 180
Corwin HL: *see* Birnholz et al ... 80
Cosimi AB (abst) ... 224, 351
Cosio FG (abst) ... 136, 205, 212
Costanzo LS (abst) ... 112
Coulson R (abst) ... 255
Cournoyer G (abst) ... 174
Couser W (abst) ... 204
Couser WG: *see* Groggel et al ... 643
Cowgill L (abst) ... 270
Cowgill LD (abst) ... 112, 113
Cowley AW (abst) ... 202
Cox M (abst) ... 141, 306
Cragoe CJ (abst) ... 334
Cragoe E (abst) ... 313
Cragoe EJ (abst) ... 308, 310
Craig DM (abst) ... 279
Craswell P (abst) ... 150
Creazzo G (abst) ... 167
Crocker B (abst) ... 134
Cronin R (abst) ... 230
Crooks PW (abst) ... 121
Crow G (abst) ... 110
Crow J (abst) ... 160

Culpepper RM (abst) 255
Cumming AC (abst) 233
Cunningham EE (abst) 159, 338
Curd JG (abst) 226
Curreri R (abst) 200
Currie J (abst) 171
Currie MG (abst) 104, 294
Currier CB (abst) 342
Curtis JJ (abst) 339
Cutler JA (abst) 342

Dabbagh S (abst) 113, 324
D'agati V (abst) 224
Dagher F (abst) 150, 348
Dagher FJ (abst) 346
Daha MR: *see* de Heer et al 388
Daikos G (abst) 352
Dal Canton A: *see* Conte et al 792
Dana N (abst) 204
Dandavino R (abst) 346
Daniels F (abst) 304
Daniels FH: *see* Brensilver et al 497
Danielsson A (abst) 157
Danovitch G (abst) 151
Dantzler WH (abst) 325
Darby C: *see* Groggel et al 643
Darby C: *see* Salant et al 938
Das C (abst) 238
Datzman MA (abst) 178
Daugirdas JT (abst) 145, 159, 164, 168, 170, 176
Davidson R (abst) 188
Davis BB (abst) 239, 255, 275
Davis GA (abst) 245
Davis JO (abst) 201, 257
Davis S (abst) 144
Davison JM: The effect of pregnancy on kidney function in renal allograft recipients 74
Dawidson I (abst) 342
Dawson D (abst) 321
De Chadarevian JP (abst) 214
de Heer E, Daha MR, Bhakdi S, Bazin H, van Es LA: Possible involvement of terminal complement complex in active Heymann nephritis 388
de Jong PE, van Eps LWS: Sickle cell nephropathy: New insights into its pathophysiology (Editorial Review) 711
De La Rosa JP (abst) 243
de Rouffignac C: *see* Di Stefano et al 394
de Vernejoul MC (abst) 159
de Vernejoul MC, Marchais S, London G, Morieux C, Bielakoff J, Miravet L: Increased bone aluminum deposition after subtotal parathyroidectomy in dialyzed patients 785
De Villa LF (abst) 199
Debermudez LG (abst) 136
Debold AJ (abst) 104
Decker JL (abst) 204
Defronzo RA (abst) 136, 243
Deftos L (abst) 349
Deganello S (abst) 110
Degraphenried RL (abst) 252
Deguchi F (abst) 193
Deguzman A (abst) 213, 293
Delacroix DL: *see* Melvin et al 685
Delano BG (abst) 137
Delarue F: *see* Baud et al 855
Delawari E: *see* Charhon et al 426
Delmonico FL (abst) 351
Delosangeles A (abst) 145, 170, 339
Delvalle CJ (abst) 342
Dennis VW (abst) 213
Denny KM (abst) 159
Depner T (abst) 244
Dequattro V (abst) 201
Deraps G (abst) 184
Desai K (abst) 284
Desai TK (abst) 113
Desir GV (abst) 299
Devlin VJ (abst) 109
Devney P (abst) 339
Devore KW (abst) 329
Dewitt SF (abst) 160
Diakoumakis E (abst) 157
Diamond JR (abst) 230
Diamond LH (abst) 160, 200
Diaz Diaz FD (abst) 280
Diaz-Buxo JA (abst) 179
Dibona DR (abst) 328
Dibona GF (abst) 194, 292, 313
Diciani N (abst) 251
Dickerman R (abst) 342
Diederich D (abst) 166
Diethelm AG (abst) 339
Dietrich RL (abst) 270
Dillingham MA (abst) 252, 325
Dillman B (abst) 171
Dipps S (abst) 205
Dirks JH (abst) 127, 129
Diskin CJ (abst) 160
Di Stefano A, Elalouf J-M, Garel J-M, de Rouffignac C: Modulation by calcitonin of magnesium and calciumurinary excretion in the rat 394
Distler A (abst) 235
Dittmer JE (abst) 209
Dittmer JE: *see* Salant et al 938
Dix JA (abst) 337
Dixon BS (abst) 258, 325
Dixon TE (abst) 280
Dobyan D (abst) 232
Dobyan DC (abst) 304, 319
D'occhio MA (abst) 190
Doehring E, Vester U, Ehrich JHH, Feldmeier H: Circadian variation of ova excretion, proteinuria, hematuria, and leukocyturia in urinary schistosomiasis 667
Dolson GM (abst) 113
Dombrouski J (abst) 128
Dominguez JH (abst) 114
Domoto DT (abst) 136
Donker AJ (abst) 137, 300
Donker AJM (abst) 236
Donoso VS (abst) 325
Doppelt S (abst) 127
Dornfeld LP (abst) 143
Dosa S (abst) 342
Dossetor JB (abst) 343, 345
Doucet A (abst) 110
Douglas JG (abst) 256
Douglas SD (abst) 179
Dousa TP (abst) 261, 277, 306, 333
Dousa TP: *see* Turner et al 879

Downs JA (abst) 197
Dreslinski GR (abst) 189, 343
Drezner MK: *see* Wilson et al 565
Droz D (abst) 208, 219
Drueke T (abst) 112, 118
Drueke T: *see* Roullett et al 420
D'souza V (abst) 203
Duarte CG (abst) 326
Dubick MA (abst) 245
Dubose TD (abst) 280
Dubost C (abst) 112, 118
Dubrow A (abst) 160
Duchin KL (abst) 161
Dulawa J (abst) 307
Dumler F (abst) 137, 274
Duncan R (abst) 334
Duncan RL (abst) 256, 269
Dunn BR (abst) 252
Dunn JK (abst) 151
Dunn MJ (abst) 199, 220, 256, 267
Dunn SR (abst) 243, 245
Duran MA (abst) 232
Durham JH (abst) 278
Durr JA (abst) 326
Dusing R (abst) 194
Dustan HP (abst) 189, 198
Dutch Society of Nephrology Abstracts, Rotterdam, The Netherlands, October 20, 1984 703
Dworkin LD (abst) 189, 235
Dwyer HJ (abst) 176
Dye E (abst) 111
Dytko G (abst) 280, 289
Dzau VJ (abst) 258

Eaton DC (abst) 280
Ebben J (abst) 158
Eby B (abst) 116, 128
Edelman A (abst) 287
Edelstein S (abst) 115
Edwards BR (abst) 326
Edwards RM (abst) 336
Egan JD (abst) 178
Eggers PW (abst) 151
Ehrich JHH: *see* Doehring et al 667
Einhorn TA (abst) 109
Eisele G (abst) 190
Eisenbarth GS (abst) 105
Eiser AR (abst) 157
Eisinger RP (abst) 174
Eisner GM (abst) 311
Eknoyan G (abst) 139
El Mernissi G (abst) 110
Elalouf JM: *see* Di Stefano et al 394
Elam R (abst) 250
Elema JD: *see* Grond et al 405
Elliott C (abst) 230
Ellis D (abst) 205
Ellis E (abst) 135
Ellis EN (abst) 209
Ellison KE (abst) 258
Emancipator SN (abst) 220
Emerson W (abst) 342
Endou H (abst) 219
Endres D (abst) 122
English J (abst) 231
Enia G (abst) 167
Epstein FH (abst) 107, 228, 238, 265, 266
Epstein M (abst) 296, 307
Erdmann E (abst) 163
Erdös EG: *see* Noda et al 630
Erickson AE (abst) 328
Erikson ME (abst) 213
Ersley VA (abst) 262
Esparza A (abst) 156
Evan AP (abst) 191, 231, 244, 330
Evan AP: *see* Kenner et al 739
Evans D (abst) 348
Evans M (abst) 162
Eveloff J (abst) 307
Evelyn M (abst) 338

Fabris A: *see* Oldrizzi et al 553
Falardeau P (abst) 256
Falck KR (abst) 268
Falk RJ (abst) 209, 212
Falke L (abst) 316
Fallon M (abst) 127, 129
Fallon MD (abst) 119
Fang LST (abst) 135
Fang LST: Light-chain nephropathy (Nephrology Forum) 582
Fanti P (abst) 137
Farge D (abst) 340, 346
Farquhar MG (abst) 207, 215, 218
Faubert PF (abst) 293
Faugere MC (abst) 114, 122, 161
Favus MJ (ast) 120, 124
Fearon D (abst) 162
Feduska N (abst) 337, 339, 349
Feduska NJ (abst) 340
Feig PU (abst) 190
Feiner H (abst) 248
Feiner HD (abst) 189, 209
Feingold J, Bois E, Chompret A, Broyer M, Gubler M-C, Grünfeld J-P: Genetic heterogeneity of Alport syndrome 672
Feinstein EI (abst) 176
Feintzeig ID (abst) 209
Feintzeig ID: *see* Salant et al 938
Felder RA (abst) 297, 311
Feldman GM (abst) 280
Feldmeier H: *see* Doehring et al 667
Felsen D (abst) 269
Felsenfeld A: *see* Wilson et al 565
Felsenfeld AJ (abst) 114, 121, 125, 169
Fenton SSA (abst) 181
Fernandez-Repollet E (abst) 231
Ferran N (abst) 114
Ferran NL (abst) 137
Ferris TF (abst) 346
Ficken V (abst) 193
Fidelman ML (abst) 269
Field MJ, Giebisch GH: Hormonal control of renal potassium excretion (Editorial Review) 379
Fillipone EJ (abst) 115
Finberg L (abst) 154
Finch J (abst) 116
Fine A (abst) 272
Fine LG (abst) 241, 247, 249, 254, 257, 281, 317, 321
Fine P (abst) 188

Fine RN (abst) 142, 185
Fineberg N (abst) 132
Finn WF: *see* Racusen et al 517
First MR: *see* Maryniak et al 799
Fischer FM (abst) 300
Fischer H (abst) 146
Fischer HW (abst) 296
Fisher JW (abst) 100, 101
Fisher DC (abst) 291
Fitz A (abst) 192
Fitzgibbons J (abst) 161, 304
Fitzgibbons R (abst) 178
Fivush BA (abst) 220
Flaa C (abst) 210
Flamenbaum W (abst) 160
Flanigan MJ (abst) 246
Flatmark A: *see* Bergrem et al 459
Fleming PC (abst) 131
Flye W (abst) 238
Foegh ML (abst) 257
Foley J (abst) 185
Fong JSC (abst) 214, 218
Fontana S (abst) 202
Forbes RDC (abst) 346
Forbush B (abst) 303
Ford CE (abst) 194
Forrest JN (abst) 312
Forrester T (abst) 190
Fosberg M (abst) 162
Fotino M (abst) 338
Foulks CJ (abst) 108, 115
Fournier A (abst) 310
Francis J (abst) 172
Franki N: *see* Rapoport et al 726
Fraser CL (abst) 115
Fraser WD (abst) 307
Freeman RB (abst) 146, 148
Freeman RH (abst) 201, 257
Freeman RM (abst) 246
Freitag T (abst) 194
Frelin C (abst) 281
French J (abst) 343
French Society of Nephrology Abstracts, Tunis, Tunisia, October 18, 1984 828
Fresco R (abst) 140
Freundlich M (abst) 130
Frey HJ (abst) 185
Freyschuss U (abst) 157
Fried TA (abst) 197, 266, 294, 297
Fried W (abst) 342
Friedlander MA (abst) 190
Friedler R (abst) 137
Friedler RM (abst) 161
Friedman AL (abst) 138
Friedman EA (abst) 137, 138, 145, 150
Friedman RA (abst) 157
Friedman WN (abst) 145
Frigon RP (abst) 251, 329
Froidart JM (abst) 219
Frommer JP (abst) 132, 281, 290
Fromter E (abst) 309
Fromter RO (abst) 319
Fryd D (abst) 345
Fuiano G: *see* Conte et al 792
Gabow P (abst) 153
Gabow PA: Disorders associated with an altered anion gap (Nephrology Forum) 472
Gafter U (abst) 115, 200
Gagnan M (abst) 303
Gagnon RF (abst) 210, 211
Galceran T (abst) 116, 122
Gale D (abst) 126
Galla JH (abst) 101, 210, 279, 308, 316
Galla JH: *see* Holland et al 46
Gallo GR (abst) 210
Galloway RR (abst) 311
Gambertoglio J (abst) 141, 349
Gambini DJ (abst) 118
Gammaro L: *see* Oldrizzi et al 553
Gan A (abst) 132
Ganousis L (abst) 189
Ganten D (abst) 201, 260
Gapstur S (abst) 261, 333
Garcia-Austt J (abst) 282
Garcia-Sainz JA (abst) 252, 262
Gardenswartz MH (abst) 181
Gardin JP (abst) 149
Gardner KD (abst) 244, 330
Gardner PW (abst) 174
Garel JM: *see* Di Stefano et al 394
Garg LC (abst) 308
Garno J (abst) 116
Garovoy MR (abst) 337, 349
Garrick R (abst) 179
Garvin JL (abst) 308
Garwood M (abst) 270
Gattone VH (abst) 191
Gaudiani LM (abst) 146
Gaudio K (abst) 338
Gaulton G (abst) 349
Gavellas G (abst) 241, 242
Gavin JR (abst) 272
Gay-Bellile V (abst) 221
Geha R (abst) 140
Geheb MA (abst) 113
Gehr M (abst) 116
Gehring JJ (abst) 295
Gekker G (abst) 232
Gelberg HB (abst) 237
Gelfand J (abst) 131, 138, 224
Gelfand MC (abst) 220
Gellai M (abst) 295
Geller DM (abst) 104
Gentile DE (abst) 183
Geokas MC (abst) 245
Gephardt GM (abst) 190
Gerdes JS (abst) 179
Germain M (abst) 161, 304
Gerstein W (abst) 211
Gesek FA (abst) 301
Gharagozloo M (abst) 308
Giacomelli F: *see* Olivetti et al 31
Gibb FR: *see* Hursh et al 898
Gibson SM (abst) 340
Giebisch G (abst) 279, 302, 309
Giebisch G: *see* Zalups et al 636
Giebisch GH: *see* Field et al 379
Gifford DR (abst) 312
Gilbert DN (abst) 231

Gillit D (abst) ... 173
Gillum D (abst) ... 142
Gillum DM (abst) ... 162
Gingras D (abst) ... 304
Ginsberg NS (abst) ... 173
Ginzler E (abst) ... 154
Giocondi MC (abst) ... 329
Glabman S (abst) ... 241, 245
Glanzer K (abst) ... 194
Glas-Greenwalt P (abst) ... 213
Glaser T (abst) ... 273
Glaser TC (abst) ... 210
Glassock RJ (abst) ... 211, 252, 296
Glatfelter A (abst) ... 226
Gleim GW (abst) ... 181
Glickman JL (abst) ... 138
Glocheski SK (abst) ... 340
Gluck S (abst) ... 282
Glurich I (abst) ... 204
Gold J (abst) ... 211
Gold RM (abst) ... 335
Goldberg D (abst) ... 154
Goldberg LI (abst) ... 292
Goldberg M (abst) ... 116
Goldfarb D (abst) ... 257, 317
Goldfarb S (abst) ... 129
Goldstein CS (abst) ... 179
Goldstein G (abst) ... 341
Goldstein J: *see* Goligorsky et al ... 774
Goldstein M (abst) ... 258
Goldstein MB (abst) ... 272
Goldstein S (abst) ... 145
Goldstein SJ (abst) ... 170
Goligorsky MS, Chaimovitz C, Rapoport J, Goldstein J, Kol R: Calcium metabolism in uremic nephrocalcinosis: Preventive effect of verapamil ... 774
Golper TA (abst) ... 139, 147
Goltzman D (abst) ... 104
Gonzalez FM (abst) ... 165
Gonzalez OF (abst) ... 237
Good DW (abst) ... 282
Goodman AI (abst) ... 247
Goodman S (abst) ... 191
Goodyer PR (abst) ... 211, 214, 218
Gorkin JU (abst) ... 139
Gotch F (abst) ... 162, 242, 246, 250
Gouge S (abst) ... 133, 341
Gouge SF (abst) ... 235
Gougoux A (abst) ... 174, 272
Gould AB (abst) ... 191
Graf H (abst) ... 139
Granger JP (abst) ... 305, 309, 318, 326
Granholm NA (abst) ... 207, 211
Grantham JJ (abst) ... 325, 336
Graor RA (abst) ... 159
Grassl SM (abst) ... 282
Graves K (abst) ... 207, 211
Gray RW (abst) ... 119, 211
Grecos GP (abst) ... 196
Green L (abst) ... 341
Green N (abst) ... 309
Green W (abst) ... 350
Greenberg A (abst) ... 123, 283
Greene ER (abst) ... 291
Greenfield BA (abst) ... 139
Greger R (abst) ... 322
Gregory MC (abst) ... 244
Greven J (abst) ... 307
Griffin MJ (abst) ... 333
Grippo RS (abst) ... 299
Grogan WM (abst) ... 269
Groggel GC (abst) ... 212
Groggel GC, Salant DJ, Darby C, Rennke HG, Couser WG: Role of terminal complement pathway in the heterologous phase of antiglomerular basement membrane nephritis ... 643
Groggel GC: *see* Salant et al ... 938
Grond J, Koudstaal J, Elema JD: Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis ... 405
Gross C (abst) ... 143
Gross ML (abst) ... 191, 196
Gross P (abst) ... 309
Grosskopf T (abst) ... 202
Gruber KA (abst) ... 191
Grünfeld J-P: The clinical spectrum of hereditary nephritis (Nephrology Forum) ... 83
Grünfeld J-P: *see* Feingold et al ... 672
Gruskin A (abst) ... 177, 181
Gubler M-C: *see* Feingold et al ... 672
Guckian V (abst) ... 279
Guggenheim S (abst) ... 223
Guggino SE (abst) ... 309
Guggino WB (abst) ... 309
Guiseppe R (abst) ... 100, 101
Gullans SR (abst) ... 302
Gulyassy P (abst) ... 244
Gumbert M (abst) ... 349
Guntupalli J (abst) ... 116
Gupta RK (abst) ... 314
Gurland HJ (abst) ... 163
Gurwith M (abst) ... 238
Gusowski N (abst) ... 113, 324
Gustafson AB (abst) ... 119
Guthrie GP (abst) ... 192
Gutierrez A (abst) ... 240
Gutierrez L (abst) ... 143
Gutterman C (abst) ... 283
Guttmann RD (abst) ... 340, 346
Guzman N (abst) ... 155

Haas JA (abst) ... 309
Hafezi A (abst) ... 257, 317
Hagege J, Richet G: Proximal tubule dopamine histofluorescence in renal slices incubated with L-dopa ... 3
Hagedorn HH (abst) ... 163
Haimes J (abst) ... 348
Hain H (abst) ... 179
Hak LJ (abst) ... 180
Hakim R (abst) ... 127
Hakin RM (abst) ... 161, 162, 163, 204
Halasz N (abst) ... 349
Halbwachs-Mescarelli L (abst) ... 218
Halevy J (abst) ... 310
Hall JE (abst) ... 192
Hall PW (abst) ... 300
Hall-Craggs M (abst) ... 346
Hällgren R: *see* Odlind et al ... 9
Halloran PF (abst) ... 212
Halperin ML (abst) ... 272, 284

Halstenson CE (abst) ... 146, 163
Hamburger RJ (abst) ... 117, 312
Hamilton W (abst) ... 164
Hamm L (abst) ... 270
Hammeke M (abst) ... 178
Hammerman MR (abst) ... 126, 272
Hammond D (abst) ... 210
Hammond TG (abst) ... 117, 199, 306
Hamzeh A (abst) ... 241
Hancock WW (abst) ... 341
Handler JS (abst) ... 332
Handt AE (abst) ... 180
Hanley JA (abst) ... 340
Hanna M (abst) ... 192
Hano JE (abst) ... 119, 140
Hanrahan JW (abst) ... 310
Hansen HE: *see* Pedersen et al ... 780
Hansen RM (abst) ... 242
Hansen WP (abst) ... 151, 351
Hanson G (abst) ... 165
Haramati A (abst) ... 117, 308
Hardy M (abst) ... 224
Harford AM (abst) ... 118
Harmon W (abst) ... 140, 162
Harrah J (abst) ... 249
Harrington A (abst) ... 149
Harris CA: *see* Burnatowska et al ... 864
Harris HW (abst) ... 140
Harris R (abst) ... 314
Harris RC (abst) ... 310
Harris TM (abst) ... 256
Harrison J (abst) ... 185
Hartley B (abst) ... 345
Hartman J (abst) ... 147
Haschemeyer R (abst) ... 347
Hassler R (abst) ... 163
Hatch D (abst) ... 346
Haupt MT (abst) ... 113
Hawkins T (abst) ... 351
Haygood C (abst) ... 169
Haygood EC (abst) ... 342
Haynie J (abst) ... 613
Haynie JD: *see* Ruder et al ... 768
Häyry P: *see* von Willebrand et al ... 616
Hays RM: *see* Rapoport et al ... 726
Hayslett JP (abst) ... 118, 310
Hayslett JP: *see* Stern et al ... 652
Hebert LA (abst) ... 147, 212
Hebert RL (abst) ... 263, 310
Hebert SC (abst) ... 311, 327, 331
Heidland A (abst) ... 171
Heifets M (abst) ... 244
Heil JE (abst) ... 228
Heineken F (abst) ... 162, 163
Heinz E (abst) ... 315
Held PJ (abst) ... 160
Helderman JH (abst) ... 342
Helfrich GB (abst) ... 220, 257, 342
Henderson LW (abst) ... 251, 329
Henrich W (abst) ... 131
Henrich WL (abst) ... 295
Henry H (abst) ... 140
Hercz G (abst) ... 143, 180
Hermann J (abst) ... 273
Herrman J (abst) ... 155
Hibbert J (abst) ... 204
Hill G (abst) ... 251
Hill M (abst) ... 149
Hillebrand H (abst) ... 163
Hintze T (abst) ... 104
Hirsch DJ (abst) ... 327
Hirsch J (abst) ... 115
Hirszel P (abst) ... 182
Hise MK (abst) ... 113, 273
Hjemdahl P (abst) ... 292
Hjøllund E: *see* Pedersen et al ... 780
Ho LT (abst) ... 156
Ho P: *see* Baines et al ... 848
Hodder R (abst) ... 133
Hodder S (abst) ... 216
Hodsman AB: *see* Kaye et al ... 574
Hoeldtke R (abst) ... 143
Hofling B (abst) ... 163
Hogg R (abst) ... 223
Hoggard JG (abst) ... 326
Holdsworth SR: *see* Tipping et al ... 530
Holland MD, Galla JH, Sanders PW, Luke RG: Effect of urinary pH and diatrozoate on Bence Jones protein nephrotoxicity in the rat ... 46
Holland SD (abst) ... 327
Holliday M (abst) ... 249
Holly RW (abst) ... 247
Holmberg DL (abst) ... 236
Holmes AW (abst) ... 173
Holt KL (abst) ... 179
Holtzclaw BJ (abst) ... 197
Holtzclaw D (abst) ... 232
Homadani BM (abst) ... 254
Hong SK (abst) ... 248
Hopla AK (abst) ... 193
Hoppel CL (abst) ... 170
Horl WH (abst) ... 170, 175
Horton C (abst) ... 296, 307
Hosoda S: *see* Terao et al ... 951
Hosokawa S (abst) ... 140
Hostetter TH (abst) ... 248
Houghton DC (abst) ... 139, 227, 231
Hoving P (abst) ... 212
Howlin KJ (abst) ... 302
Hoy C (abst) ... 304
Hoyer JR (abst) ... 300
Hricak H (abst) ... 340
Hruska K (abst) ... 119
Hruska KA (abst) ... 117, 334
Hsu A (abst) ... 216
Hsu C (abst) ... 111
Huang CL (abst) ... 258
Huang TP (abst) ... 156
Huebner K (abst) ... 337
Hughes M (abst) ... 295
Huhnke GE (abst) ... 197
Hull A (abst) ... 342
Humes HD (abst) ... 106, 231, 239
Humphreys MH (abst) ... 305
Humphries A (abst) ... 164
Hunt D (abst) ... 106, 239, 321
Hunt JM (abst) ... 326
Hunt W (abst) ... 153
Hurley RM (abst) ... 140

Hursh JB, Clarkson TW, Nowak TV, Pabico RC, McKenna BA, Miles E, Gibb FR: Prediction of kidney mercury content by isotope techniques 898
Husdan H (abst) 182
Husni L (abst) 161
Hussein M (abst) 152, 173
Hutchison FN (abst) 141
Hwang SD (abst) 182
Hwang SK (abst) 183
Hydlebeerg-Davis D (abst) 234
Hymes L (abst) 225

Iancu M (abst) 132
Ibanez RJ: *see* Lemieux et al 908
Ibarra ME (abst) 262
Ichikawa I (abst) 232, 247, 270, 295, 311, 337
Idatte JM (abst) 149
Igarashi P (abst) 244
Ikeda M (abst) 193
Illingworth DR (abst) 140
Illowsky B (abst) 141
Ilstrup K (abst) 158, 165
Imai H, Nakamoto Y, Asakura K, Miki K, Yasuda T, Miura AB: Spontaneous glomerular I_gA deposition in ddY mice: An animal model of I_gA nephritis 756
Imai M (abst) 267
Imai T (abst) 140
Inagami T (abst) 317
Ing IL (abst) 168
Ing TS (abst) 145, 159, 164, 170, 176
Inglefinger JR (abst) 258
Ingram R (abst) 198
Ingram S (abst) 235
Inkinen K: *see* von Willebrand et al 616
Innes D (abst) 141
Insel PA (abst) 317
Insogna K (abst) 104
Iseki K (abst) 242
Ishidate T (abst) 300
Israel R (abst) 296
Itabashi A (abst) 229, 311, 348
Italian Society of Nephrology Abstracts, Abano, Terme, Italy, May 30–June 2, 1984 93
Ito K (abst) 193
Itoh S, Carretero OA, Murray RD: Renin release from isolated afferent arterioles 762
Ives HE (abst) 283
Iwai J (abst) 201, 268
Izzo JL (abst) 170

Jacob M (abst) 111
Jacobs DB (abst) 327
Jacobson HR (abst) 102, 278, 317
Jaeger P (abst) 118
Jahrling PB (abst) 301, 315
James H: *see* Baines et al 848
Jamison RL (abst) 295, 302, 317
Jamison RL: *see* Milanes et al 919
Jarrard E (abst) 244
Jarrell B (abst) 344
Jenkins AC (abst) 189, 343
Jennette JC (abst) 180, 209, 212
Jensen DM (abst) 180
Jermanovich N (abst) 213
Jerome E (abst) 233
Jervell J: *see* Bergrem et al 459
Jiminez I (abst) 141
Jo O (abst) 118
Johannsson SL (abst) 239
Johns CA (abst) 110
Johnson AK (abst) 191
Johnson DW (abst) 146
Johnson HK (abst) 350
Johnson JP (abst) 235, 258, 341
Johnson KJ (abst) 220
Johnson KJ: *see* Rehan et al 503
Johnson KS (abst) 169
Johnson R (abst) 125, 166
Johnston JR (abst) 311
Joiner C (abst) 198
Jones D (abst) 230
Jones ER (abst) 283
Jones FS (abst) 213
Jones H (abst) 141
Jones KLO (abst) 160
Jones P (abst) 339
Jones W (abst) 118
Jorkasky D (abst) 141, 351
Jose PA (abst) 297, 311
Josepovitz C (abst) 237
Josselson J (abst) 164, 175
Julian BA (abst) 226
Jung CY (abst) 327, 336
Jungas RL (abst) 284

Kablitz C (abst) 236
Kad SK (abst) 328
Kahan B (abst) 341
Kahn AM (abst) 328
Kahn T (abst) 320
Kaiser B (abst) 177, 181
Kalhan S (abst) 249
Kaloyanides GJ (abst) 237
Kamata K (abst) 213
Kaminetsky B (abst) 248
Kanayama Y (abst) 226
Kangarloo H (abst) 142
Kant K (abst) 169
Kant JS (abst) 170, 213
Kanwar YS (abst) 210, 214
Kanz L (abst) 349
Kaplan AA (abst) 164
Kaplan BS (abst) 211, 214, 218
Kaplan F (abst) 127
Kaplan M (abst) 338
Kaplan MR (abst) 343, 347
Kapur SP (abst) 220
Karanja N (abst) 122, 140, 193
Karapanos G (abst) 273, 274
Karmali MA (abst) 131
Karmi S (abst) 342
Karniski LP (abst) 282, 312
Karnovsky MJ (abst) 230
Karsenty G (abst) 118
Karttunen T: *see* Autio-Harmainen et al 662
Kashgarian M (abst) 303
Kashyap ML (abst) 213
Kasinath BS (abst) 134, 214
Kasinath BS: *see* Birnholz et al 80
Kasiske BL (abst) 245, 297

Kasperbauer J (abst) ... 178
Katz MS (abst) ... 327
Katz SM (abst) ... 223
Katzberg RW (abst) ... 146, 296
Kauffman HM (abst) ... 342
Kauffman S (abst) ... 274
Kaufman CE (abst) ... 193
Kaufman D (abst) ... 248
Kaufman GM (abst) ... 158
Kaufman JS (abst) ... 117, 312
Kawala K (abst) ... 142
Kawasaki H (abst) ... 219
Kay DA (abst) ... 179
Kaye M, Zucker SW, Leclerc YG, Prichard S, Hodsman AB, Barré P-E: Osteoclast enlargement in endstage renal disease ... 574
Kaysen GA (abst) ... 141, 245
Keane W (abst) ... 187
Keane WF (abst) ... 146, 232, 245, 249, 297
Kearney JF (abst) ... 336
Keating A (abst) ... 184
Keavey P (abst) ... 351
Keeley P (abst) ... 188
Keen M (abst) ... 162
Kefalides NA (abst) ... 208
Keiser H (abst) ... 190
Keiser J (abst) ... 312
Kelepouris E (abst) ... 130
Kelleher S (abst) ... 142
Kelley DJ (abst) ... 342
Kelley VE (abst) ... 214, 227, 349
Kellner D (abst) ... 254
Kelly C (abst) ... 215, 219, 240
Kelly DL: *see* Ruder et al ... 768
Kelly G (abst) ... 312
Kelly R (abst) ... 155
Kelly RA (abst) ... 193
Kempson SA (abst) ... 118
Kenner CH, Evan AP, Blomgren P, Aronoff GR, Luft FC: Effect of protein intake on renal function and structure in partially nephrectomized rats ... 739
Kenny M (abst) ... 188
Kenny MA (abst) ... 186
Kerjaschki D (abst) ... 207
Kerkar S (abst) ... 243
Keshaviah P (abst) ... 158, 165
Khanna R (abst) ... 179
Kherlakian G (abst) ... 142
Khirabi BS (abst) ... 257
Kiesel G (abst) ... 269
Kim CH (abst) ... 182
Kim D (abst) ... 181
Kim JK (abst) ... 328
Kim Y: *see* Melvin et al ... 685
Kimes A (abst) ... 232
Kimmel PL (abst) ... 343
Kimura G (abst) ... 193
King LR (abst) ... 142
Kinne R (abst) ... 279
Kinter LB (abst) ... 295
Kirby RG (abst) ... 191
Kirchner KA (abst) ... 259, 261
Kirk K (abst) ... 303
Kirk KL (abst) ... 328
Kirkendol PL (abst) ... 165
Kirkman RL (abst) ... 349
Kirschbaum BB (abst) ... 329
Kirschenbaum MA (abst) ... 259
Kiss A-L: *see* Lemieux et al ... 908
Kjellstrand C (abst) ... 143
Klahr S (abst) ... 198, 244, 247, 270
Kleeman CR (abst) ... 143
Kleeman K (abst) ... 198
Kleinert H (abst) ... 105
Kleinert HD (abst) ... 202, 316
Kleinert HD: *see* Maack et al ... 607
Kleinfeld M (abst) ... 320
Kleinman KS (abst) ... 296
Kleyman TR (abst) ... 313
Kliger A (abst) ... 338
Klimas V (abst) ... 159
Klippel J (abst) ... 204
Klok MA (abst) ... 164
Klose R (abst) ... 241
Klotman PE (abst) ... 253, 339
Klotz LH (abst) ... 151, 351
Kluge R (abst) ... 135
Kluin K (abst) ... 128
Knauss TC (abst) ... 252, 259
Knepper M (abst) ... 289
Knepper MA (abst) ... 282, 321
Knochel JP: Complications of total parenteral nutrition (Editorial Review) ... 489
Knopp LC (abst) ... 231
Knox FG (abst) ... 109, 117, 306, 309, 318, 326
Knutson DW (abst) ... 218, 224
Koch KM (abst) ... 338
Koepke JP (abst) ... 194
Koeppen BM (abst) ... 313
Koerner J (abst) ... 300
Koffler A (abst) ... 168
Koh SW (abst) ... 183
Kohan R: *see* Baczynski et al ... 718
Kohen J (abst) ... 143
Kohrs MB (abst) ... 168
Kojima S (abst) ... 193
Kokko JP (abst) ... 278
Kokko JP: Primary acquired hypoaldosteronism (Nephrology Forum) ... 690
Kol R: *see* Goligorsky et al ... 774
Kon V (abst) ... 232, 337
Kondur R (abst) ... 164
Kongcharden S (abst) ... 225
Kopp UC (abst) ... 313
Kopple J (abst) ... 167, 233
Kopple JD (abst) ... 135, 253
Kopyt N (abst) ... 143
Koretsky AP (abst) ... 273, 277, 313
Korkor AB (abst) ... 119
Korsak R (abst) ... 250
Kortas C (abst) ... 133
Koshy V (abst) ... 215
Kostianovsky M (abst) ... 213
Kotchen T (abst) ... 322
Kotchen TA (abst) ... 192, 197
Koudstaal J: *see* Grond et al ... 405
Koulentianos E (abst) ... 352
Kovan J (abst) ... 158
Kovithavongs T (abst) ... 343, 345
Kownacki JJ (abst) ... 259

Kozeny GA (abst) 119, 140
Kramer HJ (abst) 194
Kramer M (abst) 145
Kramer MS (abst) 170
Kramer NC (abst) 343
Kraus AP (abst) 178, 181
Kraus LM (abst) 181
Kraut JA (abst) 110, 121, 168
Krawiec DR (abst) 143, 237
Kreis H: *see* Wolff et al 469
Kreisberg J (abst) 106
Kreisberg JI (abst) 236, 237, 259, 269, 323
Kreisberg R (abst) 238
Krensky AM (abst) 215
Krevolin LE (abst) 157
Krishna G (abst) 143, 250
Krishna GG (abst) 143
Kristensen C (abst) 144, 314
Kriz W (abst) 309
Kronfol NO (abst) 232
Krothapalli R (abst) 132, 323
Krous HF (abst) 154
Krueger TC (abst) 350
Kucharczyk J (abst) 284
Kücherer H: *see* Zimmerhackl et al 17
Kudelka S (abst) 267
Kuhn K (abst) 338
Kuhnline MA (abst) 294
Kumar AM (abst) 314
Kumar DN (abst) 181
Kumar V (abst) 137
Kumor K (abst) 232
Kunau RT (abst) 284
Kunis C (abst) 131
Kunkel RG: *see* Rehan et al 503
Kunneman M (abst) 330
Kupiec-Weglinski JW (abst) 347
Kuramochi M (abst) 193
Kurlander RJ (abst) 213
Kurnik BRC (abst) 119
Kurokawa K (abst) 286, 335
Kurtz TW (abst) 194, 196
Kurtzman NA (abst) 152, 168, 274, 283, 284, 287
Kusek A (abst) 178
Kuwata S (abst) 219
Kwong M (abst) 182
Kylander JE (abst) 212

Labelle EF (abst) 280
Lacour B: *see* Roullet et al 420
Lagraone L (abst) 157
Laidlaw S (abst) 233
Lair M: *see* Bachelet et al 401
Lajeunesse D (abst) 329
Lam M (abst) 144
Lambert B (abst) 126
Lamm ME (abst) 210
Lamourex C (abst) 263
Lancman I (abst) 242
Landwehr DM (abst) 144, 340
Lang CA (abst) 134
Lang F (abst) 309
Lang HL (abst) 134
Lang RE (abst) 201, 260
Lange J (abst) 201
Langford HG (abst) 194
Langman C (abst) 116, 128
Langman CB (abst) 120
Lapierre L (abst) 174
Laradi A (abst) 126, 314
Laragh J (abst) 105
Laragh JH (abst) 199, 202, 316
Laragh JH: *see* Maack et al 607
Larsson S (abst) 314
László K: *see* Bálint et al 892
Laski ME (abst) 284
Latos D (abst) 144
Lau A (abst) 165
Lau K (abst) 166, 123, 128, 129, 200
Lauer A (abst) 241, 245
Laughry EG (abst) 120
Laungani G (abst) 138
Laureno R (abst) 141
Lautenschlager I: *see* von Willebrand et al 616
Laveri LA (abst) 240
Laveri LA: *see* Oken et al 871
Lawler RG: *see* Brem et al 51
Lawton W (abst) 260
Lazarus JM (abst) 161, 162
Lazarus M (abst) 127
Lazdunski M (abst) 281
Le Grimellec C (abst) 329
Leach W (abst) 139
Leahy A (abst) 260
Lear S (abst) 260
Lechene C (abst) 314
Leclerc YG: *see* Kaye et al 574
Lee C (abst) 274
Lee CH (abst) 183
Lee CO (abst) 315
Lee D (abst) 193
Lee DBM (abst) 120, 243, 331
Lee HB (abst) 182, 183
Lee HS (abst) 216
Lee J (abst) 120
Leehey DJ (abst) 145, 159, 164, 176
Leenhardt L (abst) 112
Lefavour G (abst) 304
Lefavour GS: *see* Brensilver et al 497
Legrimellec C (abst) 324
Lehto V-P: *see* von Willebrand et al 616
Lele P (abst) 245, 344
Lemann J (abst) 119, 121
Lemieux C: *see* Lemieux et al 908
Lemieux G, Kiss A-L, Lemieux C, Ibanez RJ, Aranda MR, Quenneville A: Renal tubular biochemistry during acute and chronic metabolic alkalosis in the dog . 908
Lemke JH (abst) 190
Leonard JC (abst) 193
Leriche N (abst) 204
Lerner A (abst) 145
Lerner AM (abst) 170
Lesavre P (abst) 218
Lessard L (abst) 276
Leveille M (abst) 174
Levi J (abst) 115
Levi M (abst) 121
Levi-Setti R (abst) 110
Leviel F (abst) 149, 278
Levin NW (abst) 137, 169, 274

Levin RI (abst) 235
Levine BS (abst) 121
Levine DZ (abst) 284
Levine M (abst) 242, 246, 250
Levine R (abst) 237
Levine SD (abst) 102, 334
Lew S (abst) 241, 245
Lewicki J (abst) 105, 258
Lewicki JA (abst) 202
Lewis EJ (abst) 134, 142, 214, 221, 222
Lewis SA (abst) 310
Lewis-Finch J (abst) 165
Leypoldt JK (abst) 251, 329
Li JB (abst) 251
Lianos E: *see* Alavi et al 411
Lianos EA (abst) 216
Lichter M (abst) 176
Liebau H (abst) 338
Lieberman E (abst) 201
Lifschitz M (abst) 160
Light JA (abst) 342
Lim C (abst) 131
Lim V (abst) 337
Lim VS (abst) 246
Lin HY (abst) 285
Lin J-T (abst) 315
Linares H (abst) 323
Linas SL (abst) 187, 195
Lindheimer M (abst) 314
Lindsay RM (abst) 100, 166, 175, 233
Lindstrom B: *see* Odlind et al 9
Ling K (abst) 237
Linker A (abst) 212
Linton AL (abst) 166, 175, 233
Lior H (abst) 131
Lipkowitz MS (abst) 315
Lisby SM (abst) 178
Litkowski (abst) 150
Litwack G (abst) 265
Liu CT (abst) 301, 315, 333
Llach F (abst) 114, 121, 125, 169, 182
Llach F: *see* Wilson et al 565
Lobatto S (abst) 225
Loertscher R (abst) 344
Loewenherz JW (abst) 145
London G (abst) 159
London G: *see* de Vernejoul et al 785
Lopez S (abst) 122, 173
Lorch JA: *see* Brensilver et al 497
Lordon RE (abst) 344
Lorenzen M (abst) 315
Loschiavo C: *see* Oldrizzi et al 553
Lotan D (abst) 218
Loutzehniser R (abst) 297, 307
Loveluck RJ (abst) 144
Lowder GM (abst) 145
Lowe AG (abst) 285
Lowenstein J (abst) 195
Lowenstein LM (abst) 236, 262
Lu DSK (abst) 210
Luban NLC (abst) 220
Lubansky H (abst) 288
Lucas BA (abst) 344
Luden JH (abst) 268
Lufburrow RA (abst) 310
Luft F (abst) 201, 260
Luft FC (abst) 195
Luft FC: *see* Kenner et al 739
Lui FYH (abst) 146
Luke RG (abst) 264, 279, 308, 316, 339
Luke RG: *see* Holland et al 46
Lumlertgul D (abst) 246
Lund BJ (abst) 128
Lund K (abst) 167
Lupo A (abst) 246
Lupo A: *see* Oldrizzi et al 553
Lymangrover JR (abst) 191
Lynn RI (abst) 173

Maaba M (abst) 214
Maack T (abst) 105, 202, 316
Maack T, Camargo MJF, Kleinert HD, Laragh JH, Atlas SA: Atrial natriuretic factor: Structure and functional properties (Editorial Review) 607
Maayan ML (abst) 166
Maayan MM (abst) 125
MacCarthy EP (abst) 216
MacDonnel RM (abst) 350
MacDougall M (abst) 166, 301
Mackenzie HS, Morrill AL, Ploth DW: Pressure dependence of exaggerated natriuresis in two-kidney, one clip Goldblatt hypertensive rats 731
MacKenzie TA (abst) 166
MacLaren C (abst) 167
Madaio MP (abst) 216
Madias NE (abst) 110
Madias NE, Wolf CJ, Cohen JJ: Regulation of acid-base equilibrium in chronic hypercapnia 538
Madsen KM (abst) 103
Madubuko GC (abst) 181
Maesaka JK (abst) 340
Maggiore Q (abst) 167
Magott M (abst) 109
Magott M: *see* Baczynski et al 718
Mahajan SK (abst) 345
Mahan J: *see* Sibley et al 544
Mahan JD (abst) 217
Maher JF (abst) 182
Maheux P (abst) 263
Mahnensmith RL (abst) 316
Maier B (abst) 349
Maierhofer WJ (abst) 342
Maierhofer WU (abst) 121
Mailoux L (abst) 133, 178
Majumdar APN (abst) 245
Makker SP (abst) 223
Makoff R (abst) 246, 250
Malangone J (abst) 167
Malavasi F (abst) 207
Malluche HH (abst) 114, 122, 137, 161
Malnic G (abst) 279
Maloney NA (abst) 148
Malseptic RM: *see* Brensilver et al 497
Mandal AK (abst) 233
Mandel LJ (abst) 271, 275, 308
Mandin H: *see* Masri et al 807
Mann R (abst) 208, 217, 219, 240
Manna S (abst) 268
Manohar NL (abst) 233
Manzini C (abst) 133

Mar G (abst) 245
Marchais S (abst) 159
Marchais S: *see* de Vernejoul et al 785
Marck B (abst) 273
Marin-Grez M (abst) 261
Marinelli K (abst) 220
Marino R (abst) 321
Marion DN (abst) 316
Markell M (abst) 313
Marks E (abst) 190
Maroni B (abst) 155
Maroni BJ (abst) 273
Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure 58
Mars D (abst) 150
Marshall WG (abst) 146
Marti- C (abst) 261
Marti.. D (abst) 250, 278
Martin K (abst) 116, 122, 165, 198
Martin KJ (abst) 109
Martineau A (abst) 256
Martinez E (abst) 241
Martinez-Maldonado M (abst) 231
Martino JA (abst) 166, 285
Martinzez-Hefnandez A (abst) 208
Marumo F (abst) 174, 329
Marver D (abst) 285
Maryniak R (abst) 155
Maryniak RK, First MR, Weiss MA: Transplant glomerulopathy: Evolution of morphologically distinct changes 799
Marzec-Calvert R (abst) 195
Maschio G (abst) 128, 246
Maschio G: *see* Oldrizzi et al 553
Mason J (abst) 234
Masri MA, Boyd ND, Mandin H: Role of fibrinogen in the glomerular permeability of the perfused, isolated dog kidney (Technical Note) 807
Massry SG (abst) 109, 126, 176, 226, 242, 314
Massry SG: *see* Baczynski et al 718
Masur SK (abst) 330
Mathew M (abst) 245
Matsor G (abst) 270
Matsuo S (abst) 207, 217
Matter G (abst) 139
Matthys E (abst) 106
Matzke GR (abst) 146, 163
Mauer SM (abst) 135, 209, 348
Mauer SM, Steffes MW, Brown DM: Effects of mesangial localization of polyvinyl alcohols on glomerular basement membrane thickness 751
Mauer SM: *see* Sibley et al 544
Mavichak V (abst) 127, 129
Maxwell DR (abst) 132
Maxwell MH (abst) 143
May R (abst) 229
May RC (abst) 274
Mayor G (abst) 128, 158, 231, 238
McAteer JA (abst) 330
McCarron D (abst) 122, 193, 195, 196, 200, 202
McCarron DA (abst) 127, 140
McCauley CR (abst) 341
McClung DE (abst) 203
McCluskey RT (abst) 213, 224
McConkey C (abst) 109
McCoy RN (abst) 294, 297
McCrory WW (abst) 343, 347
McCullough A (abst) 249
McCullough K (abst) 232
McDevitt HO (abst) 100
McDonald FD (abst) 160, 254, 260, 345
McGarry L (abst) 264
McGloin C (abst) 167
McKay C (abst) 111
McKenna BA (abst) 146, 148, 296
McKenna BA: *see* Hursh et al 898
McKeown JW (abst) 120, 122
McKinney TD (abst) 327, 330, 332
McLeish KR (abst) 217
McMichael C (abst) 158
McMoran A (abst) 335
McNeil JS (abst) 234, 258
McNeil K (abst) 185
McRae-Degueurce A (abst) 191
McVicar M (abst) 178
Meggs LG (abst) 247
Meglin NJ (abst) 112
Mehandru S (abst) 131
Mehandru SK (abst) 147
Mehta BR (abst) 337
Mehta RL (abst) 218
Meier KE (abst) 317
Meijer S (abst) 237
Mela-Riker L (abst) 227
Melvin TR, Kim Y, Conley ME, Delacroix DL, Michael AF: Hidden IgA subclass determinants in human renal disease (Technical Note) 685
Melzer J (abst) 337, 339, 349
Meng RL (abst) 146
Mento P (abst) 269, 297, 298
Mercier O (abst) 278
Merrill RH (abst) 196
Mestecky J (abst) 210
Metcoff J (abst) 182
Mettauer B (abst) 133
Metz J (abst) 122, 193
Meunier PJ: *see* Charhon et al 426
Meyer R (abst) 296
Meyer TW (abst) 247, 252, 295
Michael AF: *see* Melvin et al 685
Michael UF (abst) 169
Michaud L (abst) 208
Michelis MF (abst) 181
Middendorf DF (abst) 147
Miettinen A (abst) 218
Migdal S (abst) 345
Migliori P (abst) 345
Miki K: *see* Imai et al 756
Milanes CL, Jamison RL: Effect of acute potassium load on reabsorption in Henle's loop in chronic renal failure in the rat 919
Miles E: *see* Hursh et al 898
Millard K (abst) 221
Miller J (abst) 210
Miller JH (abst) 174
Miller ML (abst) 105
Miller RT (abst) 287
Miller-Diener A (abst) 265
Milliner DS (abst) 148, 180

Millington DS (abst) 126
Mills GM (abst) 115
Mills JW: *see* Rapoport et al 726
Mills M (abst) 211
Mills S (abst) 117
Milner LS (abst) 214, 218
Minuth W (abst) 309
Miranda B (abst) 199
Miravet L (abst) 159
Miravet L: *see* de Vernejoul et al 785
Misefari V (abst) 167
Mishler DR (abst) 121
Misler S (abst) 316
Mitch W (abst) 155, 229
Mitch WE (abst) 193, 273, 274
Mitch WE: *see* Maroni et al 58
Mitchell LD (abst) 191
Mitchell P (abst) 286
Mitro R (abst) 123
Mittman N (abst) 160
Mitwalli A (abst) 183
Miura AB: *see* Imai et al 756
Miyazawa H (abst) 247, 270
Mize GN (abst) 233
Moel D (abst) 152, 261
Molina RB (abst) 139
Molitoris BA (abst) 121, 234
Moller G (abst) 207
Molony DA (abst) 317
Moncada S (abst) 254
Mongeau JG (abst) 192
Montani JP (abst) 192
Monteon F (abst) 167
Montiero RC (abst) 218
Moody ML (abst) 234
Mookerjee BK (abst) 327
Mookerjee BK: *see* Alavi et al 411
Moore H (abst) 179, 183
Moore J (abst) 133, 235, 341
Moore LC (abst) 330
Moore T (abst) 222
Mora EC (abst) 160
Moran A (abst) 285
Moran M (abst) 235
Moran N (abst) 285
Moran SM, Myers BD: Course of acute renal failure studied by a model of creatinine kinetics 928
Moreau JF (abst) 118
Morelli H (abst) 138
Morgan VE (abst) 284
Morgenstern B (abst) 177
Morieux C: *see* de Vernejoul et al 785
Morodian J (abst) 350
Morone T (abst) 262
Morres DN (abst) 342
Morrill AL: *see* Mackenzie et al 731
Morris C (abst) 196, 200
Morris CD (abst) 140
Morris RC (abst) 194, 196
Morris T (abst) 146
Morris TW (abst) 296
Morrison AR (abst) 265
Morrison G (abst) 127
Morrissey JJ (abst) 123
Moss N (abst) 187
Mossey R (abst) 296
Mountz JD (abst) 105
Mueller R (abst) 261
Muirhead EE (abst) 198
Mujais SK (abst) 229, 274
Mullen JP (abst) 112
Muller J (abst) 332
Muller-Suur R (abst) 317
Mummaw N (abst) 238
Mundo A (abst) 167
Mundy GR (abst) 103
Murayama N (abst) 261, 333
Murdaugh S (abst) 275
Murphy RP (abst) 155
Murphy WM (abst) 154
Murray BM (abst) 262, 346
Murray RD (abst) 317
Murray RD: *see* Itoh et al 762
Mushinski JF (abst) 105
Myers BD (abst) 235, 250
Myers BD: *see* Moran et al 928

Na H (abst) 182
Nadler RJ (abst) 253
Nadler SP (abst) 331
Nagami GI (abst) 286
Nagineni CN (abst) 331
Nahum H (abst) 149
Najarian J (abst) 345
Najarian JS (abst) 348
Nakagawa Y (abst) 314
Nakagawa YN (abst) 251
Nakamoto S (abst) 159
Nakamoto Y: *see* Imai et al 756
Nakamura KT (abst) 297
Nakhoul NL (abst) 286
Nally JV (abst) 191, 196
Nance WE (abst) 144
Nanninga JB (abst) 274
Narang N (abst) 308
Narasimhan N (abst) 147
Narins RG (abst) 283
Narkates AJ (abst) 263
Nasri H (abst) 247
Nast CC (abst) 135
Nath KA (abst) 248
Navar LG (abst) 263
Nawab ZM (abst) 159, 164, 168
Neale TJ: *see* Tipping et al 530
Nebeker HG (abst) 147, 148, 180
Needleman P (abst) 104, 294
Neff MS (abst) 157
Negri AL (abst) 235
Neiders M (abst) 204
Neild G (abst) 345
Neilson E (abst) 208, 215, 217, 219, 240
Neilson EG (abst) 179
Nelson D (abst) 169
Nelson P (abst) 185
Nelson-Worel J (abst) 149
Nesbit R (abst) 164
Nesser D (abst) 342
Neu HC (abst) 138
Neu KM (abst) 113
Neugarten J (abst) 248

Neumayer HH (abst) 235
Nevarez MD (abst) 185
Nevins TE (abst) 348
Newmark KJ (abst) 142
Newton DE (abst) 269
Niblack G (abst) 350
Nicastri A (abst) 149
Nicastri AD (abst) 150
Nicholls K (abst) 148, 154
Nicholson JP (abst) 199
Nielsen JT, Christensen EI: Basolateral endocytosis of protein in isolated perfused proximal tubules 39
Nielsen LH (abst) 183
Nisengard R (abst) 204
Nishi T (abst) 219
Nishio T (abst) 140
Nissenson AR (abst) 183
Noble B (abst) 207, 248
Noda Y, Takada Y, Erdös EG: Activation of human and rabbit prokallikrein by serine and metalloproteases .. 630
Noddin JL (abst) 252
Noël LH (abst) 218, 219
Nolph KD (abst) 179, 183
Nord EP (abst) 249, 257, 317
Noreen H (abst) 345
Norman AW (abst) 226
Norman DJ (abst) 346
Norris KC (abst) 169, 174
Norris SH (abst) 168
Northrup T (abst) 123
Norwood K (abst) 173
Nosaka K (abst) 219
Notohamibrodjo M (abst) 307
Novick AC (abst) 190
Nowak TM: *see* Hursh et al 898
Nunley R (abst) 207
Nunn AW (abst) 252

Oberleithner H (abst) 309
O'Brien M (abst) 185, 186
O'Brien M (abst) 343
Odell G (abst) 202
O'Dell-Smith RM (abst) 306
Odlind B, Hällgren R, Sohtell M, Lindström B: Is ^{125}I iothalamate an ideal marker for glomerular filtration?.. 9
O'Donnell MP (abst) 245, 297
Oettinger CW (abst) 168, 169
Offerman JJG (abst) 236
Ogden DA (abst) 169
Ogilvie R (abst) 182, 183
Ogino T (abst) 302
Oh MS (abst) 149
O'Hara DS (abst) 193
Ohlstein EH (abst) 197
Ohman LE (abst) 191
Oken DE (abst) 232, 240
Oken DE, Wolfert AI, Laveri LA, Choi SC: Effects of intra-animal nephron heterogeneity on studies of glomerular dynamics 871
Oken KR (abst) 240
Okubo M (abst) 174
Olbricht CJ (abst) 331
Old CW (abst) 326
Old LJ (abst) 151, 351
Oldrizzi L (abst) 128, 246
Oldrizzi L, Rugiu C, Valvo E, Lupo A, Loschiavo C, Gammaro L, Tessitore N, Fabris A, Panzetta G, Maschio G: Progression of renal failure in patients with renal disease of diverse etiology on a protein-restricted diet 553
Oliver JC (abst) 168, 169
Oliver L (abst) 274
Olivetti G, Giacomelli F, Wiener J: Morphometry of superficial glomeruli in acute hypertension in the rat... 31
Olmer J (abst) 172
Olmer MJ: *see* Charhon et al 426
Olshan AR (abst) 157, 177
Olson D (abst) 236
Olson PL (abst) 163
O'Neil RG (abst) 319
Ooi BS (abst) 216
Ooi YM (abst) 216
Oparil S (abst) 263
Opgenorth T (abst) 312
Opgenorth TJ (abst) 305, 318, 326
Opsahl J (abst) 143
Ordonez J (abst) 150
Oreopoulos DG (abst) 182, 183, 184, 185
Osborn JL (abst) 197
Osgood RW (abst) 197, 294, 297
Oshima T (abst) 104, 194
Osikowska B (abst) 292
Oster JF (abst) 286
Oster JR (abst) 290
Otsuka DC (abst) 251
Ott C (abst) 322
Ott CE (abst) 197
Ott SM (abst) 148
Ott TW (abst) 274
Ottensmeyer FP (abst) 239
Overhage JM (abst) 191

Pabico RC (abst) 146, 148, 296
Pabico RC: *see* Hursh et al 898
Pacholski M (abst) 324
Pacholski M: *see* Brem et al 51
Paddock JK (abst) 236, 262
Pae H (abst) 259
Paganini EP (abst) 159
Pahilan AN (abst) 132
Paielli D (abst) 274
Paillard M (abst) 149, 278
Painter P (abst) 149
Paller MS (abst) 262, 346
Palmer D (abst) 136
Palmisano J (abst) 286
Palumbo MJ (abst) 160
Pang PKT (abst) 176
Pantelos G (abst) 236
Panzetta G: *see* Oldrizzi et al 553
Papadakis MA (abst) 149
Papadea C (abst) 225
Pardo V (abst) 241
Parekh N: *see* Zimmerhackl et al 17
Parfrey PS (abst) 340, 346
Park CH (abst) 331
Park EK (abst) 248
Park HS (abst) 183
Parker TP (abst) 161
Parnell S (abst) 169

Parra G (abst) 219
Pasko MT (abst) 159
Patchin D (abst) 230
Patel Y (abst) 106, 236
Patz A (abst) 155
Paunier L (abst) 142
Payne W (abst) 345
Paz-Martinez V (abst) 243
Pearson JE (abst) 165
Pechan BW (abst) 342
Pedersen O, Schmitz O, Hjøllund E, Richelsen B, Hansen HE: Postbinding defects of insulin action in human adipocytes from uremic patients 780
Pederson J (abst) 169, 182
Pedraza-Chaverri J (abst) 262
Pelayo JC (abst) 298
Pena JC (abst) 262
Penning J (abst) 261
Pennline KJ (abst) 220
Perkins SK: *see* Ruder et al 768
Perkinson D (abst) 204
Perloff JK (abst) 151
Perras ST (abst) 186
Perrone SD (abst) 263
Perry GJ (abst) 198
Persson AEG (abst) 292, 298, 299
Perzanowski C (abst) 163
Pesigan M (abst) 200
Peters CJ (abst) 301, 315
Petersen B (abst) 186
Petersen W (abst) 185
Peterson LN (abst) 184
Peterson P (abst) 344
Peterson PK (abst) 232
Petraglia A (abst) 118
Petric M (abst) 131
Pettinger WA (abst) 262, 266, 268
Pettit J (abst) 185
Petzel DH (abst) 263
Pezzullo J (abst) 167
Phadke K (abst) 149, 350
Phanouvong T (abst) 193
Philips T (abst) 343
Phisphumuithi P (abst) 225
Picache AA (abst) 145
Pichlmayr R (abst) 338
Piering WF (abst) 342
Pierratos A (abst) 184
Piers-Becht TP (abst) 137
Piesco NP (abst) 205
Piette Y (abst) 174
Piper DJ (abst) 131, 151
Piraino B (abst) 123, 283
Pirani C (abst) 224
Pisano JJ (abst) 321
Pisetsky DS (abst) 213
Piskorska G (abst) 263
Pitcock JA (abst) 198
Pitts TO (abst) 123, 123, 124
Planelles G (abst) 287
Plant SB (abst) 127
Plante GE (abst) 263, 310
Plonk G (abst) 203
Ploth DW (abst) 198
Ploth DW: *see* Mackenzie et al 731
Polin RA (abst) 179
Polinsky M (abst) 177, 181
Pollak VE (abst) 169, 170, 213
Pollard RB (abst) 337
Pollock AS (abst) 287
Ponte M (abst) 304
Ponte ML: *see* Brensilver et al 497
Popovtzer MM (abst) 169
Port F (abst) 162
Porter C (abst) 220
Porter GA (abst) 139
Porush JG (abst) 172, 293
Posner JN (abst) 346
Potvin W (abst) 191
Poujeol P (abst) 276
Powell D (abst) 249
Prat J-J: *see* Roullet et al 420
Pratt RE (abst) 258
Preisig (abst) 332
Preston AS (abst) 332
Price PA (abst) 137
Prichard S: *see* Kaye et al 574
Prigent A (abst) 149, 278
Privette M (abst) 134, 150
Prud'homme M (abst) 174
Pukerson M (abst) 198, 244, 247
Pulliam JP (abst) 155
Puschett J (abst) 123
Puschett JB (abst) 112, 123, 124, 283

Quamme GA (abst) 124
Quebbemann AJ (abst) 228
Quenneville A: *see* Lemieux et al 908
Quinn J (abst) 260
Quinn R (abst) 236

Raasch RH (abst) 180
Rabin J (abst) 298
Rabinowitz L (abst) 318, 323
Rabito CA (abst) 124, 305
Rabkin R (abst) 273
Racusen LC, Finn WF, Whelton A, Solez K: Mechanisms of lysine-induced acute renal failure in rats 517
Raffelt M (abst) 235
Rahatzad M (abst) 147
Rahimizadeh H (abst) 257
Rahman MA (abst) 220
Raij L (abst) 187, 249
Raimondo J (abst) 177
Raja R (abst) 145, 339
Raja RM (abst) 170
Ram SJ (abst) 336
Ramsammy L (abst) 237
Ramsdell R (abst) 166
Ramsey KM (abst) 337
Ramwell PW (abst) 257
Rance PC: *see* Cattran et al 436
Randall P (abst) 300
Randazzo J (abst) 189
Rao KV (abst) 342

Rao M (abst) 154
Rao TKS (abst) 145, 150
Rapola J: *see* Autio-Harmainen et al 662
Rapoport J, Mills JW, Franki N, Church HH, Hays RM: Autoradiographic studies of solute transport across the toad bladder 726
Rapoport J: *see* Goligorsky et al 774
Rapp JP (abst) 198
Rapp N (abst) 122
Rasmussen H (abst) 230
Raum WJ (abst) 167
Raymond KH (abst) 327, 332
Rayson BM (abst) 318
Razma PE (abst) 170
Read K (abst) 177
Rees ED (abst) 192
Regnier FE (abst) 172
Rehan A (abst) 220
Rehan A, Johnson KJ, Kunkel RG, Wiggins RC: Role of oxygen radicals in phorbol myristate acetate-induced glomerular injury 503
Reid GM (abst) 199
Reif MC (abst) 332
Reinherz EL (abst) 106
Reisin E (abst) 165
Reisman L (abst) 343, 347
Reitz R (abst) 122, 137
Remuzzi G (abst) 100, 101
Renner J (abst) 153
Rennke HG (abst) 247
Rennke HG: *see* Groggel et al 643
Rennke HG: *see* Salant et al 938
Resnick LM (abst) 199
Retuta E (abst) 233
Reuben R (abst) 345
Revie D (abst) 150
Reyes MP (abst) 160
Ribadeneira M (abst) 303
Ribeiro C (abst) 287
Ricanati ES (abst) 170
Riccobono J (abst) 191
Richardson RMA (abst) 184
Richelsen B: *see* Pedersen et al 780
Richet G: *see* Hagege et al 3
Richie RE (abst) 350
Riera GS (abst) 124
Rifai A (ast) 221
Riggio RR (abst) 188, 338, 347, 350
Rightsel W (abst) 198
Riley KM (abst) 240
Risius B (abst) 159
Rissell MT (abst) 221
Risteli J: *see* Autio-Harmainen et al 662
Risteli L: *see* Autio-Harmainen et al 662
Ritchie SM: *see* Cattran et al 436
Ritz E (abst) 150, 307
Ritz R (abst) 225
Rivero D (abst) 330
Rives D (abst) 164
Roberson J (abst) 227, 234
Robert D (abst) 112
Roberts CE (abst) 174
Robertson CR (abst) 302
Robertson GL (abst) 145
Robillard JE (abst) 297
Robson M (abst) 170
Roch-Ramel F (abst) 333
Rocher LL (abst) 347
Rodela H (abst) 182, 183
Rodicio JL (abst) 199
Rodriguez GR (abst) 290
Rodriguez M (abst) 114, 121, 125, 169
Roe CR (abst) 126
Roedersheimer LR (abst) 142
Roholt OA (abst) 207
Roman RJ (abst) 298
Romanski RN (abst) 137
Romero JC (abst) 199, 312, 318, 326
Ronco P (abst) 221, 276
Ronstadt C (abst) 169
Rood KL (abst) 252
Root A (abst) 181
Rosansky SJ (abst) 151
Roscoe JM (abst) 184
Roscoe JM: *see* Cattran et al 436
Rosen S (abst) 107, 228, 238
Rosivall L (abst) 263
Rosman JB (abst) 137
Ross EA (abst) 151
Rossi NP (abst) 146
Rostand SG (abst) 264
Roth D (abst) 210
Roth E (abst) 218
Rouleau JL (abst) 133
Roullet J-B, Lacour B, Yvert J-P, Prat J-J, Drueke T: Factors of increase in serum triglyceride-rich lipoproteins in uremic rats 420
Rourke L (abst) 155
Rouse D (abst) 264, 333
Rowe JR (abst) 151
Rowe PH (abst) 153
Roy DR (abst) 125
Royse VL (abst) 180
Rubenstein AH (abst) 100
Rubenstein H (abst) 152
Rubin AL (abst) 188
Rubin J (abst) 184
Rubin JE (abst) 125, 166
Rubin M (abst) 347
Rubin RH (abst) 151, 351
Rubin SI (abst) 143, 237
Rudd MA (abst) 299
Ruddy MC (abst) 188, 199
Ruder MA, Alpert MA, Van Stone J, Selmon MR, Kelly DL, Haynie JD, Perkins SK: Comparative effects of acetate and bicarbonate hemodialysis on left ventricular function 768
Rudofsky U (abst) 223
Ruggles BT (abst) 261, 333
Rugiu C (abst) 128, 246
Rugiu C: *see* Oldrizzi et al 553
Ruilope LM (abst) 199
Runbin AL (abst) 338
Russell MW (abst) 210
Russell PS (abst) 351
Ryals C (abst) 193
Rydell D (abst) 200

Sabatini S (abst) ... 125, 165, 287
Sabatini S: Effect of cyclic AMP on acidification in the isolated turtle bladder ... 25
Sabbatini M: *see* Conte et al ... 792
Sablay LB (abst) ... 139
Sabnis S (abst) ... 200
Sabo C (abst) ... 284
Sachs H (abst) ... 152
Sacktor B (abst) ... 251, 309
Sadler J (abst) ... 150
Sadler JH (abst) ... 164, 175
Sagalowsky A (abst) ... 342
Saglikes Y: *see* Baczynski et al ... 718
Sahin A (abst) ... 352
Sahud M (abst) ... 153
Said R (abst) ... 152, 173
Saito T (abst) ... 267
Sakhrani LM (abst) ... 126, 314
Salant D (abst) ... 247
Salant DJ (abst) ... 209
Salant DJ, Adler S, Darby C, Capparell NJ, Groggel GC, Feintzeig ID, Rennke HG, Dittmer JE: Influence of antigen distribution on the mediation of immunological glomerular injury ... 938
Salant DJ: *see* Groggel et al ... 643
Salehmoghaddam S (abst) ... 249
Sallman A (abst) ... 288
Salmon JA (abst) ... 254
Salomon DR (abst) ... 347
Salusky IB (abst) ... 142, 180, 185
Salvatierra O (abst) ... 337, 339, 349
Sanders PW: *see* Holland et al ... 46
Sanders RP (abst) ... 315, 333
Sandroni S (abst) ... 148, 171
Saneii HH (abst) ... 268
Sanfilipp F (abst) ... 348
Sansom SC (abst) ... 319
Sapirstein V (abst) ... 330
Sargent I (abst) ... 250
Sarnacki P (abst) ... 115
Sastry KSS (abst) ... 274
Satlin LM (abst) ... 319
Satriano JA (abst) ... 264
Saubermann AJ (abst) ... 304, 319
Saunders M (abst) ... 196
Savin S (abst) ... 249
Savin VJ (abst) ... 299
Savory J (abst) ... 211
Sawanishi K (abst) ... 140
Sawyer DB (abst) ... 306, 319
Scaduto RC (abst) ... 275
Scakin H (abst) ... 318
Schacht RG (abst) ... 248
Schaefer RM (abst) ... 171
Schafer JA (abst) ... 320, 328, 332, 336
Schambelan M (abst) ... 146
Scharschmidt L (abst) ... 264
Schechter N (abst) ... 338
Scheid J (abst) ... 152, 271
Scheid VL (abst) ... 304, 319
Scheinman JI (abst) ... 126
Scheinman SJ (abst) ... 255
Schieppati A (abst) ... 247
Schilb TP (abst) ... 172
Schild L (abst) ... 333
Schiller A (abst) ... 127
Schilling H (abst) ... 183, 185
Schleich T (abst) ... 270
Schleifer CR (abst) ... 177
Schlondorff D (abst) ... 264, 334
Schlondorff D: *see* Baud et al ... 855
Schlueter W (abst) ... 152
Schmidt M (abst) ... 171
Schmitz O: *see* Pedersen et al ... 780
Schnaper HW (abst) ... 222
Schneeberger EE (abst) ... 224
Schneider HW (abst) ... 147
Schnermann J (abst) ... 261, 293
Schoenberg L (abst) ... 341
Schoeppe W (abst) ... 171
Schollmeyer P (abst) ... 175, 267, 349
Schonfeld J (abst) ... 194
Schoolwerth AC (abst) ... 271, 275
Schreiber M (abst) ... 249
Schreiber MJ (abst) ... 135
Schreiner GE (abst) ... 257
Schreiner GF (abst) ... 222, 257
Schrier R (abst) ... 148, 154, 226, 237, 246
Schrier RW (abst) ... 121, 135, 229, 234, 326, 328, 348
Schubert G (abst) ... 261
Schuler F (abst) ... 123
Schulman G (abst) ... 127, 162, 265
Schultz TW (abst) ... 157
Schuster VL (abst) ... 288, 321
Schwab SJ (abst) ... 126
Schwartz AB (abst) ... 157, 177
Schwartz EN (abst) ... 153
Schwartz GJ (abst) ... 288, 319
Schwartz J (abst) ... 348
Schwartz K (abst) ... 158
Schwartz MM (abst) ... 134, 142, 221, 222
Schwertschlag U (abst) ... 252
Schwertz DW (abst) ... 237
Scicli AG (abst) ... 317
Scoble JE (abst) ... 334
Scribner BH (abst) ... 186
Sebastian A (abst) ... 146
Sedensky J (abst) ... 171
Sedman A (abst) ... 153
Sedor J (abst) ... 265
Sedor JR (abst) ... 222
Seely JF: *see* Burnatowska et al ... 864
Segre G (abst) ... 118, 123
Seifter JL (abst) ... 291, 310, 336
Seiler R (abst) ... 223
Sellitto RC (abst) ... 166
Sellitto RV (abst) ... 125
Selmon MR: *see* Ruder et al ... 768
Seney FD (abst) ... 299
Sensibar J (abst) ... 274
Serra RM (abst) ... 271
Sethi K (abst) ... 200
Sever P (abst) ... 292
Sexton J (abst) ... 213
Shah I (abst) ... 171
Shah SV (abst) ... 205, 238
Shaib J (abst) ... 167
Shaker R (abst) ... 320
Shankel SW (abst) ... 153
Shanley P (abst) ... 107, 238

Shapiro H (abst) 142
Shapiro HM (abst) 344
Shapiro J (abst) 311
Shapiro JI (abst) 229, 348
Shapiro M (abst) 148, 154, 242, 246, 250
Shapiro RJ (abst) 250
Shapiro W (abst) 165
Shapiro WB (abst) 172
Sharma HM (abst) 136
Shavelle HS (abst) 153
Shay R (abst) 283
Shayman JA (abst) 265
Sheahan MM (abst) 341
Shelp W (abst) 149
Shemesh O (abst) 250
Shen S (abst) 150, 346, 348
Shen TY (abst) 267
Sherlock J (abst) 172
Sherman RA (abst) 174
Sherman SS (abst) 197
Sherrard DJ (abst) 148, 168
Sherrill K (abst) 126
Shettigar UR (abst) 244
Shihab-Eldeen A (abst) 158, 172
Shimada H (abst) 174
Shimamura T (abst) 340
Shinaberger JH (abst) 174, 176
Shneidman R (abst) 202
Shuffield J (abst) 289
Shulman RG (abst) 302
Shultz P (abst) 265
Shusterman N (abst) 127
Sibbald WJ (abst) 166, 175
Sibley RK, Mahan J, Mauer SM , Vernier RL: A clinicopathologic study of forty-eight infants with nephrotic syndrome 544
Sica DA (abst) 168
Siccion Z (abst) 185
Siddhanta A (abst) 268
Siebens AW (abst) 288
Siegel NJ (abst) 230
Sillix DH (abst) 172
Silva F (abst) 126, 223
Silva P (abst) 107, 228, 238, 260, 265, 266, 291
Silverman M (abst) 201, 334
Silvers W (abst) 215
Simenhoff ML (abst) 243, 245
Simmons RL (abst) 345, 348
Simon E (abst) 250
Simon F (abst) 234
Simon FR (abst) 121
Simon GT (abst) 239
Simon SA (abst) 308
Simonson DC (abst) 136
Simonson M (abst) 256
Simpson E (abst) 104, 266
Singh AK (abst) 223
Singhal PC (abst) 173
Sirois P (abst) 263
Sirota RA (abst) 177
Sisson SP (abst) 217
Skelton MM (abst) 202
Skorecki K (abst) 323
Skorecki KL (abst) 336
Slatopolsky E (abst) 109, 110, 111, 116, 122, 129, 142, 165, 173
Sleight S (abst) 238
Sleyffer DT (abst) 236
Slifkin RF (abst) 157
Sloan RS (abst) 195
Sloand JA (abst) 224
Sluiter WJ (abst) 137, 300
Smead WL (abst) 212
Smith A (abst) 137
Smith CL (abst) 144
Smith CR (abst) 220
Smith D (abst) 111, 338
Smith HR (abst) 105
Smith J (abst) 254
Smith LA (abst) 313
Smith M (abst) 304
Smith TW (abst) 193
Smolens P (abst) 238
Smyth DD (abst) 262, 266, 268
Snowdowne KW (abst) 114
So SKS (abst) 348
Soderblom RE (abst) 183
Soeldner C (abst) 117
Sohtell M: *see* Odlind et al 9
Solez K (abst) 206, 233
Solez K: *see* Racusen et al 517
Solomon R (abst) 265, 266
Soltoff SP (abst) 275
Sonke P (abst) 297, 307
Sonnenberg H (abst) 105
Sonu CM (abst) 286
Soowamber B (abst) 276
Sorger M (abst) 194
Soroka C (abst) 264
Southwest Pediatric Nephrology Study Group: A clinical-pathologic study of crescentic glomerulo-nephritis in 50 children. A report 450
Southwest Pediatric Nephrology Study Group: Continuous ambulatory and continuous cycling teritoneal dialysis in children. A report 558
Southwest Pediatric Nephrology Study Group: Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome. A report 442
Spalding CT (abst) 185
Spargo BH (abst) 216
Specht HD (abst) 139
Speck J (abst) 171
Speck JP (abst) 160
Spector D (abst) 232, 251
Spees EK (abst) 348
Spencer P (abst) 232
Spiegel N (abst) 249
Spielman WS (abst) 291
Spital A (abst) 320
Spitzer A (abst) 314
Spitzer E (abst) 239
Spokes K (abst) 228, 238
Spotswood M (abst) 210
Spragg J (abst) 163
Spring KR (abst) 334
Springer TA (abst) 215
Spry LA (abst) 275
Sraer J: *see* Baud et al 855
Sraer J-D (abst) 266

Sraer J-D: *see* Baud et al 855
Srirasanosomboon L (abst) 225
St-Louis G (abst) 174
St-Pierre S (abst) 310
Stabile B (abst) 176
Stabile C (abst) 337, 349
Stahl RAK (abst) 267, 349
Staley EC (abst) 301
Stanbaugh GH (abst) 173
Stanfel L (abst) 127, 129
Stanton B (abst) 103
Stanton BA: *see* Zalups et al 636
Stanton J (abst) 200
Stanton RC (abst) 127
Stanziale P: *see* Conte et al 792
Stapleton FB (abst) 154
Star R (abst) 289
Staros E (abst) 223
Stathakis H (abst) 352
Steblay RW (abst) 223
Steele TH (abst) 200
Steffes MW: *see* Mauer et al 751
Steffes W (abst) 135
Stein G (abst) 238
Stein HD (abst) 177
Stein JH (abst) 197, 294, 297
Steinberg AD (abst) 105
Steinberg BJ (abst) 105
Steinbert H (abst) 188
Steiner R (abst) 203, 349
Steinhausen M: *see* Zimmerhackl et al 17
Steinman RM (abst) 209
Steinman TI: *see* Maroni et al 58
Steinmetz PR (abst) 286, 289
Stenzel K (abst) 350
Stenzel KH (abst) 188, 338, 347, 350
Stephens MS (abst) 181
Stephenson R (abst) 280
Stelzer GT (abst) 217
Stern L, Backman KA, Hayslett JP: Effect of cortical-medullary gradient for ammonia on urinary excretion of ammonia 652
Sterns R (abst) 320
Stetson DL (abst) 286, 289
Stewart A (abst) 104
Stewart D (abst) 188
Stinson MW (abst) 204
Stivelman J (abst) 127, 162
Stoeppler M (abst) 150
Stokes JB (abst) 321
Stokes TJ (abst) 109
Stone DK (abst) 126, 289
Stoner LC (abst) 291
Stork JE (abst) 267
Stow JL (abst) 218
Strandhoy JW (abst) 301
Strange K (abst) 334
Strauss G (abst) 340
Strauss J (abst) 130
Strevey J (abst) 303
Strewler GJ (abst) 287
Striker G (abst) 204
Striker L (abst) 204
Strimel D (abst) 144
Strom TB (abst) 344, 249
Strugill BC (abst) 141
Strup A (abst) 350
Stubenbord WT (abst) 338, 347
Sturgill BC (abst) 138, 208, 224
Suarez-Isla BA (abst) 309
Subramanian L (abst) 171
Sudhof TC (abst) 126
Sugarman A (abst) 320
Sugimoto S (abst) 226
Suki WN (abst) 128, 264, 287, 333
Summer SN (abst) 328
Susin M (abst) 133
Suthanthiran M (abst) 338, 347, 350
Sutherland D (abst) 345
Sutton RAL (abst) 127, 129
Sutton RAL: *see* Burnatowska et al 864
Suzuki M: *see* Terao et al 951
Swartz R (abst) 128, 167
Sweeney WE (abst) 205
Sweet WD (abst) 201, 257
Sylva V (abst) 243
Sztorc D (abst) 284

Taddeo AR (abst) 236
Tago K (abst) 321
Takada Y: *see* Noda et al 630
Takahashi H (abst) 218, 224
Takaichi K (abst) 335
Takano T (abst) 275
Takeda K (abst) 267
Takekoshi Y (abst) 219
Tallent MB (abst) 350
Talor Z (abst) 288, 289, 335
Tannen RL (abst) 130, 152, 271, 290, 321
Tannenbaum J (abst) 268, 299
Tanner GA (abst) 231
Tapia L (abst) 188, 347, 350
Tarloff JB (abst) 335
Tasaki T (abst) 233
Tauc M (abst) 276
Taylor CJ (abst) 268
Teitelbaum I (abst) 253, 335
Teitelbaum S (abst) 116, 165
Tejani A (abst) 149, 154, 242, 350
Teller D (abst) 232, 251
Teplick R (abst) 135
Ter Wee JA (abst) 203
Ter Wee PM (abst) 300
Terao N, Suzuki M, Asano Y, Hosoda S: Enhanced reabsorption of bicarbonate and phosphorus by the addition of amino acids in the isolated perfused rat kidney (Technical Note) 951
Terribile M: *see* Conte et al 792
Terrier F (abst) 340
Tessitore N (abst) 128
Tessitore N: *see* Oldrizzi et al 553
Tetreault J: *see* Brem et al 51
Tetta C (abst) 206
Teubner E (abst) 110
Teulon J (abst) 287
Textor SC (abst) 156
Thaiss F (abst) 175, 267
The TH (abst) 225
Thippeswamy HP (abst) 324
Thoelken H (abst) 260

Thomas D (abst) 128
Thomas J (abst) 130
Thomas M: *see* Bachelet et al 401
Thomas SR (abst) 287
Thomasson D (abst) 255
Thome F (abst) 181
Thompson AM (abst) 342, 343
Thompson B (abst) 134
Thompson CI (abst) 291
Thompson R (abst) 150
Thompson RE (abst) 151, 351
Thornberry D (abst) 149
Thornhill T (abst) 127
Thulin G (abst) 230
Tiedemann K (abst) 322
Tilney NL (abst) 347
Tipping PG, Neale TJ, Holdsworth SR: T lymphocyte participation in antibody-induced experimental glomerulonephritis 530
Tisher CC (abst) 102, 331
Tobian L (abst) 201, 268
Todd RF (abst) 204
Tolkoff-Rubin NE (abst) 151, 351
Tomaszewski J (abst) 224
Tomford R (abst) 300
Tomita K (abst) 321
Tomoyoshi T (abst) 140
Toor P (abst) 184
Torhorst J (abst) 234
Torikai S (abst) 267
Torretti J (abst) 300
Toto R (abst) 268, 299
Trachtman H (abst) 149, 154, 350
Traeger J: *see* Charhon et al 426
Trigg D (abst) 250, 278
Trivedi B (abst) 290
Trizna W (abst) 249, 321
Tropp I (abst) 200
Troutman SL (abst) 320
Troy JL (abst) 252, 295
Troyer D (abst) 106
Truong L (abst) 224
Tsai CC (abst) 136
Tsai HC (abst) 341
Tsukamoto Y (abst) 128
Tuazon TV (abst) 224
Tuck ML (abst) 243
Tucker BJ (abst) 298
Tucker FL (abst) 224
Turner G (abst) 153
Turner M (abst) 201
Turner ST, Dousa TP: Phosphate transport by brushborder membranes from superficial and juxtamedullary cortex 879
Twardock AR (abst) 143
Tyson T (abst) 208

Uchida S (abst) 335
Uehara Y (abst) 268
Uhteg LC (abst) 347
Ulich TR (abst) 205
Ulm K (abst) 201
Ulmann A: *see* Bachelet et al 401
Umen A (abst) 347
Umermura S (abst) 262, 266, 268
Umetsu D (abst) 140
Unger T (abst) 201, 260
Updike S (abst) 185, 186
Uribarri J (abst) 137, 148

Vaamonde CA (abst) 286, 290
Vacca C (abst) 300
Valvo E: *see* Oldrizzi et al 553
Van Adelsberg J (abst) 290
Van Asbeck BS (abst) 232
Van Der Giessen M (abst) 225
Van Der Hem GK (abst) 225
Van Der Woude FJ (abst) 225
van Eps LWS: *see* de Jong et al 711
van Es LA: *see* de Heer et al 388
van Es LA (abst) 225
Van Liew JB (abst) 188, 248
Van Liew JB: *see* Alavi et al 411
Van Putten V (abst) 237, 242
Van Stone J (abst) 163
Van Stone J: *see* Ruder et al 768
Vanaman ME (abst) 212
Vanapruks V (abst) 225
Vance EE (abst) 330
Vandewalle A (abst) 276
Vari RC (abst) 201, 257
Vasquez E (abst) 273
Vaughn ED (abst) 202, 269, 316
Vaughn ED Jr: Renovascular hypertension (Nephrology Forum) 811
Vaughn WK (abst) 348
Vaustub S (abst) 257, 317
Veelken R (abst) 201
Velasquez MT (abst) 202
Velázquez H (abst) 322
Velez R (abst) 342
Venkatachalam MA (abst) 106, 206, 236, 237, 259, 269
Venuto RC (abst) 254, 338
Verani R (abst) 221, 341, 351
Vergne-Marini P (abst) 342
Verkman AS (abst) 236
Vernier RL: *see* Sibley et al 544
Vernier RL (abst) 217, 219
Vernillo A (abst) 215
Verroust P (abst) 221, 276
Vertuno LL (abst) 119, 140
Vester U: *see* Doehring et al 667
Veverbrandts E (abst) 152
Veverbrants E (abst) 173
Vidt DG (abst) 187, 190
Viet TP (abst) 276
Vigne P (abst) 281
Vignery A (abst) 104
Vinay P (abst) 174, 272, 276
Vincenti F (abst) 337, 339, 340, 349
Vincenzi F (abst) 196
Vinet B (abst) 174
Virtanen I: *see* von Willebrand et al 616
Volpe M (abst) 202
Volpert EM (abst) 125, 166
Von Albertini B (abst) 174, 176
Von Oeyen P (abst) 304
Von Riotte A (abst) 152, 202

von Willebrand E, Lautenschlager I, Inkinen K, Lehto V-P, Virtanen I, Häyry P: Distribution of the major histocompatibility complex antigens in human and rat kidney ... 616
Voyles WF (abst) ... 291

Wade J (abst) ... 306
Wade JB: *see* Zalups et al ... 636
Wagaman P (abst) ... 225
Wagner E (abst) ... 351
Wagner K (abst) ... 235
Wakabayashi Y (abst) ... 174
Wakatani K (abst) ... 104
Wakitani K (abst) ... 294
Walherr R (abst) ... 225
Walker JA (abst) ... 174
Walker JF (abst) ... 166, 175, 233
Walker KA (abst) ... 284
Walker PD (abst) ... 238
Walker VC (abst) ... 174
Walker WG (abst) ... 155
Wall SD (abst) ... 212
Wallace JH (abst) ... 217
Wallia R (abst) ... 283
Wallin J (abst) ... 255
Walling MW (abst) ... 120
Walser M: Phenomenological analysis of renal regulation of sodium and potassium balance (Editorial Review) ... 837
Walser MM (abst) ... 228
Walters F (abst) ... 239
Walzyck M (abst) ... 155
Wang F (abst) ... 312
Wang J (abss) ... 188, 242, 246
Wang N (abst) ... 250
Wang Y (abst) ... 110
Wanless I (abst) ... 183
Wanner C (abst) ... 175
Ward HJ (abst) ... 300
Warner HE (abst) ... 350
Warnock D (abst) ... 285
Warnock DG (abst) ... 287, 307
Warshaw BL (abst) ... 225
Wasserstein A (abst) ... 127
Wassner SJ (abst) ... 251
Watlington CO (abst) ... 169, 256, 258, 334
Watson AR (abst) ... 175
Watson KE (abst) ... 344
Waxman FJ (abst) ... 212
Weaver JC (abst) ... 153
Weaver M (abst) ... 109
Webb DE (abst) ... 336
Webster HK (abst) ... 225
Wedeen RP (abst) ... 206
Weerts C (abst) ... 173
Wegener L (abst) ... 195, 202
Weinberg JM (abst) ... 106, 231, 239
Weinberger MH (abst) ... 195
Weiner MW (abst) ... 273, 277, 313
Weinman EJ (abst) ... 113, 273, 328
Weinstein A (abst) ... 149
Weir E (abst) ... 104
Weir MR (abst) ... 164, 175, 346
Weise M (abst) ... 232
Weisinger JR (abst) ... 243
Weisman SM (abst) ... 269
Weismann WP (abst) ... 225
Weiss J (abst) ... 129
Weiss MA (abst) ... 155
Weiss MA: *see* Maryniak et al ... 799
Weiss RJ (abst) ... 251
Welch WJ (abst) ... 322
Welik R (abst) ... 150, 348
Welling DJ (abst) ... 322
Welling LW (abst) ... 322
Wells JO (abst) ... 203
Welsch J (abst) ... 234
Werness JL (abst) ... 261, 333
Wertheim SW (abst) ... 271
Wesson D (abst) ... 175
Wesson DE (abst) ... 281, 290
Westbrook S (abst) ... 117
Westbrook SL (abst) ... 334
Westenfelder C (abst) ... 228, 236, 239, 253
Whelchel JD (abst) ... 339
Whelton A: *see* Racusen et al ... 517
White C (abst) ... 256
White M (abst) ... 231, 239
White S (abst) ... 220
Whiteside C (abst) ... 301
Whittembury G (abst) ... 323
Widener LL (abst) ... 227
Wiegmann T (abst) ... 166, 301
Wiener J: *see* Olivetti et al ... 31
Wiggins RC (abst) ... 220, 226
Wiggins RC: *see* Rehan et al ... 503
Wiik A (abst) ... 225
Wijeyesinghe ECR (abst) ... 351
Wilcox C (abst) ... 155
Wilhelm MM (abst) ... 306, 319
Wilk BJ (abst) ... 276
Wilkes B (abst) ... 297
Wilkes BM (abst) ... 269, 293
Wilkin LD (abst) ... 191
Wilkinson R (abst) ... 351
Williams GM (abst) ... 206
Williams J (abst) ... 344
Williams JC (abst) ... 336
Williams S (abst) ... 351
Williamson F (abst) ... 264
Wills MR (abst) ... 111
Wilson CB (abst) ... 205
Wilson DJ (abst) ... 203
Wilson DR (abst) ... 239
Wilson L, Felsenfeld A, Drezner MK, Llach F: Altered divalent ion metabolism in early renal failure: Role of $1,25(OH)_2D$ ... 565
Wilson P (abst) ... 226
Wilson PD (abst) ... 106, 234, 252
Windhager EE (abst) ... 315
Windham J (abst) ... 191
Windham JP (abst) ... 196
Windus D (abst) ... 173
Windus DW (abst) ... 277
Wingo CS (abst) ... 322
Wingo CS: Cortical collecting tubules potassium secretion: Effect of amiloride, ouabain, and luminal sodium ... 886
Witztum J (abst) ... 250
Wold L (abst) ... 201
Wolf CJ: *see* Madias et al ... 538

Wolf J (abst) 129
Wolfe GA (abst) 176
Wolfe L (abst) 162
Wolfert AI (abst) 240
Wolfert AI: *see* Oken et al 871
Wolff DW (abst) 301
Wolff J-L, Beaurain G, Campos H, Kreis H, Chatenoud L, Bach J-F: Characterization of T cells cultured from fine needle aspirates of human renal allografts during rejection (Technical Note) 469
Wolfson B (abst) 181
Wolfson M (abst) 147
Womack A (abst) 299
Wong BM (abst) 156
Wong NLN (abst) 127, 129
Wong S (abst) 305
Wood D (abst) 337
Woodson L (abst) 203
Woodworth T (abst) 156
Wooles WR (abst) 196
Worcester EM (abst) 251
Work J (abst) 264, 336
Wray C (abst) 164
Wright FS (abst) 299
Wu G (abst) 182, 183, 185
Wu KJ (abst) 134
Wu SHW (abst) 233
Wyatt RJ (abst) 226
Wydner CJ (abst) 318, 323

Xuan A (abst) 273

Yaffe SR (abst) 301
Yamaguchi DT (abst) 176
Yamauchi H (abst) 318, 323
Yanagawa N (abst) 118, 129, 331
Yang E (abst) 262, 266
Yang MCM (abst) 176
Yang S (abst) 344
Yant T (abst) 176
Yang WC (abst) 156, 202
Yao SJ (abst) 134
Yared A (abst) 232, 247, 270, 337
Yarger WE (abst) 339
Yasuda T: *see* Imai et al 756
Yates J (abst) 198
Yee VJ (abst) 285
Yen MC (abst) 175
Yip C (abst) 284
Ynares CM (abst) 350
Yokouchi M (abst) 193
Yoo MH (abst) 182
Yoshioka T (abst) 270
Young JR (abst) 159
Young L (abst) 155
Ythier A (abst) 349
Yucha CB (abst) 291
Yudis M (abst) 177
Yusufi ANK (abst) 277, 306
Yvert J-P: *see* Roullet et al 420

Zabetakis PM (abst) 181
Zaccuri F (abst) 167
Zager PG (abst) 185
Zager RA (abst) 136, 147, 240
Zalups RK, Stanton BA, Wade JB, Giebisch G: Structural adaptation in initial collecting tubule following reduction in renal mass 636
Zappacosta AR (abst) 186
Zasuwa G (abst) 169
Zatz R (abst) 252
Zawada ET (abst) 203
Zegel HG (abst) 177
Zeidel ML (abst) 291
Zenser TV (abst) 239, 255, 275
Zerefos M (abst) 352
Ziegler M (abst) 203, 349
Ziemek H (abst) 177
Zikos D (abst) 123, 129, 200
Zilleruelo G (abst) 130
Zimmerhackl B (abst) 302
Zimmerhackl B, Parekh N, Kücherer H, Steinhausen M: Influence of systematically applied angiotensin II on the microcirculation of glomerular capillaries in the rat. 17
Zimmerman S (abst) 185, 186
Zingraff J (abst) 112, 118
Zink M (abst) 173
Zipser R (abst) 211, 233
Ziyadeh FN (abst) 130
Zonozi SM (abst) 200
Zoranski BS (abst) 177
Zorbas YG (abst) 156
Zucker SW: *see* Kaye et al 574
Zurier RB (abst) 179

Subject Index For Volume 27

Acetate
a. buffered solutions made in France (abst) 182
a. inhibits KCl-stimulated Ca influx in rat (abst) 176
antagonizes vasoconstriction by adrenergic agonists (abst) 176
comparison of *a.* tolerant or intolerant patients (abst) 161
comparison with bicarbonate as dialysate (abst) 168
effect on HD hemodynamics in non-anesthetized model (abst) 168
effect on left ventricular function in HD 768
inappropriate metabolism of *a.* in HD (abst) 174
sclerosing peritonitis on CAPD: *a.* vs. lactate 183
Acetazolamibe
acidification 25
inhibits exocytosis in turtle bladder (abst) 280
Acid handling
surface nephron *a.h.* during acidosis (abst) 278
Acid loading, oral
effect of amiloride on total CO_2 absorption (abst) 284
Acid-base balance
factors influencing *a.-b.b.* during IPD (abst) 184
Acid-base disorders
total parenteral nutrition, Editorial Review on 489
Acid-base equilibrium
chronic hypercapnia 538
Acidemia
anion gap, Nephrology Forum on 472
Acidification
cyclic AMP 25
role of HCO_3 and PCO_2 in rabbit (abst) 278
voltage regulation of carbonic anhydrase (abst) 287
Acidification defect
in obstruction uropathy 287
Acidosis
and volume expansion in hyporenin/hypoaldosteronism (abst) 285
prior potatassium depletion and *a.* changes in plasma (abst) 290
acute *a.*
effect on phosphate transport (abst) 121
lactic *a.*
amelioration of *l.a.* by *r.a.* or *m.a.* (abst) 130
anion gap, Nephrology Forum on 472
effect of NaDCA in hypoxic *l.a.* in rats (abst) 152
effects of $NaHCO_3$ therapy (abst) 139
metabolic *a.*
amelioration of lactic *a* by *m.a.* (abst) 130
ammonia production by proximal tubules (abst) 286
and insulin-mediated protein turnover (abst) 274
effect on surface calcium (abst) 110
effect on vitamin D synthesis (abst) 120
effects of vitamin D on calcium and phosphorus absorption (abst) 115
glutamate dehydrogenese and ammonia formation (abst) 270
in mineralocorticoid-resistant renal hyperkalemia (abst) 149
measurement of renal pH by 31P NMR (abst) 277
reduction of insulin binding (abst) 284
side effect of cyclosporine (abst) 349
organic *a.*
and hyperkalemia (abst) 148
pseudo-distal renal tubular *a.*
due to laxative abuse (abst) 152
respiratory *a.*
amelioration of lactic *a.* by *r.a.* (abst) 130
effect on bone composition (abst) 110
effect on intracellular pH in proximal tubule (abst) 290
influence on urinary calcium excretion (abst) 110
surface nephron handling of acid (abst) 278
Acquired Immune Deficiency Syndrome (AIDS)
AIDS associated with nephropathy (abst) 150
Acyclovir
effects on canine renal function (abst) 232
Adenine nucleotide metabolism
effects of verapamil after warm ischemia in kidney (abst) 229
Adenosine
action on conductivity in rabbit cortical collecting tubule (abst) 325
mediator in renal hemodynamics (abst) 291
receptors in renal tubules 255
Adenylate cyclase
action of vasopressin and forskolin (abst) 333
effect of renal α 2-adrenoceptor 262
effects of K deficiency and vasopressin (abst) 327
regulation in rectal gland of shark (abst) 312
Adenylate levels
effects of anoxia in thick ascending limb (abst) 271
Adipocytes
postbinding defects of insulin action 780
Adrenalectomy
and glucocorticoid replacement in loop of Henle (abst) 322
Adrenergic dysfunction
in uremia (abst) 247
α 2-adrenergic action
inhibition of fluid absorption in proximal tubules (abst) 333
α 2-adrenergic agonist
enhances Na-H antiport (abst) 317
α 2-adrenoceptor
depends on adenylate cyclase system activation (abst) 262
effects on renal vascular function (abst) 301
in isolated single nephron segments (abst) 268
renal tubular postsynaptic and extract synaptic (abst) 266
β adrenergic blockers
increased serum K, combined with Ca channel blockers (abst) 142
β adrenergic stimulation
effect on glomerular hemodynamics (abst) 298
Aging
effect on lysosome absorption and proteinase activity (abst) 331
physiological modifications in rat kidney (abst) 329
Aglutinin, wheat germ
effect on function of isolated perfused kidney (abst) 213

Alanine
amiloride inhibits transport in BBM (abst) 310
vasorelaxant effects of (abst) 159
Albumin
activities in perfused proximal tubule (abst) 331
excretion of (abst) 94
influence of ultrafiltration barrier (abst) 294
Albuminuria
effect of reduced dietary protein intake (abst) 141
effects of lower arterial pressur .n diabetes (abst) 252
Alcoholism, in rat
balance of calcium and phosphate (abst) 115
Alcoholization
ultrasonically guided fine-needle *a.* (abst) 98
Aldosterone
atypical action in target tissues (abst) 310
colonic *a.* receptor 265
effect on 3H-phenamil binding in toad bladder (abst) . . . 308
effect on Na and K excretion (abst) 323
extra-renal role in potassium intake (abst) 258
a.-induced proteins by chromatography (abst) 306
modulation of Na-K-ATPase by dietary K^+ (abst) 308
potassium excretion, Editorial Review on 379
potassium-*a.* axis in dogs with chronic renal insufficiency (abst) 242
reduced by synthetic atrial natriuretic factor (abst) 202
role in potassium secretion 886
role of angiotension II in sodium retention (abst) 318
transepithelial transport (abst) 51
plasma *a.*
effect of dopaminergic blockade (abst) 143
Alkalemia, severe
anion gap, Nephrology Forum on 472
Alkalinization
by depolarization of tubules in tiger salamander (abst) . 288
myeloma nephrotoxicity (abst) 46
Alkalinization, luminal
VIP is messenger for cAMP-dependent *l.a.* (abst) 278
Alkalosis
citrate reabsorption and utilization (abst) 271
chloride depletion *a.*
chloride as remedy (abst) 279
gastric *a.*
renal concentrating defect (abst) 284
metabolic *a.*
ADH (abst) 598
bicarbonate secretion by distal nephron (abst) 281
chronic and acute renal tubular biochemistry in dog . 908
glutamine (abst) 602
medullary bicarbonate gradients (abst) 281
morbidity and mortality of in hosp. patients (abst) . . . 131
role of cortical and medullary collecting tubules (abst) 102
role of GRF (abst) 102
role of proximal tubular bicarbonate reabsorption (abst) 102
symposium introduction (abst) 101
Alkalosis, respiratory
morbidity and mortality of in hospitalized patients (abst) 113
Allograft
morphological changes 800
Allograft, irradiated spleen
effector cells (abst) 595
Allograft, renal
de novo membranous glomerulonephropathy (abst) 224
phenotypic identification of lymphocytes (abst) 206
pregnancy (abst) 74
T cells, Technical Note on 469
cadaveric *r.a.*
presensitization by flow cytometry (abst) 337
rejection of *r.a.*
causal role of thromboxane (abst) 257
diagnosis by urinary assay for antigen (abst) 351
findings of sequential renal biopsies (abst) 341
humoral, clinico-pathologic correlation (abst) 350
insidius rejection in long-term *a.* recipients (abst) . . . 347
outbreak of Legionella pneumophila after drug therapy (abst) 830
thromboxane as indicator (abst) 257
treatment with orthoclone OKT*3 (abst) 341
value of eosinophilia (abst) 346
Alloimmune memory cells
activation by recombinant interleukin-2 receptor (abst) . 350
Allopurinol
effects on ischemic injury to tubules (abst) 239
Alport's syndrome
genetic heterogeneity of 672
hereditary nephritis, Nephrology Forum on 83
segregation analysis of 672
Aluminum
biological effects on perfused bone (abst) 116
bone *a.* content (abst) 706
carbon filters as a source of *a.* in water treatment (abst) 167
causes osteomalacia and osteopenia (abst) 161
effects of i.p. and i.v. desferrioxamine during CAPD (abst) 180
effects on PTH (abst) 109
in bone of HD patients (abst) 114
increased bone *a.* deposition after PTX 785
influence on induction of hypocalcemia (abst) 125
parathyroidectomy (abst) 426
role in calcium absorption and vitamin D balance (abst) 120
serum levels after desferrioxamine (abst) 706
stainable bone *a.* after PTHx in dialysis patients (abst) . 159
urate lithiasis in HD patients (abst) 830
vitamin D3 metabolism (abst) 599
a. absorption
influence of vitamin D (abst) 108
a. excretion
role of vitamin D (abst) 111
a. toxicity
connection with microcytic anemia (abst) 128
role of hypocalcemia (abst) 121
role in osteomalacia (abst) 114
Ambystoma tigrinum
intracellular alkalization (abst) 288
Amiloride
and Na transport in rat colon (abst) 263
and Na-H antiporter in LLC-PK cells 285
binding of 3H bromobenzamil in kidney cortex (abst) . . 313
effect of acid loading and *a.* on total CO_2 absorption (abst) 284
effect on Na-H exchange (abst) 316
effects on HCO_3 reabsorption in rat (abst) 281
effects on sodium uptake (abst) 285
effects on transepithelial potential difference 842
inhibits Na-glucose and alamine (abst) 310

regulation of Cl transport in cortical collecting tubule (abst) 321
role in potassium secretion 886
site of action in rat distal convoluted tubule (abst) 112
Amino acid
CAPD improves intracellular *a.a.* levels (abst) 182
effect of i.v. infusion in human hemodynamics (abst) 243
effect on GFR, oxygen uptake, and Na^+ reabsorption (abst) 272
effect on reabsorption of bicarbonate and phosphorus 951
effect on renal function (abst) 300
influence of cAMP on *a.a.* accumulation (abst) 113
ketoanalogs of *a.a.* as treatment of uremia (abst) 829
normal concentration and basolateral transport (abst) 232
a.a. branch chained
metabolism in CRF (abst) 249
Amino acid uptake
role of chloride in BBM (abst) 324
through basolateral membrane (abst) 276
Aminoglycoside
nephrotoxicity (abst) 705
Aminoglycoside antibiotic
value of a restrictive policy (abst) 138
Aminoglycoside therapy
TEM of urinary sediment (abst) 233
Amino-peptidase
renal brush border *a-p.* by monoclonal antibody (abst) 276
Ammonia
and bicarbonate transport by rat cortical collecting ducts (abst) 282
and glutamate dehydrogenase during acute metabolic acidosis (abst) 270
excretion during acute and chronic metabolic alkalosis 908
production in proximal tubules, effects of metababolic acidosis (abst) 286
role of lactate metabolism in dog (abst) 272
urinary excretion 652
Ammoniagenesis
effect of adrenal steroids (abst) 271
LLC-PK, cells exposure to oxygen and effect on *a.* (abst) 271
measurement of renal pH by 31P NMR (abst) 277
prostaglandins inhibit via intracellular effect (abst) 283
Ammonium
interaction with bicarbonate flux (abst) 280
Amphiuma
electical heterogeneity in *a.* proximal tubule (abst) 309
Amphotericin B
nephrotoxicity of, rapid vs. slow i.v. administration (abst) 237
peritoneal ultrafiltration is increased by *a.* (abst) 182
Amyloidosis
abdominal fat tissue aspirate (abst) 830
case of Muckle and Wells syndrome (abst) 829
generalyzed *a.*
in regular dialysis treatment (abst) 830
primary renal *a.*
presenting as nephrotic syndrome (abst) 132
renal *a.*
complicates psoriatic arthritis (abst) 828
study by immunofluorescence (abst) 830
transplantation as treatment (abst) 828
Analgesic toxicity
and relation to indomethacin (abst) 228
Anaphylatoxin
release and leukopenia during cool hemodialysis (abst) 167
Anastomosis, pancreatic duct
transplantation (abst) 595
9-anthroic acid
modifies urinary bicarbonate secretion (abst) 286
Anemia
of uremia, influence of CAPD (abst) 183
microcytic *a.*
connection with aluminum toxicity (abst) 128
renal *a.*
role of erythropoietin (abst) 101
Angio access
comparison of autogenous fistula vs. prosthetic grafts (abst) 142
Angioplasty
Nephrology Forum on Renovascular hypertension 812
Angiotensin
localization by RNA-DNA dot blot hybridization (abst) 266
Angiotensin II
acute hypertension 31
affects contractile response and PGE_2 synthesis (abst) 256
and decreased vascular responsiveness (abst) 187
degradation by isolated glomeruli (abst) 253
de nova formation and renin secretion (abst) 263
effect on Ca^{2+} levels in mesangium (abst) 323
effects on glomerulus (abst) 299
functional interaction with PGI_2 (abst) 270
hemodynamics effects in chronic partial ureterial obstruction (abst) 293
inhibition of renal nerve activity in conscious dogs (abst) 197
intracellular messengers (abst) 114
microcirculation of glomerular capillaries (abst) 17
modulation of *a.* receptors in glomerulonephritis (abst) 222
Na-H antiport in proximal tubular cell mediated by PGE_2 (abst) 254
non-receptor mediated degradation (abst) 269
pressor response in SHR, with calcium and sodium (abst) 195
receptor alterations during pregnancy (abst) 254
receptor coupling to nucleotide regulatory unit (abst) 253
receptor after administration in cirrhotic rats (abst) 262
response in pregnant rat (abst) 294
role in aldosterone-induced sodium retention (abst) 318
a. channels
basolateral *a.c.* in rabbit epithelium (abst) 310
a. exchange
presence in luminal and basolateral membranes (abst) 335
a. gap, urine
ketoacidosis (abst) 599
a. sites
altered GBM *a.s.* in nephrotic syndrome (abst) 217
loss in GBM in acute serum sickness nephritis (abst) 219
surface *a.s.* of peritubular capillaries (abst) 215
a. transport
in rat basolateral membrane (abst) 328
Anoxia
cell injury in proximal tubule (abst) 275
effects on adenylate levels and K uptake in thick ascending limb (abst) 271
increases Ca influx in rat nephron segments (abst) 237
Anoxic injury
indomethacin improves renal medullary function (abst) 228
Anti-aldosterone

action in dogs with ascites (abst) 257
Anti-renin
action in dogs with ascites (abst) 257
Anti-tubular basement membrane disease
isolation of nephritogenic tubular antigen (abst)..... 208
Antibody
anticytoplasmatic (ACPA) (abst)..... 704
anti-DNA *a.* role with murine lupus nephritis (abst) ... 221
anti-GBM *a.*, effects of age, sex and diet on glomerular reabsorption (abst)..... 247
anti-thymocyte *a.* (abst)..... 703
bind to lamina rarae and induce proteinuria (abst)..... 218
chemiluminescence assay (abst) 595
cross-reactivity of anti-DNA *a.* (abst)..... 703
deposition in left and right kidney (abst) 300
glomerulonephritis induced by anti-endothelial *a.* (abst) 217
Hepatitis-B (HBsAb) and T cells (abst) 150
induced redistribution of Heymann's antigen (abst)..... 207
influence on glomerular injury in anti-GMB nephritis .. 938
marker for Wegener's granulomatosis (abst) 225
monoclonal heterogeneity of the antigen antibody system (abst)..... 221
monoclonal anti-DNA *a.* bind to antigens (abst) 216
nephritogenic potential to GBM constitutents (abst) ... 209
transfer of anti-GBM nephritis by plasma anti-GMB *a.* (abst)..... 223
vasopressin (abst) 597
monoclonal *a.*
brush border amino-peptidase (abst)..... 276
graft tolerance produced an anti-interleukin-2 receptor (abst)..... 349
interaction with vasopressin (abst) 336
lymphocyte activation antigen (abst)..... 594
study of Na^+-K^+-ATPase (abst) 303
study of puromycin aminonucleoside nephrosis (abst) 219
Antidiuresis, maximal
in chronic primary glomerulonephritis (abst) 279
Antigen
autologous tubular suppressor T cell mediates tolerance (abst) 215
diagnosis for rejection by urinary assay (abst)..... 351
effect of *a.* charge on glomerulonephritis (abst)..... 212
effect of charge on immune complex and eicosanoid (abst)..... 220
effect of discontinuation of *a.* injections with serum sickness glomerulonephritis (abst)..... 248
environmental, in IgA nephropathy (abst) 210
GP600 cross reacts with Heymann nephritis (abst) 223
Hepatitis-B (HBsAg) and T cell subsets (abst)..... 150
heterogeneity of the *a.* antibody system (abst)..... 221
human lymphocyte function-associated *a.* (abst) 215
in experimental autoimmune glomerulonephritis (abst) . 208
in rat serum that cross reacts with Heymann nephritis (abst)..... 223
influence on mediation of immunological glomerular injury 938
kidney *a.* (abst) 703
lymphocyte activation *a.* monoclonal antibody (abst) .. 594
MHC *a.*, distribution in human and rat kidney 616
monoclonal anti-DNA antibodies bind and deposit (abst)..... 216
non-MHC renal endothelia *a.* (abst) 704
plasma membrane formation of immune complexes, Heymann glomerulonephritis (abst)..... 207
to diagnose proximal tubular injury by urinary assay (abst)..... 151
brush border-related *a.*
immunopathological significance (abst)..... 221
carcinoembyonic *a.*
levels in HD and TX patients (abst) 352
nephritogenic tubular *a.*
producing anti-tubular basement membrane disease (abst)..... 208
Antihypertensive drugs
and sodium restriction: effects on renal function (abst) . 193
Antihypertensive therapy
to treat nephrotoxic serum nephritis (abst)..... 248
Anti-interleukin-2 receptor
produced by graft tolerance (abst) 349
Antinaturesis
effects on metabolite of corticosterne (abst)..... 258
Antiporters
and enchanced Na-H antiport activity of BBM (abst) .. 281
Anti-renin
action in dogs with ascites (abst) 257
Anti-thymocyte globulin (ATG)
in secondary proliferative glomerulonephritis (abst).... 338
rejection treatment with cyclosporine (abst)..... 338
Aprotinin
kallikrein (abst) 572
Arachidonic acid
alters renal hemodynamics in dog (abst)..... 299
role in oxidatine metabolism (abst)..... 253
stimulates vasopressin secretion in vitro (abst) 255
Arachidonic acid metabolism
involvement of oxygen radical (abst) 232
Arginine vasopressin
effect in hypothyroid rat tubules (abst)..... 328
effect on flow rate and hydraulic conductivity (abst)... 325
effect on vasa recta blood flow (abst)..... 301
pertussis toxin reverses PGE_2 inhibition (abst) 252
Arterial pressure
effects on glomerular hypertension and albuminuria in diabetes (abst) 252
Arterioles, afferent
microdissected and measured for renin in rabbit 762
Arteriolosclerosis, hyaline
and focal segmental glomerulosclerosis (abst) 216
Arthritis, psoriatic
complicated by renal amyloidosis (abst)..... 828
Artificial organs, heart
renal function in calves with *a.* heart (abst)..... 236
Ascites
anti-renin/anti-aldosterone actions in dogs (abst)..... 257
deterioration in non-azotemic patients (abst) 149
Aspiration
abdominal fat tissue to detect amyloidosis (abst)..... 830
Assay, chemiluminescence
antibodies (abst)..... 595
Atheroembolic renal disease
causes hypocomplementemia (abst) 136
ATP
dependent intracellular pH regulation (abst)..... 291
glycolysis and membrane integrity in LLC-PK_1 cells (abst)..... 236
ATP synthesis
and oxygen consumption and Na reabsorption (abst) .. 273
ATPase activity
DCCD-sensitivity in proximal and distal segments (abst)..... 285

Atrial natriuretic factor
actions on dogs with caval constriction and ascites (abst) ... 257
an overview (abst) ... 104
effect in newborn puppies (abst) ... 308
effect in SHR (abst) ... 295
effect on kidney function and renin-aldosterone system (abst) ... 316
effect on renal hemodynamics (abst) ... 105
effects in pregnant rat (abst) ... 314
effects on renal function and renin release (abst) ... 305
effects on renal tubules (abst) ... 105
hemodynamic and natriuretic effects (abst) ... 317
inhibition by haloperidol (abst) ... 261
inhibits Na-coupled solute reabsorption (abst) ... 306
reduces BP and aldosterone in hypertension (abst) ... 202
renal action mechanism (abst) ... 258
role in tubular capacity for phosphate reabsorption (abst) ... 117
structural and functional properties, Editorial Review on ... 607
study of the vascular mechanism (abst) ... 197
Atriopeptin
natriuresis depends on renal vasodilation (abst) ... 194
spasmolytic and natriuretic properties (abst) ... 104
stimulates chloride in shark rectal gland (abst) ... 265
stimulates shark rectal gland secretion (abst) ... 266
Atriopeptin III
intra renal effects during perfusion (abst) ... 311
Auriculin
effect on kidney function and renin-aldosterone system (abst) ... 316
Autograft
parathyroid growth and function in HD patients (abst) ... 118
Autoimmune
studies of experimental *a.* glomerulonephritis (abst) ... 224
Autoradiography
studies of solute transport in toad bladder ... 726
Autosomal dominant inheritance
renal magnesium wasting (abst) ... 707
Autotransplantation
cyclosporin (abst) ... 593
Azathioprine
autopsy findings in renal transplants (abst) ... 351
lymphocyte functions in *a.* treatment (abst) ... 343
treatment of renal transplants (abst) ... 341
Azathioprine-prednisone
zinc metabolism in treatment (abst) ... 345
Azotemia
in sodium restricted rat (abst) ... 298

B cell
extracellular material and *b.c.* in SLE (abst) ... 208
Backfiltration
effect with highly permeable membranes (abst) ... 171
Balance study
sodium (abst) ... 497
Barium
Ba^{++} and sensitivity of K^+ channels in thick ascending limb (abst) ... 309
Baroreceptor
ethanol impairs human function (abst) ... 196
Bartter syndrome
effects of enalapril (abst) ... 706
Basement membrane components
collagenous and noncollagenous in non-amyloid light chain disease (abst) ... 219
Basolateral membrane
amino acid uptake dependent on hormones (abst) ... 276
Cl-HCO_3 exchange (abst) ... 282
effects of different inhibitors (abst) ... 124
fasting and citrate uptake (abst) ... 277
KCl transport in vesicles (abst) ... 307
organic anion transport (abst) ... 328
phosphate transport across (abst) ... 124
presence of anion exchanger (abst) ... 335
water permeability in cortical collecting duct (abst) ... 334
b. transport
maintaining normal amino acid concentration (abst) ... 232
Bence Jones protein
hypercalcemia increases nephrotoxicity (abst) ... 238
Benzyl alcohol
effects on enzyme and transport system (abst) ... 324
Bicarbonate
and regulation of acidification in cortical collecting tubule (abst) ... 278
Bicarbonate
anion gap, Nephrology Forum on ... 472
compared with acetate as dialysate (abst) ... 168
cyclic AMP (abst) ... 25
D-lactate, and L-lactate balance in IPD (abst) ... 184
effect of amino acid on reabsorption ... 951
effects in HD on left ventricular function ... 768
inhibition of succinate dehydrogenase (abst) ... 275
b. absorption
effect of chloride transport (abst) ... 304
effects of chronic hyperparathyroidism (abst) ... 118
b. flux
in cortical collecting ducts from DOC-treated rabbit (abst) ... 282
interaction with ammonium (abst) ... 280
b. gradients
medullary *b.g.* during metababolic alkalosis (abst) ... 281
b. reabsorption
effect of amino acid ... 951
in collecting tubules with obstructed kidneys (abst) ... 284
in rat with low k diet (abst) ... 279
b. secretion
by distal nephron during metabolic alkalosis (abst) ... 281
cAMP stimulated in cortical collecting tubules (abst). 288
modification by cAMP and 9-anthroic acid ... 286
role in chloride exchange (abst) ... 289
b. transport
and ammonia by rat cortical collecting ducts (abst) ... 282
by amphibian nephron (abst) ... 291
Biliary diversion
for removal of uremic toxins (abst) ... 243
Bilirubin
sodium, water, and urea transport (abst) ... 51
Bioassay
to determine effects of ischemia (abst) ... 262
Biopsy, bone
end-stage renal disease (abst) ... 574
parathyroidectomy (abst) ... 426
Biopsy, kidney
in diagnosis and management of renal disease (abst) ... 135
Biopsy, needle
renal graft recipients (abst) ... 596
Biopsy, renal
children ... 442

crescentic glomerulonephritis in 50 children (abst) 450
Heymann nephritis (abst) 388
membranoproliferative glomerulonephritis (abst) 93
proliferative glomerulonephritis (abst) 94
to determine allograft rejection (abst) 341
ultrasound-guided percutaneous *r.b.*, Technical Note on 80
Biopsy, renal allograft
prognostic value (abst) 597
Blood flow
organ *b.f.* and cyclosporin (abst) 594
untapped reserve for dialysis (abst) 176
renal *b.f.*
decreased after cyclosporine infusion (abst) 346
effect of dopamine on sheep (abst) 297
effects by imidazole and indomethacin 892
effects of MK421 in rat (abst) 297
vasa recta *b.f.*
effect of arginine vasopressin (abst) 301
Blood pressure
and impaired urinary concentration mechanism 792
effects of diet and weight in rats (abst) 193
effects of dietary sodium and calcium (abst) 200
effects of long- and short-term dietary changes (abst) .. 202
elevations in kidney donors after uninephrectomy (abst) 190
essential hypertension (abst) 97
hypertension (abst) 96
linoleic acid improves *b.p.* in rat (abst) 244
Nephrology Forum on renovascular hypertension 812
Blood transfusion
and cytomeglovirus infectious (abst) 596
Bone density
role of diet in spontaneously hypertensive rat (abst) ... 122
Bone disease
in children on CAPD (abst) 142
Bone formation
parthyroidectomy (abst) 426
Bone GLA-protein
interrelation with PTH and VTD in renal failure (abst) . 137
Bowel
function with cyclosporin (abst) 593
Bowman's capsule
crescentic glomerulonephritis in 50 children (abst) 450
Bowman's space pressure
intra-animal coefficients for variation 871
Bradykinin
cortical-interstitial cell induce sensitivity 255
effect on Na and K transport (abst) 321
increases release of inositol polyphosphates in renal papillary collecting tubule (abst) 265
inhibits ADH-induced fluid absorption in rabbit cortical collecting tubule (abst) 264
role in renal oxidation metabolism (abst) 253
Brain mitochondria
uremia (abst) 523
Brush border membrane
amiloride inhibits Na-glucose and alanine to transport (abst) 310
amino-peptidase by a monoclonal antibody (abst) 276
antigen related activity, immunopathology (abst) 221
effect of phlorizin on fluorescence of BBM (abst) 329
effect of triiodothyronine (abst) 277
effects of Ca on transport (abst) 315
effects of lithium on sodium uptake (abst) 285
enchanced Na-H antiport (abst) 281
fasting and citrate uptake (abst) 277
H^+/OH^- permeability 283
Na-dependent phlorizin receptors (abst) 334
organic base transport (abst) 330
phosphate transport across 879
role of chloride in amino acid uptake (abst) 324
study of *b.b.* water and urea transport (abst) 336
Bufo marinus
bilirubin (abst) 51

Calcinosis, vascular
risk factors for HD patients (abst) 828
Calcitonin
magnesium/calcium urinary excretion (abst) 394
Calcitriol
for secondary hyperparathyroidism (abst) 168
Calcium
activated K^+ channels in thick ascending limb (abst) .. 309
anoxia increases influx in rat nephron (abst) 237
calcitonin (abst) 394
cerebral mitochondrial concentrations (abst) 523
changes induced by *c.* may be due to magnesium (abst) 203
chronic uremia (abst) 523
CO_2 causes exocytosis by increasing *c.* (abst) 290
CO_2 stimulation of H^+ secretion (abst) 280
conservation and deprivation as evidence for loop of Henle adaption (abst) 129
deprivation causes of secondary hyperparathyroidism (abst) 169
excretion and calcitonin (abst) 394
effects of dietary *c.* on blood pressure (abst) 200
effects of PTH on myocardial energy metabolism 718
effects of vitamin D on *c.* handling 864
hypertension (abst) 96
hypertension (abst) 96
in post-ischemic acute renal failure 234
ionizable plasma *c.* disassociation from thiazides (abst) 202
metabolism and hypertension (abst) 199
metabolism in renal cortex 774
radiocontrast-induced reductions, Technical Note on .. 465
role in cAMP synthesis in medullary collecting tubule (abst) 335
role in renin secretion by renal nerve stimulation (abst) 254
swelling increases *c.* in toad bladder (abst) 305
vasopressin and angiotensin II levels in mesangium (abst) 323
c. antagonist
effect on mesangial prostaglandin production (abst) .. 259
post-ischemic acute renal failure in dogs (abst) 235
c. carbonate
as a phosphate binder in children on dialysis (abst) .. 185
as phosphorus binder in dialysis (abst) 173
Ca^{2+}-ATPase
activity in human hypertension (abst) 196
regulation in basolateral membrane of rat (abst) 128
c. channel blocker
effects on blood pressure, renin and nervous systems (abst) 195
enhances extrarenal K disposal (abst) 320
increased serum K (abst) 142
protection from ARF (abst) 233
c. deficiency
role in SHR (abst) 200
c. entry

and sodium excretion in perfusion (abst) 307
c. entry blockade
effects in healthy subjects (abst) 194
intracellular *c.*
regulation in renal cells (abst) 126
c. ion
detects inhibition of calcium oxalate mineralization (abst) 134
effect on cAMP concentration in thick ascending limb and collecting tubule (abst) 335
ionophores accumulation induced by ischemia 234
c. malabsorption
effect of chlorathalidone (abst) 116
c. metabolism
dietary NaCl as a determinant in Dahl S rats (abst) .. 194
effects of dialysis modalities, in children (abst) 181
c. nephrothiliasis
risk factors during pregnancy (abst) 144
c. oxalate
mineralization, use of Ca^{++} ion electrode with (abst) 134
c. oxalate monohydrate
and supersaturated uremic serum (abst) 251
c. reabsorption
role of thiazides in turtle bladder (abst) 125
c. supplementation
effects on blood pressure, renin and nervous system (abst) 195
c. transport
effects in BBM (abst) 315
relationship with chloride transport in frog skin (abst) 130
c. uptake
abnormalities in uremic rats (abst) 115
Calciuria
effect of PTX (abst) 230
Calelectrin
immunocytochemical localization in tissue (abst) 126
Capillary
glomerular *c.* ultrafiltration, acute hypertension (abst) .. 31
c. function
with cationic DEAE-3H-Dextran (abst) 301
glomerular *c.*
angiotensin II 17
peritubular *c.*
surface anionic sites (abst) 215
Captopril
antihypertensive effect (abst) 97
antihypertensive effects of in dialysis (abst) 189
diagnostic value for renal disease (abst) 199
effect in SHR (abst) 299
effects on excretion of saline load in patients (abst) 199
effects on hemodynamics and hippuran excretion (abst) 193
increases renal blood flow in hypertensives (abst) 339
monotherapy in hemodialysis patients (abst) 160
Nephrology Forum on renovascular hypertension 812
renal function during cisplatin treatment (abst) 236
to separate hypertension patients (abst) 203
treatment in hypertensive renal transplant recipients (abst) 343
Carbamoylation
of plasma proteins in CAPD and HD (abst) 181
Carbon
C3
binding and release of fragments from soluble IgG125 (abst) 224
activation in IgA nephropathy (abst) 226
demonstration of receptors on glomerular cells (abst) 214
^{14}C-labeled sucrose
transport across toad bladder 726
^{14}C-labeled urea
transport across toad bladder 726
Carbon dioxide
causes exocytosis by increasing calcium in epithelium (abst) 290
effect of acid loading and amiloride (abst) 184
effects of acid loading and amiloride on absorption (abst) 284
stimulation of H^+ secretion (abst) 280
P_{CO_2}
and regulation of acidification in rabbit (abst) 278
change of luminal pH and HCO_3 in intracellular pH (abst) 287
significance of negative urine-blood P_{CO_2} gradient (abst) 283
Carbon filters
as source of aluminum in water treatment (abst) 167
Carbonic anhydrase
cells in turtle bladder, role in HCO_3 secretion (abst) ... 289
HCO_3 reabsorption, effects of ethoxzolamide (abst) ... 290
proximal fluid reabsorption and inhibition (abst) 311
voltage regulation, acidification (abst) 287
Carcinoma, cell
renal metabolism and chemicals (abst) 275
Cardiac homotransplantation
sodium bicarbonate (abst) 593
Cardiac output
alterations in renal vasoactive hormonal systems (abst) 293
Cardiovascular system
total parenteral nutution, Editorial Review on 489
Carnitine
HD in CRF does not produce depletion 170
Catechol
abnormal production in transplant recipients (abst) 203
Catecholamine
β catecholamine
and cAMP system in proximal tubule (abst) 261
potassium excretion, Editorial Review on 379
renin activity in CAPD (abst) 181
Catheter
central venous for access in children (abst) 175
indwelling peritoneal (abst) 95
low failure with curved peritoneal dialysis *c.* (abst) 186
peritoneal *c.* complications and survival (abst) 178
placement of *c.* using introducer with peelaway sleeve (abst) 185
Tenckhoff drainage problems abolished with placement (abst) 186
Cation transport
effect of cisplatin in cortex (abst) 228
Cationic DEAE-3H-Dextran
and glomerular capillary function (abst) 301
Cationic molecules
movement across glomerular walls (abst) 292
Cells
composition
response to therapy in glomerulonephritis (abst) 141
cortical interstitial *c.*
induces sensitivity to bradykinin (abst) 255
distal *c.*
isolation by immunoadsorbent chromatography (abst) 276
effector *c.*

irradiated spleen allograft (abst) 595
endothelial *c.*
lipoproteins alter balance of plasminogens (abst) 213
epithelial *c.*
anoxic injury to (abst) 106
glomerular *c.*
demonstration of C3 receptors..... 214
effects of β-D-xyloside on Golgi apparatus (abst).... 214
glomerular epithelial *c.*
redistribution of Heymann's antigen (abst)..... 207
c. injury
in anoxia in rabbit proximal tubule (abst)..... 275
renal tubular *c.* injury
involvement of oxygen radical (abst)..... 232
intercalated *c.*
after nephrectomy 636
c. line MDCK
morphogenetic clonal growth, epithelial cysts (abst) . 330
neuroblastoma *c.*
K channels and voltage dependency (abst)..... 316
peritoneal *c.*
dialysis solution (abst) 601
principal *c.*
after nephrectomy 636
c. proliferation
preceeds cyst formation in renal cystic disease (abst) 244
suppressor *c.*
spleen transplantation (abst) 595
T *c.*
human renal allografts, Technical Note on..... 469
renal transplantation (abst) 596
c. volume
in isolated perfused proximal tubule (abst)..... 328
c. volume regulation
and water content in rats (abst)..... 190
Central pontine mylelinolysis
overcorrection induces *c.p.m.* in severe hyponatremia (abst)..... 132
CH 50
Heymann nephritis..... 388
Chelating agent
in mercury poisoning..... 898
Chemiluminescence
renal transplantation (abst) 594
Chemiluminescence assay
antibodies (abst)..... 595
Chemoreceptor
activation during reductions in perfusion pressure (abst)..... 187
Chloride
as correction for chloride depletion alkalosis (abst).... 279
atriopeptins stimulate in shark rectal gland (abst) 265
effect of changes on blood pressure and renin (abst)... 197
PGE_2 in medullary thick ascending limb (abst) 260
reabsorption effect of guanabenz on papillary collecting duct (abst)..... 197
role in BBM amino acid uptake (abst) 324
role of *c.*/bicarbonate exchange..... 289
c. absorption
in rat proximal convoluted tubule (abst)..... 302
prostaglandin inhibits ADH-stimulated *c.a.* (abst) ... 316
c. depletion
alkalosis treated with chloride (abst)..... 279
role of (abst)..... 101
dietary *c.*
effect of Cl uptake in collecting duct (abst)..... 308
c.-HCO_3 exchange
in rabbit basolateral membrane (abst)..... 282
c. inhibition
by PGE_2 in medullary thick ascending limb (abst)... 260
c. permeability
in early distal convoluted tubule (abst)..... 322
c. transport
effect of bicarbonate absorption (abst) 304
effect of furosemide during prostaglandin synthesis inhibition (abst)..... 259
hormonal regulation in cortical collecting tubule (abst)..... 321
relationship with calcium transport (abst)..... 130
c. uptake
effect of dietary chloride in collecting duct (abst).... 308
Chlorothiazide
site of action in rat distal convoluted tubule (abst) 112
Chlorthalidone
effects of calcium absorption (abst)..... 116
Cholera toxin
action in perfused rabbit tubule (abst) 331
Cholesterol
renal embolization and hypertension (abst) 190
Chromatography
and study of middle molecular clearance (abst)..... 172
interaction of sulfamethoxazole and cyclosporin (abst). 343
of aldosterone-induced proteins (abst) 306
study of dextran clearance (abst) 329
immunoadsorbent *c.*
isolation of distal cell in rabbit (abst) 276
Circadian rhythm
of ova excretion in urinary schistosomiasis 667
Circulatory impairment
renal sympathetic nerves mediate hypoperfusion (abst). 232
Cirrhosis
outcome for transplantation in patients with *c.* (abst) .. 338
liver *c.*
dopminergic response (abst) 94
c. in rat
angiotension post-receptor activity (abst)..... 262
Cisplatin
effect on organic cation transport in cortex (abst)..... 228
effects on transepithelial potential difference 842
protective effect of quinine (abst)..... 228
renal function studies and captopril protection (abst) .. 236
renal magnesium wasting following therapy (abst)..... 127
Cis-platinum
abnormalities of magnesium after repeated doses (abst) 144
massive electrolyte wasting following (abst)..... 154
Citrate
and fasting in brush border and basolateral membranes (abst)..... 277
c. reabsorption
and utilization from tissue (abst)..... 271
in the proximal tubule (abst) 270
c. utilization
and reabsorption from tissue (abst)..... 271
Clamping, infra-aortic
renal function (abst)..... 598
Clathrin
partial resolution of *c.*-coated proton pump (abst)..... 289
Clearance techniques
reliability (abst) 296
Clinical follow-up

progression of chronic renal failure (abst) 240
Clonal growth, morphogenetic
of cell line MDCK (abst) 330
Clonidine
effect on renal sympathetic nerve activity in SHR (abst) 194
Cloning
of T lymphocytes from ESRD kidneys (abst) 210
Coagulation
alterations in the contact phase during HD (abst) 163
Colchicine
proteinuria (abst) 600
Colitis
vancomycin in HD patients with *c.* (abst) 163
Collagen
type IV, accumulation in congenital nephrosis 662
Colloidal carbon
glomerular sclerosis (abst) 405
Colon
adaptation of K^+ transport to dietary K^+ restriction (abst) 321
Complement
and oxygen radical-induced proteinuria (abst) 220
proteinuria (abst) 503
c. depletion
effect on prostaglandin and thromboxane synthesis (abst) 216
Complex system
MOVIE. BYU (Mosaic program) osteoclast enlargement in early renal failure (abst) 574
Computerized tomography
compared with Grey scale ultrasonography (abst) 147
Conductivity, hydraulic
dependence on arginine vasopressin (abst) 325
in rabbit cortical collecting tubule (abst) 325
Contractile response
cell-to-substrate adhesion in mesangium (abst) 259
isotomic *c.r.* in mesangial cells (abst) 269
Contrast media
effects on renal hemodynamics (abst) 291
Converting enzyme inhibition
effects of MK421 on renal blood flow (abst) 297
in sodium restricted rat (abst) 298
99mTc-DTPA flow studies in uRAS (abst) 196
Copper
modulation of renal membrane permeability (abst) 315
serum *c.*
in non-uremic patients (abst) 140
Coronary artery bypass
in chronic dialysis patients (abst) 145
Cortex
effect of cisplatin on organic cation transport (abst) 228
effect of triiodothyronin on brush border membrane (abst) 277
subcellular insulin in rat (abst) 273
kidney *c.*
photoincorporation of 3H bromobenzamil (abst) 313
Corticosteroid
cyclosporin (abst) 594
effects on current and morphology of toad epithelia (abst) 256
Corticosterone
effects on antinaturesis and kaluresis (abst) 258
effects on Na-transport (abst) 269
necessary for Na and K excretion (abst) 323
Coumadin
membranoproliferative glomerulonephritis (abst) 436
Creatinine clearance
correlation of predicted GFR (abst) 145
constancy in healthy, very old women (abst) 134
in acute renal failure 928
tubular and glomerular rates of excretion in glomerular disease (abst) 250
Creatinine kinase
serum *c.k.* activity in dialysis (abst) 173
Creatinine kinetics
to study acute renal failure 928
Creatinine levels
post transplantation 800
serum *c.l.* at start of chronic HD (abst) 167
Crescents, glomerular
classified in study of 50 children (abst) 450
Cushingoid renal transplant patients
prednisolone pharmacokinetics (abst) 459
Cyanotic Congenital Heart Disease (CCHD)
and abnormal renal function 151
Cyclic AMP
acetate increases *c.* AMP in rat (abst) 176
acidification (abst) 25
and β-catecholamine in proximal tubule (abst) 261
bilirubin (abst) 51
control of PGE_2 by rat inner medullary collecting tubule (abst) 253
dopamine stimulates *c.* accumulation in rat mesangium (abst) 265
early renal failure 565
effect of calcium ion (abst) 335
effects on K-depleted rabbit tubule (abst) 332
levels in isolated single nephron segments (abst) 268
modifies urinary bicarbonate secretion (abst) 286
Na-H antiporter activity and PTH (abst) 187
role of Ca and PGE_2 in medullary collecting tubule (abst) 335
stimulates bicarbonate secretion in cortical collecting tubule (abst) 288
VIP as messenger in luminal alkalinization 278
with vasopressin prostaglandins and phospholipid in toad bladder (abst) 264
Cyclooxygenase products
effects on macrophage binding 855
Cyclophosphamide
effect on skin reaction in chronic uremia (abst) 210
membranoproliferative glomerulonephritis (abst) 436
Cyclosporin
alterations in generalized Schwartzman reaction (abst) 220
antibody-induced experimental glomerulonephritis (abst) 530
as sole therapy for children (abst) 350
autopsy findings in renal transplant (abst) 351
bowel function (abst) 593
cardiac transplantation (abst) 595
decreases renal blood flow (abst) 345
effect on Heymann's nephritis (abst) 207
existence of suppressor T cells (abst) 347
glomerular thrombi in renal allografts (abst) 345
immunosuppression in cadaver kidney recipients (abst) 597
imurau (abst) 596
interaction with tegretol (abst) 344
lymphokine responses (abst) 594
lymphocyte function in treatment (abst) 343

organ blood flow (abst) 594
Technetium-99M tin colloid to test nephrotoxicity (abst) 351
test for toxicity by urinary assay (abst) 351
to treat transplant rejection (abst) 342
treatment for steroid and ATG rejection (abst) 338
treatment of renal transplants (abst) 341
Cyclosporin A
effect of liposome encapsulation (abst) 340
hyperchloremic metabolic acidosis and high serum potassium (abst) 349
interaction with sulfamethoxazole by chromatography (abst) 343
low-dose maintenance treatment (abst) 342
lymphoproliferation (abst) 597
nephrotoxicity (abst) 593
Cyclosporine-prednisone
zinc metabolism during treatment (abst) 345
Cyst formation
cell proliferation preceeds (abst) 244
proximal tubular *c.f.* and transtubular transport (abst) . 205
Cystopathy
complicating diabetic nephropathy 138
Cytochalasin B
peritoneal permeability (abst) 411
Cytomegalovirus infection
and allograft glomerulopathy, T cell phenotype (abst) .. 224
renal transplantation (abst) 596
Cytoplasm, granulocyte
antibodies a marker for Wegener's granulomatosis (abst) 225
Cytoskeletal elements
permeability 411
Cytosol
contribution to vasopressin-stimulated water flow (abst) 324
Cytosolic calcium
effects of PTH (abst) 117
Cytosolic ion activity
effect of gramicidin on luminal Na (abst) 315
Cytotoxicity
suppression (abst) 593

DCCD
sensitive ATPase activity in proximal and distal segments 285
DDAVP
1-desamino-8-D-arginine vasopressin (abst) 704
Decompression sickness
rhabdomyolysis and acute renal insufficiency (abst) 145
Decongestion, vascular
protection from ischemic, acute renal failure (abst) 234
Deoxycorticosterone (DOC)
bicarbonate flux in cortical collecting ducts (abst) 282
dietary chloride and calcium metabolism with (abst) ... 196
Depolarization
intracellular alkalizatiin in tiger salamander (abst) 288
Desferrioxamine
challenge test for chelatable iron in dialysis (abst) 162
changes hemodynamics in dog (abst) 169
effects of i.p. and i.v. administration on aluminum removal (abst) 180
effects on aluminum-induced osteomalacia (abst) 165
in aluminum-loaded rats (abst) 157
therapy in aluminum-related osteodystrophy (abst) 148
Development, postnatal
PGE_2 synthesis and degradation (abst) 261
Dexamethasone
role in cultured epithelial cells (abst) 332
Dextran
study of clearance by chromatography (abst) 329
Diabetes
bone effects of streptazotocin (abst) 109
effect of lower arterial pressure (abst) 252
effects of peritoneal transport (abst) 179
glomerular capillary pressure in rats (abst) 241
d. insipidus
effects of circulating vasopressinase (abst) 326
d. mellitus
advances in etiology and pathogenesis (abst) 100
and glomerular structure and function (abst) 209
autoimmune *d.m.* in rat model (abst) 105
patients with nephropathy (abst) 138
increased furosemide binding by Tamm Horsfall glycoprotein (abst) 307
insulin-dependent, relationship of urinary albumin to glomerular structure (abst) 135
d. mellitus, Type II
renal size (abst) 137
Dialysate
comparison of acetate and bicarbonate (abst) 157
comparison of effects of acetate and bicarbonate (abst). 168
CV and metabolic effects of mixtures (abst) 165
protein losses during IPD (abst) 184
new process for stabilization of bicarbonate (abst) 169
rifampin-induced sunset *d.* (abst) 177
solute clearance and ultrafiltration with varying temps (abst) 170
Dialysis
compared with ultrafiltration and sham-*d.* (abst) 157
for uremic prison inmates (abst) 145
physical fitness (abst) 601
pseudoangina in patients (abst) 177
uptapped blood flow reserve for *d.* 176
uremia (abst) 97
hemodialysis
parathyroidectomy (abst) 426
continuous ambulatory peritoneal *d.* (CAPD)
bone disease in children on CAPD (abst) 142
comparison with HD in same population (abst) 178
dialysance of adrenal steroids (abst) 185
glycolytic activity in erythrocytes and glucose intolerance (abst) 243
nutritional status of patients on CAPD (abst) 185
outcome of transplantation in PD patients (abst) 339
patients with polycystic kidney disease (abst) 183
peritoneal cells (abst) 601
peritoneal sediment (abst) 602
peritonitis in children undergoing CAPD (abst) 177
permeability (abst) 411
spectrum of ultrafiltration undergoing CAPD (abst) .. 181
study of 82 children (abst) 558
TSH response to TRH stimulation (abst) 182
continuous cycling peritoneal *d.* (CCPD)
safe, inexpensive disconnecting device for (abst) 179
report of 82 children (abst) 558
intermittent peritoneal *d.* (IPD)
bicarbonate, D-lactate, and L-lactate balance (abst). . 184
dialysate protein losses during IPD (abst) 184
factors influencing acid-base balance during (abst) ... 184

peritonitis in children undergoing IPS (abst) 177
regular treatment *d.*
appearance of generalized amyloidosis (abst) 830
Dialyzer
effect on proteinases during HD (abst) 171
effects of sterilizing agents on reused *d.* (abst) 166
hypersensitivity to (abst) 172
long-term multiple use of *d.* (abst) 169
prolonged re-use (abst) 599
study of *d.* with anion exchange chromatography (abst) 172
syndrome associated with use of new *d.* (abst) 170
Diatrizoate
Bence Jones protein nephrotoxicity (abst) 46
Dibutyryl AMP
cyclic AMP (abst) 25
effects on fluid absorption (abst) 120
Diet
restriction and uremia (abst) 420
Dietary changes
effects on blood pressure in SHR (abst) 202
Dietary protein
simple method for monitoring (abst) 147
Dietary sodium
versus *s.* excretion (abst) 497
Digitoxin
levels in HD patients (abst) 174
Dimercaptopropane sulfonate (DMPS)
as treatment for mercury poisoning 898
Dimethylnitrosamine
ethanol inhibition in CRF (abst) 245
Dipyridamole
Effect on diabetic nephropathy (abst) 136
membranoproliferative glomerulonephritis (abst) 436
Disease, αTBM
suppressor T cell inhibits TI nephritis in mice (abst) ... 219
cystic *d.*
cell proliferation preceeds cyst formation (abst) 244
dense deposit *d.*
prognosis in children 223
light chain *d.*
basement membrane components in non-amyloid *l.c.d.* (abst) 219
Distal segments
culture of isolated renal tubules in rabbit (abst) 267
Ditiazem
reversal of prostaglandin-induced vasoconstriction (abst) 296
Diuresis
after water loading, role of vasopressin and BP (abst) .. 202
effect of glucocorticoids (abst) 327
role of vasa recta pressure and flow (abst) 298
osmotic *c.*
in chronic primary glomerulonephritis 792
Diuretics
molecular basis of diabetogenic effects (abst) 327
effect of prostaglandin inhibition 261
non-loop *d.*
effects of prostaglandin inhibition (abst) 261
DMSO
ameliorates glomerular disease in mice (abst) 214
DNS-anti-DNA complexes
assembly and catabolism in mice (abst) 213
DOCA
regulation of Na and K pathways (abst) 319
DOC-SALT
glomerular injury despite therapy in hypertension (abst) 189
Docusate sodium
chronic use in peritoneal dialysis (abst) 180
Dog, newborn
effects of synthetic ANF (abst) 308
Donor, kidney, cadaveric
cold storage vs. machine perfusion (abst) 342
effects of hypotension, renal insufficiency, and diabetes insipidus (abst) 344
factors for improved survival results (abst) 347
factors with delayed graft function (abst) 344
with multiple vessels (abst) 350
living related *d.k.*
differences in divalent ion handling (abst) 190
effects on short-term low-protein diet (abst) 148
follow-up of living *k.d.* (abst) 706
long-term effects on sibling donor (abst) 351
tubular function, post transplant (abst) 346
Donor matching
effects on cellular immune response in recipient (abst) . 220
Dopamine
effect of blockade on plasma aldosterone (abst) 143
effect on blood flow in sheep (abst) 297
effect on renal function (abst) 300
infra-aortic clamping and renal function (abst) 598
liver cirrhosis (abst) 94
proximal tubule (abst) 3
receptors in denervated kidney (abst) 311
renal transplantation (abst) 96
stimulates cAMP accumulation in rat mesangial cells (abst) 265
to prevent oliguric renal failure (abst) 339
dopamine-4-sulfate
effect on renal vasculature (abst) 292
Duct, collecting
effect of dietary chloride on Cl uptake (abst) 308
electrical properties in culture (abst) 309
electrophysiologic heterogeneity in rabbit (abst) 313
modulation of Na-K-ATPase by dietary K^+ (abst) 308
cortical collecting *d.*
ammonia and bicarbonate transport (abst) 282
bicarbonate flux (abst) 282
DOCA regulation of Na and K pathways (abst) 319
role of chloride bicarbonate exchange (abst) 289
water permeability of basolateral membrane (abst) .. 334
medullary collecting *d.*
ATP-dependent intracellular pH regulation (abst) 291
β-D-xyloside
effects on Golgi apparatus of glomerular cells (abst) ... 214

Edema, pulmonary
deceptive patterns in uremic patients (abst) 143
ritodrine and terbutaline-induced hypokalemia (abst) ... 304
EDTA
glomerular filtration (abst) 9
Eicosanoid
effect of antigenic charge on production (abst) 220
production by isolated glomeruli in nephritis (abst) 211
Eicosapentaenoic acid
effect on PGE synthesis in mesangial cells and 5/6 NX rat (abst) 264
Electrolyte
flux in rat renal pelvis (abst) 302
role of adrenal glands and Pichinde virus (abst) 315

serum patterns in ESRD (abst) 283
total parenteral nutrition, Editorial Review on 489
e. transport
effects of K loading on Henle's loop (abst) 317
e. wasting
following cis-platinum treatment (abst) 154
Electron microscopy
nephrotic syndrome in 48 infants (abst) 544
Electron spectroscopic imaging
intracellular, in normal and ARF kidneys (abst) 230
Enalapril
effects on growth, hematocrit in SHR (abst) 191
effects with Bartter syndrome (abst) 706
Endocytosis
role of phorbol myristate acetate (abst) 330
basolateral *e.*
protein (abst) 39
Endotoxin
induced renal ischemia, antagonism of thromboxan A2 (abst) 134
Energy expenditure
in uremic patients (abst) 144
Enzyme immunoassay
for erythropoietin levels in ESRD (abst) 160
Enzyme systems
effects on benzyl alcohol and octanol (abst) 324
Enzyme, respiratory
integrity during gentamicin treatment (abst) 227
Enzymes
pancreatic, in chronic renal failure (abst) 180
Eosinophilia
diagnosis of atheroembolic renal disease (abst) 134
prognostic value in allograft rejection (abst) 346
Epithelial voltage
pertussis toxin, PGE_2, and ADH in mouse thick ascending limb (abst) 255
Epithelium
abnormalities of human polycystic kidney (abst) 226
anoxic injury to *e.* cells (abst) 106
basolateral anion channels (abst) 310
calcium and K^+ permeability in toad bladder (abst) 305
corticosteroid effects on current and morphology (abst) 256
CO_2 causes exocytosis by increasing calcium (abst) ... 290
effect of dexamethason in cultured cells (abst) 332
gentamicin causes alterations in pig kidney (abst) 237
pertussis toxin reverses PGE_2 inhibitor in rabbit (abst) . 252
polarized cysts in cell line MDCK (abst) 330
role of cell inhibitor in control of hypertrophy (abst) ... 247
transcellular route in endoplasmic reticulum (abst) 323
Epoprostenol
hemodialysis with *e.*: acetate vs. bicarbonate (abst) ... 160
Epoxyeicosatrienoic acid
isolation in human urine 268
Erythematosus, systemic lupus
abnormal antidiuretic hormone secretion (abst) 154
extracellular material and B cell marker in SLE (abst) . 208
spontaneous SLE in the rat (abst) 105
Erythrocyte
abnormalities in adolescent hypertension (abst) 192
effect of salt loading and restriction on *e.* rubidium (abst) 198
glomerular capillaries (abst) 17
glycolytic activity and glucose intolerance in uremia, HD, CAPD 243
e. binding
uptake of IgA vs. IgG_1 immune complexes in primates (abst) 212
Erythrocytosis
and hypertension in rats (abst) 188
in hemodialysis patients (abst) 157
renal transplantation (abst) 96
Erythrocyturia
ova excretion in 667
Erythropoiesis
inhibition by uremic serum (abst) 184
Erythropoietin
effects of ischemia on *e.* production (abst) 262
levels in ESRD by enzyme immunoassay (abst) 160
role in renal anemia (abst) 101
serum immunoreactive levels with CAPD (abst) 178
Estradial receptor
concentration differs in male and female rats (abst) 252
Ethanol
effect of inhibition on dimethylnitrosamine CRF (abst) . 245
impairs human baroreceptor function (abst) 196
Ethoxzolamide
carbonic anhydrase independent HCO_3 reabsorption (abst) 290
Ethylenediamine N
effect in aluminum loaded rats (abst) 158
Euro-Collins flushing solution
to protect from ischemia (abst) 337
Excretion index
role in nephron loss adaptation in CRF (abst) 246
Exercise
effects of training and physical work in HD (abst) 176
maximal *e.* during hemodialysis 161
e. training
effects while on HD 149
Exocytosis
acetazolamide inhibits in toad bladder (abst) 280
CO_2 causes by increasing calcium (abst) 290
CO_2 stimulation of H^+ secretion (abst) 280
role of phorbol myristate acetate (abst) 330
Extracellular activity
reaction with B cell marker in SLE (abst) 208
e. fluid volume
role of renal regulation, Editorial Review on 837

Fasting
and citrate uptake in brush border and basolateral membranes (abst) 277
Fatty acids
release by peritoneal macrophage in CAPD (abst) 127
utilization in proximal tubule (abst) 275
Fc-receptor
idiopathic glomerulonephritis (abst) 93
Feeding, intermittent
effects on renal function in conscious rats (abst) 295
Fenoprofen
and reversible renal failure (abst) 147
Ferritin, cationized
basolateral endocytosis of protein (abst) 39
Ferrokinetics
in CAPD patients (abst) 183
Fiber shortening, circumferential
differences in velocity in acetate and bicarbonate HD .. 768
Fibrinogen
role in glomerular permeability in perfused kidney 808
Fibronectin

binding of to immune complexes (abst) 205
decreased destruction during HD (abst) 172
decreased secretion during CAPD (abst) 179
Filtration capacity
renal reserve 706
f. fraction
intra-animal coefficients for variation 871
f. rate response
stop flow pressure in loop of Henle (abst) 293
Fistula
elevated basilic vein AV *f.* instead of PTFE graft (abst) 164
streptokinase treatment for thrombosed AVF (abst) ... 159
Flow cytometry
presentation in renal transplant recipients (abst) 337
Flow rate
adaptation in perfused tubules (abst) 311
dependence on arginine vasopressin (abst)..... 325
Fluid absorption
effects of α2-adrenergic inhibition (abst)..... 333
mediated by PGE synthesis (abst)..... 321
Fluid secretion
in proximal tubules of shark (abst) 319
Forskolin
action in perfused tubule (abst)..... 331
action on adenylate cyclase (abst)..... 333
effects on tubules of K-depleted rabbit (abst)..... 332
pertussis toxin reverses PGE_2 inhibition (abst) 252
Furosemide
and blood pressure and electrolyte homeostasis (abst) . 155
as cortical collecting duct evaluation tool (abst)..... 133
binding by Tamm Horsfall glycoproteins of diabetic (abst)..... 307
chloride transport during prostaglandin synthesis inhibition (abst)..... 259
effect on cisplatin-induced hypo-magnesemic rats (abst) 129
prostaglandins (abst) 66
to prevent oliguric renal failure (abst)..... 339
unloading reverses depressing in intrarenal PO2 (abst) . 228
Fxla
Heymann nephritis (abst) 388

Gain amplification
in chronic renal disease (abst)..... 242
role in nephron loss adaptation in CRD (abst) 246
Gallium-67
diagnostic value of scans (abst)..... 139
Gap, anion
disorders, Nephrology Forum on 472
Gentamicin
and mitochrondrial respiratory enzyme integrity (abst) . 227
causes alterations in pig kidney epithelial cells (abst) .. 237
effect of PTX (abst)..... 230
effect on lipid peroxidation in rat renal cortex (abst)... 237
generates hydrogen peroxide by renal mitrochondria (abst)..... 238
pathological renal changes (abst)..... 238
protection of thyroxine in ARF (abst)..... 230
role of thromboxane A_2 and prostaglandin I_2 with (abst)..... 235
unilateral ureteric occlusion protects from (abst)..... 234
vanadate potentiates *g.* nephrotoxicity in rat (abst).... 231
Gland, adrenal
role in electrolyte imbalance in Pichinde virus (abst)... 315
rectal *g.*
atriopeptin stimulates in shark..... 266
atriopeptins stimulate chloride in shark (abst) 265
regulation of adenylate cyclase in shark (abst)..... 312
Globulin
Minnesota antilymphoblast and renal cadaver transplantation (abst) 596
Glomerular basement membrane
Alport syndrome, Nephrology Forum on..... 83
altered GBM anionic sites in nephrotic syndrome (abst) 217
effects of antibodies in rat GMB..... 938
nephritogenic potential of antibodies (abst) 209
poly C9 and loss of anion sites in GBM in nephritis (abst)..... 219
thickening caused by antibodies to heparan sulfate (abst)..... 218
thickness after localization of polyvinyl alcohols..... 751
with heparan sulfate in membranous nephropathy (abst)..... 212
Glomerular capillary pressure
in rats with diabetes and hypertension (abst)..... 241
intra-animal coefficients for variation 871
Glomerular disease
early DMSO treatment ameliorates *g.d.* in lupus mice (abst)..... 214
primary *g.d.*
tubular and glomerular rates of creatinine excretion (abst)..... 250
Glomerular dynamics
coefficients of variation..... 871
intra-animal nephron heterogencity..... 871
Glomerular filtration rate (GFR)
acute hypertension (abst)..... 31
and protein intake in growth hormone deficient adult (abst)..... 296
calcitonin 394
calcium, Technical Note on..... 465
dopamine (abst) 96
effects of amino acid infusion (abst) 272
effects of glucose and amino acids 848
marker for (abst) 9
phorbol myristate acetate (abst) 503
pregnancy (abst)..... 74
prostaglandins modulate in rat on high protein diet (abst)..... 267
reliability of clearance techniques (abst)..... 296
Glomerular injury
control of hypertension in rats with renal ablation (abst)..... 247
influence of antigen distribution 938
Glomerular neurominidase
in puromycin aminonucleoside nephrotic syndrome (abst)..... 205
Glomerular response
effects of age, sex and diet on *g.r.* to anti-GBM (abst) . 247
Glomerular sclerosis
focal segmental, the early lesion (abst)..... 222
mechanism in the rat (abst)..... 204
Glomerular structure
and function with diabetes mellitus (abst)..... 209
Glomerulonephritis
and antigen charge on murine protein-induced *g.* (abst) 212
cryglobulinemia-associated monocytes (abst)..... 93
immune cell abnormalities in Thai children (abst) 225
induced in rabbit by anti-endothelial antibodies (abst).. 217
macrophage accumulation 855
prolonged alterate day prednisolone therapy with

akinsola (abst) ... 130
role of salt-induced hypertension and protein restriction ... 249
treatment with PGE_2 and influence on immune response (abst) ... 217
acute *g.*
modulation of angiotensin II receptors (abst) ... 222
nephron handling of potassium and sodium (abst) ... 250
autoimmune *g.*
antibody-induced experimental T lymphocyte (abst) . 530
IgG subgroup distribution (abst) ... 221
influence of antigen in experimental *a.g.* (abst) ... 208
ultrastructural studies in chickens (abst) ... 224
chronic *g.*
mechanism of impaired urinary concentration ... 792
chronic primary *g.*
cause of renal failure (abst) ... 246
crescentic *g.*
study of 50 children (abst) ... 450
Heymann *g.*
relevance of immune complexes induced by antibody (abst) ... 207
idiopathic *g.*
macrophage Fc-receptor (abst) ... 93
prednisone (abst) ... 600
immune complex *g.*
increased thromboxane B_2 formation by glomeruli ... 267
membranoproliferative *g.*
associated with hepatitis B ... 154
controlled drug trial (abst) ... 436
decline of incidence in France (abst) ... 829
IgG subgroup distribution (abst) ... 221
study of 1548 patients in Italy (abst) ... 93
type II, similarities to light chain nephropathy ... 223
necrotizing *g.*
causes and prognosis (abst) ... 601
proliferative *g.*
IgG subgroup distribution (abst) ... 221
proteinuria and intra glomerular monocytes (abst) ... 94
secondary to ATG administration (abst) ... 338
serum sickness *g.*
effect of discontinuation of daily antigen injections (abst) ... 248
Glomerulonephropathy, membranous
in renal allografts (abst) ... 224
allograft *g.*
T cell phenotype in cytomegalovirus *a.g.* (abst) ... 224
transplant *g.*
evolution of morphological changes ... 800
Glomerulosclerosis
in obese Zucker rat (abst) ... 297
focal segmental *g.*
renal hyaline arteriolosclerosis and *f.s.g.* (abst) ... 216
Glomerulotubular balance
metabolic control ... 848
Glomerulus
activates platelet thromboxane synthetase in humans (abst) ... 266
angiotensin II (abst) ... 17
capillary function with cationic DEAE-3H-Dextran (abst) ... 301
dose-dependent movement of cationic molecules (abst). 292
effects of angiotension II (abst) ... 299
influence of albumin concentration in dog (abst) ... 294
degradation of angiotension II (abst) ... 253
leukotriene B4 synthesis in rat (abst) ... 254
macrophage binding ... 855
non-receptor mediated angiotension II degradation (abst) ... 269
production of eicosanoid in nephritis (abst) ... 211
pyrimidine nucleotide metabolism in rat ... 274
release of PGE_2 in single perfused *g.* (abst) ... 297
role of fibrinogen in *g.* permeability ... 808
scanning electron microscopy of acellular *g.* ... 678
superficial *g.*
acute hypertension (abst) ... 31
Glucocorticoid
amiloride and NA transport (abst) ... 263
effect on water diuresis (abst) ... 327
potassium excretion, Editorial Review on ... 379
replacement of loop of Henle Cl^- transport and renin release (abst) ... 322
Glucose intolerance
glycolytic activity erythrocytes and *g.i.* in uremia (abst) ... 243
uremia (abst) ... 95
Glutamate dehydrogenase
and ammonium formation during acute metabolic acidosis (abst) ... 270
g. metabolism
and bicarbonate inhibition of succinate dehydrogenase (abst) ... 275
Glutamine
maleate stimulates *g.* metabolism (abst) ... 272
metabolic alkalosis (abst) ... 602
Glycolysis
ATP and membrane integrity in LLC-PK1 cells (abst) . 236
role in metabolism during alkalosis ... 908
Glycoprotein
association with granulocytopenia of HD (abst) ... 204
microvillar membrane *g.* after ischemia (abst) ... 236
Heymann nephritogenic *g.*
absence in human kidney (abst) ... 211
Tamm Horsfall *g.*
increased furosemide binding (abst) ... 307
Golgi apparatus
effect of β-D-xyloside (abst) ... 214
Graft survival
hypertension in transplant recipients (abst) ... 188
Grafts
angio access comparison of autogenous fistula vs. prothetic *g.* (abst) ... 142
Grafts, heart
T cell subset (abst) ... 594
Gramicidin
effect on cytosolic ion activity (abst) ... 315
Granulocyte
antibody to cytoplasm, marker to disease (abst) ... 225
increased adhesion with HD (abst) ... 204
Granulocytopenia
of HD, increased granulocyte adhesion (abst) ... 204
Granulomatous diseases
and vitamin D (abst) ... 103
Grey scale ultrasonography
compared with computerized tomography (abst) ... 147
Growth hormone deficiency
GFR and protein intake (abst) ... 296
Growth velocity index
CAPD and CCPD in 82 children ... 558

Guanabenz
effect on papillary collecting duct Cl reabsorption (abst) 197

Haloperidol
inhibition of natriueris by atrial natriuretic factor (abst) 261
Hearing loss
Alport syndrome, Nephrology Forum on 83
Heart failure, congestive, in rat
role of vasopressin (abst) 337
Heart rate
uremia (abst) 95
Heart, artificial
renal function in calves (abst) 236
Hematocrit
effects of enalapril in SHR (abst) 191
Hemodiafiltration
high flux (abst) 174
two strategies for small and middle molecule removal (abst) 828
Hemodialysis
a detoxifying device for (abst) 158
acute *h.* morbidity (abst) 171
Al and Mg urate renal lithiasis (abst) 830
anticoagulant problems (abst) 100
bi-weekly vs. thrice-weekly HD (abst) 175
carcinoembyonic antigen levels (abst) 352
comparison in acetate tolerant or intolerant patients (abst) 160
comparison with CAPD in same population (abst) 178
complement activation in first-use and hypersensitive (abst) 162
complement changes during citrate anticoagulation (abst) 166
contact phase of coagulation (abst) 163
dialysate bicarbonate concentration (abst) 163
does not produce carnintine depletion (abst) 170
effects of acetate and bicarbonate on left ventricular function 768
effects of exercise training during (abst) 149
effects of exercise training on physical work (abst) 176
evaluation of hepatitis B vaccine in (abst) 159
glycolytic activity in erythrocytes and glucose intolerance (abst) 243
increased bone aluminum deposition after PTX 785
maximal exercise during (abst) 161
microcomputer-based ultrafiltration monitor (abst) 705
morbidity and mortality in twice-weekly chronic *h.* (abst) 164
myocardial depression during (abst) 705
parathyroidectomy (abst) 426
polycystic kidney disease (abst) 601
protein-calorie malnutrition in chronic HD (abst) 168
risk factors of vascular calcinosis (abst) 828
role of acetate (abst) 705
short, efficient process with reduced symptoms (abst) 158
single-access, sorbent-based home *d.* (abst) 157
staphylococcus aureus carriage in *h.* (abst) 160
ultrasound-duplex scanning for complications (abst) 177
urea kinetics is not a single pool (abst) 165
uremia (abst) 95
with epoprostenol: acetate vs. bicarbonate (abst) 160
Hemodynamics
during HD, effects of acetate on non-anesthetized dog (abst) 168
effects of angiotensin converting enzyme inhibitor (abst) 293
left and right tubular antibody deposition (abst) 300
glomerular *h.*
effect of isoproterenol (abst) 298
role of increased capillary pressure in ARF (abst) 240
rat *h.*
effect of captopril in SHR (abst) 299
nephron *h.*
effects of indomethacin in pregnant rat (abst) 294
renal *h.*
arachidonic acid affects *r.h.* in dog (abst) 299
calcium, Technical Note on 465
effect of i.v. amino acid infusion (abst) 243
effect of Pichinde virus infection (abst) 301
effects of ANF (abst) 317
effects of ANF on pregnant rat (abst) 314
effects of ANF on SHR (abst) 295
influence of intrarenal adenosine (abst) 291
left and right tubular antibody deposition (abst) 300
postprandial, in humans (abst) 291
Hemofiltration
effect of predilution during AV *h.* (abst) 164
nitrogen balance/growth (abst) 97
Hemolytic uremic syndrome
association with verotoxin producing *E. coli* (abst) 131
Hemorrhage
role in post-traumatic renal insufficiency (abst) 235
sulindac accentuates ischemia (abst) 294
Hemosiderosis
effects of iron chelation in dialysis *h.* (abst) 173
Henle's loop
effect of potassium reabsorption by acute K load 919
Heparan sulfate
and immune complex, sites of extracellular matrices (abst) 210
antibodies bind and induce proteinuria (abst) 218
changes in GBM in membranous nephropathy (abst) 212
Hepatitis B
associated with membranous glomerulonephropathy (abst) 154
Hepatitis B vaccine
in hemodialysis patients (abst) 159
randomized trial for reduced dose in HD patients (abst) 132
Hepatitis, non-B
chronic in renal transplant recipients (abst) 346
Hepatocytes, centritubular
NADPH (abst) 401
Heterogeneity
electrical *h.* of Amphimna proximal tubule (abst) 309
electrophysiologic *h.* in rabbit collecting duct (abst) 313
variation of efferent arteriolar plasma protein (abst) 295
intra-animal *h.*
coefficients for variation 871
tissue *h.*
nuclear magnetic resonance techniques (abst) 270
Heymann nephritis
terminal complement nephritis (abst) 388
Histo-autoradiography
proximal tubule (abst) 3
Histofluoresence
proximal tubule (abst) 3
Homeostasis, potassium
renal regulation, Editorial Review on 837
h., sodium

renal regulation, Editorial Review on 837
Hormonal systems, vasoactive
in dogs with low cardiac output (abst) 293
Hormone
cell-to-substrate adhesion and contractile behavior (abst) 259
deprived, calcitonin (abst) 394
antidiuretic *h.* (ADH)
as cell volume regulation in thick ascending limb (abst) 327
bradykinin inhibits fluid absorption in rabbit (abst) .. 264
chronic metabolic alkalosis (abst) 598
effects on 3H phenamil binding to toad bladder (abst) 308
in systemic lupus erythematosus (abst) 154
pertussis toxin and PGE_2 effects in thick ascending limb (abst) 255
potassium excretion, Editorial Review 379
prostaglandin inhibits chloride absorption (abst) 316
study of solute transport by autoradiography 726
parathyroid *h.* (PTH)
and Na-H antiporter activity, cAMP mediated effect (abst) 287
calcium in uremia (abst) 523
effect of dibutyrl cAMP with fluid absorption (abst) .. 120
effect of lithium (abst) 123
effects of PTH and vitamin D in hamster 864
effect on acidic phospholipids (abst) 122
effect on myocardial energy metabolism in rat 718
effect on osteoblastic activity (abst) 122
effects on aluminum (abst) 109
effects of $1,25(OH)_2D_3$ (abst) 111
effects on blood ionized calcium and serum 1,25D (abst) 124
effects on renal hydrogen ion handling (abst) 278
interrelation with bone GLA-protein and vitamin D in renal failure (abst) 137
NADPH in kidney/liver (abst) 401
plasma immunoreactive PTH levels with uremic serum (abst) 184
role with norepinephrine in CRP (abst) 242
variability in induction of phosphaturia (abst) 124
verapamil blocks acute PTH-induced decrease in cAMP (abst) 127
thyroid *h.*
sodium proximal tubule transport (abst) 94
Horseradish peroxidase
basolateral endocytosis of protein (abst) 39
Houship's lacunae
osteoclast enlargement (abst) 574
Hyalinosis
malignant focal segmental *h.* and idiopathic nephrotic syndrome 155
Hybridization
RNA-DNA dot blot to localize angiotensinogen (abst) . 266
Hydration
medullary concentration of solute and water (abst) 306
Hydrogen
^3H bromobenzamil
photoincorporation into kidney cortex (abst) 313
^3H-labeled sucrose
transport across toad bladder 726
^3H-phenamil
effects of aldosterone, ADH, and trypsin (abst) 308
Hydrogen bicarbonate
change of luminal pH, and P_{CO_2} on intracellular pH (abst) 287
HCO_3 reabsorption
carbonic anhydrase independent, effect of ethoxzolamide (abst) 290
effects of amiloride in rat (abst) 281
HCO-3 secretion
role of carbonic anhydrase cells in turtle bladder (abst) 289
HCO-3 transport
intracellular pH regulation 286
Hydrogen ion
cyclic AMP (abst) 25
effect of PTH on renal handling 278
H^+/OH^- permeability of proximal tubule brush border vesicles (abst) 283
transports (abst) 103
h.i.-ATPase
in human inner medullary membrane vesicles (abst) . 280
isolated in rabbit and human medulla (abst) 288
isolation of high performance ion exchange chromatography (abst) 282
h.i. parathyroid receptors
uremia (abst) 97
h.i. secretion
CO_2 stimulation, role of exoytosis, intracellular pH, and calcium (abst) 280
Hydrogen peroxide
induced by gentamicin in renal mitochrondria (abst) ... 238
Hydronephrosis
renal protein changes (abst) 274
Hydroosmosis
role of phorbol myristate acetate (abst) 330
Hydroxyeicosatetraenoic acid (HETE)
effects of HETE production by lipoxygenase activity .. 855
Hypaque
effects of verapamil on urinary sodium (abst) 326
Hypercalcemia
associated with silicone-induced granulomas (abst) 119
effect of WR-2721 (abst) 129
effect on outcome of ischemic acute renal failure (abst) 230
in diuretic phase of ARF due to rhabdomyolysis (abst). 226
increases nephrotoxicity of Bence Jones protein (abst) . 238
non-parathyroid hormone mediated (abst) 103
of malignancy, role of PTH receptors (abst) 104
of malignancy, role of transforming growth factors (abst) 104
familial hypocalciuric *h.*
study of mineral balances (abst) 119
Hypercalciuria
in SHR (abst) 111
risk ractors for calcium nephrolithiasis during pregnancy (abst) 144
spontaneous *h.*
role of deranged vitamin D metabolism (abst) 128
Hypercapnia
enhances V-max of Na-H antiporter (abst) 289
role of low system pH (abst) 116
chronic *h.*
acid-base equilibrium (abst) 538
Hyperemia
following ischemia unaffected by indomethacin (abst) .. 229
Hypereninemia
potassium depletion in the rat (abst) 264
Hyperfiltration, glomerular
in obese Zucker rat (abst) 297
Hyperglycemia

and GFR in non-diabetic humans (abst) 155
Hyperkalemia
causes low thyroid uptake of thallium in HD (abst).... 166
in organic acidosis (abst)..... 148
incidence and etiology in hospitalization (abst) 320
metabolic acidosis in mineralocorticoid-resistant *h.* (abst)..... 149
potassium excretion, Editorial Review on 379
propranolol induced in non-diabetic uremic patients ... 156
Hyperlipidemia
treatment of *h.* of the nephrotic syndrome (abst)..... 131
Hyperparathryoidism
effect on RBC osmotic fragility (abst)..... 115
role of hypocalcemia (abst)..... 122
secondary *h.*
chronic renal failure (abst)..... 426
dietary calcium deprivation cause of (abst)..... 169
intravenous calcitriol for (abst) 168
$1,25(OH)_2D_3$ (abst)..... 565
osteoclast enlargement (abst)..... 574
ultrasonically guided fine-needle alcoholization (abst) 98
Hyperphosphatemia
control with oral calcium carbonate (abst) 108
Hyperplasia
role of epithelial cell growth inhibitor (abst)..... 247
Hypersensitivity
of skin, effect of cyclophosphamide in chronic uremia (abst)..... 210
Hypertension
abnormal sodium handling (abst)..... 189
and erythrocytosis in rats (abst) 188
and impaired urinary concentration mechanism..... 792
and inhibitors of thromboxane in SHR (abst)..... 198
antihypertensive effects of captopril in dialysis (abst) .. 189
antihypertensive therapy and nephrotoxic serum nephritis (abst) 248
captopril and nifedipine (abst)..... 97
captopril increases renal blood flow (abst) 339
captopril testing to separate patients (abst) 203
cation transport of erythrocyte in adolescent (abst).... 192
CA^{2+} ATPase activity (abst)..... 196
control retards glomerular injury in rats (abst)..... 247
cytosolic-free calcium concentration (abst)..... 96
defective tubulo-glomerular feedback in Milan rat (abst)..... 292
dietary chloride in disordered calcium metabolism (abst)..... 196
effect on peritoneal transport 179
effects of atrial natriuretic factor (abst)..... 295
effects of beta-1 receptor antagonism on renin (abst)... 188
effects of captopril and nifedipine (abst)..... 199
effects of captopril (abst)..... 193
effects of lower arterial pressure in diabetes (abst) 252
effects of potassium depletion in SHR (abst) 195
following renal donation (abst) 137
glomerular capillary pressure in rats (abst)..... 241
glomerular injury despite therapy with DOC-SALT (abst)..... 189
i.v. medroxalol for treatment of arterial *h.* (abst)..... 187
in babies following neonatal intensive care (abst) 138
in Blacks: comparison of creatinine levels (abst)..... 194
in fawn-hooded rat (abst)..... 703
in patients over age 60, resuits of operation (abst)..... 192
in 2-k, 1-c Goldblatt rat..... 731
in 50 children with crescentic glomerulonephritis (abst) 450
interstitial cells affect salt sensitivity (abst) 198
light-chain nephropathy, Nephrology Forum on..... 582
marker for natriuretic hormone in HD patients (abst) .. 186
metabolic effects of indacrinone (abst)..... 191
nephrotic proteinuria (abst)..... 200
nifedipine: non-invasive Doppler cardiac output (abst) . 188
plasma norepinephrine levels in adolescent (abst) 192
pulmonary use of thromboxane in (abst) 158
renal cholesterol embolization (abst)..... 190
renal denervation prevents one-kidney low sodium *h.* (abst)..... 201
renal dysfunction and renin-angiotensin blockade (abst) 198
salt-induced role of protein restriction in glomerulonephritis (abst)..... 249
sodium sensitivity and calcium metabolism (abst) 199
synthetic atrial natriuretic factor reduces BP (abst).... 202
systemic *h.* in diabetic nephropathy (abst)..... 155
therapy in nephritic spontaneously hypertensive rats (abst)..... 187
treatment with captopril in transplant recipients (abst) . 343
urinary calcium excretion (abst) 96
acute *h.*
angiotensin II-induced (abst)..... 31
superficial glomeruli (abst)..... 31
essential *h.*
blood pressure and sodium depletion (abst) 97
h. in rat
effect of captopril (abst)..... 299
tubulo-glomerular feedback in Milan rat (abst)..... 298
pulmonary *h.*
effects of ultrafiltration or dialysis comp. on (abst) .. 175
renovascular *h.*
Nephrology Forum on..... 812
Hypertonic radiocontrast medium
effects on para-aminohippurate extraction (abst) 146
Hypertriglyceridemia
lipo- and apo-protein abnormalities in HD (abst)..... 174
Hypertrophy
Na-H antiport induces *h.* in proximal tubules (abst) ... 241
role of epithelial cell inhibitor (abst)..... 247
renal compensatory *h.*
$1,25(OH)_2D_3$ (abst)..... 598
Hypoaldosteronism
primary acquired *h.*, Nephrology Forum on..... 690
reversible hyporeninemic *h.* in SLE (abst)..... 140
Hypobicarbonatremia
anion gap, Nephrology Form on..... 472
Hypocalcemia
EDTA-induced in early renal failure (abst)..... 565
effect of WR-2721 (abst) 129
effects of aluminum on plasma calcium, ionized calcium, and PTH (abst)..... 125
in critically ill patients (abst)..... 113
post parathyroidectomy in HD patients (abst) 112
role in secondary hyperparathyroidism (abst)..... 122
role of aluminum toxicity (abst) 121
Hypocapnia
phosphate reabsorption (abst)..... 109
Hypocomplementemia
atheroembolic renal disease (abst) 136
Hypokalemia
and pulmonary edema (abst)..... 304
total parenteral nutrition, Editorial Review on..... 489
Hypokinesia
morphological changes in rat kidney (abst)..... 156

Hypomagnesemia
effect of furosemide in cisplatin-induced *h.* rats (abst).. 129
hemodynamic and metabolic effects on SHR (abst).... 189
total parenteral nutrition, Editorial Review on..... 489
Hyponatremia
clinical evaluation for extracellular fluid volume (abst) . 135
during converting enzyme inhibition (abst)..... 298
history of untreated, severe *h.* (abst) 323
myelinolysis in rabbits (abst)..... 141
overcorrection induces central pontine myelinolysis (abst)..... 132
permanent neurological disability in healthy women after elective surgery (abst)..... 132
reduced peripheral resistance in ultrafiltration (abst)... 170
Hyponatriuria
dopamine (abst)..... 94
Hypo-osmolality
in spinal cord injury patients (abst)..... 145
Hypoperfusion
renal sympathetic nerves mediate (abst)..... 232
Hypophosphaturia
role of sodium transport (abst) 110
Hyporenin/hypoaldosteronism
plasma potassium and acidosis 285
Hypothryoidism
action of arginine vasopressin in renal tubules (abst)... 328
h. in rat
function of perfused kidney (abst)..... 300
Hypoxemia
during citrate anticoagulation (abst) 166
Hypoxia
effects of ultrafiltration or dialysis (abst) 175

^{125}I iothalamate
marker for glomerular filtration (abst)..... 9
Ibopamine
renal transplantation (abst) 96
Ibuprofen
prostaglandins (abst) 66
IgA
hidden subclass determinants 685
molecular nephritogenicity and immune complex (abst) 221
spontaneous glomerular deposition in ddY mice 756
IgA nephropathy
C3 activation (abst) 226
mesangial IgA
charge restriction of *m.I.* in primary IgA nephropathy (abst)..... 218
IgG
acute hypertension (abst)..... 31
glomerular distribution in glomerulonephritis (abst).... 221
IgG synthesis
transferrin restores serum (abst) 225
IgG125
binding and release of C3 fragments (abst)..... 224
Imidazole
effects on renal hemodynamics 892
Immune cell
in Thai children with glomerulonephritis (abst) 225
i. complex
alterations by donor-specific blood transfusion (abst). 338
binding of human fibronectin (abst)..... 205
clearance modulation by polyclonal B cell activation (abst)..... 207
deposits during renal failure in acute pancreatitis (abst)..... 131
effect of antigenic charge and eicosanoid production (abst)..... 220
formed by antibody, antigens relevance to Heymann glomerulonephritis (abst) 207
IgA nephritogenicity correlates formation (abst)..... 221
role of dietary protein in *i.*-mediated TBM disease (abst)..... 240
uptake of IgA vs. IgG_1: erythrocyte binding (abst)... 212
with heparan sulfate-rich sites of matrices (abst) 210
i. deposits
effect of protamine sulfate (abst)..... 206
monoclonal anti-DNA antibodies (abst) 216
i. injury
effects of complement depletion and hemodynamics (abst)..... 216
i. response
effect of donor matching in transplant recipient (abst) 220
genes in histocompatibility complex (abst)..... 100
soluble suppressor in urine of nephrotic patients (abst)..... 222
treatment of PGE_2 in glomerulonephritis (abst) 217
Immunity, cell-mediated
and tubulo-interstitial nephritis in Lewis rat (abst)..... 205
in chronically uremic mice (abst) 211
Immunofluorescence
study of 50 children with crescentic glomerulonephritis (abst)..... 450
study of renal amyloidosis (abst)..... 830
Immunoglobin
altered status in congenital nephrotic syndrome (abst) . 140
receptor mediated binding by U937 cells (abst) 218
Immunopathology
significant of brush border related antigen (abst)..... 221
Immunosuppressive drugs
pregnancy..... 74
Immunosuppressive therapy
for lupus nephritis (abst)..... 204
use in corticosteroid-resistant minimal change nephropathy (abst)..... 134
Imuran
cyclosporin (abst)..... 596
Indacrinone
metabolic effects in essential hypertension (abst)..... 192
Indomethacin
effect on single nephron hemodynamics in pregnant rats (abst)..... 294
effects on renal hemodynamics 892
improves renal medullary function and anoxic injury (abst)..... 228
inhibits prostaglandin E_2 release in uremic rats (abst).. 233
no effect on hyperemia following ischemia..... 229
Infiltrate
leucocyte interstitial *i.* in nephritis (abst) 225
Infra-aortic clamping
and renal function (abst) 598
Injury, glomerular
phorbol myristate acetate-induced (abst) 503
tubular *i.*
difference in hypoxic and ischemic *t.i.* (abst) 231
Inositol polyphosphates
bradykinin releases in renal papillary collecting tubule (abst)..... 265
Insulin
actions on isolated perfused rabbit renal proximal tu-

tubules (abst) ... 129
effect on transport properties in renal cells (abst) ... 314
effects on metabolic acidosis in protein turnover (abst) ... 274
postbinding defects in human adipocytes ... 780
subcellular *i.* in rat cortex (abst) ... 273
i. binding
chemical basis in metabolic acidosis (abst) ... 284
Insulin-like growth factors
receptors in proximal tubule (abst) ... 272
Interferon-a, recombinant
treatment with renal transplant (abst) ... 337
Interstitial chronicity index
value in membranoprolific glomerulonephritis (abst) ... 139
Intestine
absorption in nephrotic syndrome (abst) ... 98
Inulin clearance
correlation with predicted GFR (abst) ... 145
myeloma nephrotoxicity (abst) ... 46
Ion exchange chromatography
isolation of solubilized renal H^+ ATPase (abst) ... 282
Iron
desferrioxamine challenge test for chelatable *i.* (abst) ... 162
effects of *i.* chelation in dialysis hemosiderosis (abst) ... 173
overload in chronic renal failure patients (abst) ... 171
i. transfusion
role in metabolic bone disease (abst) ... 127
Ischemia
effects of verapamil on renal function (abst) ... 229
effects on production of erythropoietin (abst) ... 262
improving Euro-Collins flushing solution (abst) ... 337
induces accumulation of putative Ca^{2+} ionophores (abst) ... 234
loss of epithelial surface membrane polarity (abst) ... 234
microvillar membrane glycoprotein after renal *i.* (abst) ... 236
protective effects of verapamil (abst) ... 348
responses of normal kidney to sequential events (abst) ... 240
sulindac accentuates during hemorrhage (abst) ... 294
renal *i.*
antagonism of thromboxane A_2 ameliorates endotoxin *i.* (abst) ... 227
i. unilateral
hyperemia unaffected by indomethacin (abst) ... 229
Isobutyl methyl xanthine
effects on cortical collecting tubule in K depletion (abst) ... 332
Isografts, in rat
native nephrectomy improves (abst) ... 339
Isoproterenol
effect on glomerular hemodynamics (abst) ... 298
to study renin release ... 762

Kallikrein
in human and rat kidney ... 630
Kallikrein-kinin system
in Madin Darby canine kidney ... 260
Kaluresis
effects of metabolite of corticosterone (abst) ... 258
Ketoacidosis
urine anion gap (abst) ... 599
Ketoanalogs
of amino acids as treatment of uremia (abst) ... 829
Kidney, aging, in rat
physiological and physio-chemical modification (abst) ... 329
Madin Darby canine *k.*
kinin-generating activity (abst) ... 260
denervated *k.*
dopamine receptors and sodium excretion (abst) ... 311
hydronephrotic *k.*
cells stimulate sensitivity to bradykinin (abst) ... 255
Kidney International, About Editorial ... 1
Kidney obstruction
bicarbonate reabsorption in collecting tubules (abst) ... 284
perfused *k.*
function in hypothyroid rat (abst) ... 300
Kinin
vasopressin-stimulated water flow (abst) ... 512

L-dopa
incubation (abst) ... 3
Lactate
sclerosing peritonitis on CAPD: acetate vs. *l.* (abst) ... 183
vasorelaxant effects (abst) ... 159
l. metabolism
role in ammonia production in dog (abst) ... 272
Lactic acid, levo
effects on plasma phosphorus (abst) ... 286
Lactic acid, racemic
effects on plasma phosphorus ... 286
Laminin
accumulation in congenital nephrosis ... 662
Laxative abuse
pseudo-distal renal tubular acidosis (abst) ... 152
Lead excretion
pre-eclampsia ... 139
l. intoxication
risk of renal failure (abst) ... 150
l. poisoning
later renal function after *l.p.* in childhood (abst) ... 152
Leucocytes
phenotype in the human kidney (abst) ... 209
Leucocyturia
Ova excretion in ... 667
Leukopenia
anaphylatoxin release during cool hemodialysis (abst) ... 167
during citrate anticoagulation (abst) ... 166
Leukotriene B4
sodium excretion (abst) ... 263
synthesis in rat glomerulus ... 254
Leukotreine C4
effects on rat mesangium (abst) ... 256
Leukotriene D4
sodium excretion (abst) ... 263
Leukotrienes, sulfidopeptide
ameliorates endotoxin-induced renal ischemia (abst) ... 227
Ligand binding
impaired small *l.g.* in uremic plasma ... 244
Limb, medullary thick ascending
ADH and cell volume regulation (abst) ... 327
anoxic injury (abst) ... 107
effect of anoxia on adenylate levels and K uptake (abst) ... 271
effect of calcium ion on cAMP concentration (abst) ... 335
K^+ channels in rabbit (abst) ... 309
pertussis toxin and PGE, effect on epithelial voltage (abst) ... 244
PGE_2 inhibits chloride transport (abst) ... 260
Linoleic acid
improves renal function in rat (abst) ... 244
Lipid
protein modulation with stressed uremic rats (abst) ... 251

role in renal membrane order (abst) 273
role of membrane damage *l.* alterations (abst) 106
l. levels
dietary and serum, response to oral CA^{2+} 140
l. peroxidation
effect of gentamicin (abst) 237
Lipogenesis
postbinding defects in uremic patients 780
Lipoprotein
altered metabolism in CRF (abst) 250
plasminogen activator and inhibitor in cells (abst) 213
uremia (abst) 420
Liposome
effect of encapsulation on toxicity of cyclosporin (abst) 340
Lipoxygenase products
effects on macrophage binding 855
Lithiasis, urate renal
result of A1 salt HD (abst) 830
Lithium
effect on Na-H exchange (abst) 316
effect on PTH secretion and phophatidylinositol cycle (abst) 123
effects on sodium uptake (abst) 285
Liver
dimethylnitrosamine growth and ethanol inhibition (abst) 245
transplantation (abst) 595
acute fatty *l.*
and nephrotic syndrome (abst) 153
LLC-PK1 cells,
exposure to oxygen and effect on ammoniagenesis (abst) 271
glycolysis, ATP and membrane integrity (abst) 236
Na^+-H exchange (abst) 305
pH dependency of amiloride sensitive Na-H antiporter. 285
Loop of Henle
effects of adrenalectomy (abst) 322
effects of K loading and electrolyte transport (abst) ... 317
stop flow pressure and filtration rate response (abst)... 293
Luminal calcium
role in fluid absorption (abst) 120
Luminal membrane
effects of vasopressin-stimulated water flow (abst) 324
presence of anion exchanger (abst) 335
Luminal sodium
effect on cystosolic ion activities (abst) 315
role in potassium secretion 886
Lymphocyte
action of MLR-generated suppressor T (abst) 344
antibody-induced experimental glomerulonephritis (abst) 530
effect of single dose prednisolone (abst) 349
function-associated antigen (abst) 215
monoclonal antibody (anti-act I) (abst) 594
phenotypic identification in allograft rejection (abst) ... 206
transferrin restores serum for IgG synthesis (abst) 225
with cyclosporine and azathioprine treatments (abst) .. 343
Lymphokine response
cyclosporin (abst) 594
Lympholysis
donor-specific studies in allograft recipients (abst)..... 345
Lymphoma
vitamin D (abst) 103
Lymphoproliferation
cyclosporin A (abst) 597
Lysine
acute renal failure (abst) 517
Lysosome absorption
effect of age in proximal tubules (abst) 331

99mTc-DTPA nuclear imaging
to determine GFR (abst) 143
Macrophage
accumulation in Bowman's space 855
antibody-induced experimental glomerulonephritis (abst) 530
attachment to glomeruli 855
decreased fibronectin secretion during CAPD (abst) ... 179
Fc-receptor (abst) 93
release of eicosanoid precursor fatty acids (abst)..... 179
supernatants stimulate mesangial proliferation (abst)... 216
Macula densa
visualization of isolated and perfused *m.d.* (abst) 303
Magnesium
abnormalities after repeated doses of cis-platinum..... 144
calcium-induced vascular changes (abst) 203
effects of vitamin D on *m.* handling 864
renal wasting in autosomal dominant inheritance (abst). 707
urate lithiasis in HD patients (abst)..... 830
uremia (abst) 523
m. depletion
effects on skeletal muscle cellular bioenergetics (abst) 109
m. excretion
cacitonin (abst) 394
m. transport
and NaCl transport (abst) 306
effect of salmon calcitonin (abst)..... 125
m. wasting
following cisplatin therapy (abst)..... 127
Magnetic resonance imaging
following renal transplantation (abst) 340
Maleate
stimulates glutamine metabolism (abst)..... 272
Maleic acid
effects on vasopressin-stimulated water flow (abst) 328
Mannitol
cyclosporin (abst)..... 594
infra-aortic clamping and renal function (abst)..... 598
Matrix, extracellular
immune complexes and heparan sulfate-rich sites (abst) 210
Medroxalol
i.v. treatment for arterial hypertension (abst)..... 187
Medulla
damage due to impaired urinary concentration mechanism 792
isolation of H^+ ATPase..... 288
state of hydration and solute concentration (abst)..... 306
Medullary membrane
presence of H^+-ATPase (abst) 280
Membrane, basolateral cell
endocytosis (abst) 59
Membrane order
role of specific lipids (abst) 273
Membrane permeability, renal
modulation by copper (abst) 315
Mercury
distribution in kidney..... 898
m. poisoning
effects on lung and kidney..... 898

excretion of mercury post poisoning ... 898
treatment ... 898
Mesangium
acute hypertension (abst) ... 31
and spontaneous glomerular IgA deposition ... 756
cell-to-substrate adhesion and hormones (abst) ... 259
effect of calcium antagonist on prostaglandin production (abst) ... 259
effects of eicosapentaenoic acid on PGE synthesis in 5/6 NX rat ... 264
effects of leukotriene C4 in culture (abst) ... 256
function in glomerular sclerosis (abst) ... 405
localization of polyvinyl alcohols ... 751
PGE_2 and TXB_2 production by platelet activating factor (abst) ... 267
platelet activator stimulates oxygen radical release (abst) ... 222
pyrimidine nucleotide metabolism in rat ... 274
serotonin stimulates PGE in rat (abst) ... 252
stimulates cAMP accumulation (abst) ... 265
techniques for isotonic contraction (abst) ... 269
Metabolic bone disease
role of transfusion iron in maint. dialysis patients (abst) 127
Metabolism
altered divalent iron *m.* in early renal failure (abst) ... 565
dialysis (abst) ... 601
intracellular *m.*
prostaglandins inhibit ammoniagenesis ... 283
myocardial *m.*
effect of PTH ... 718
oxidative *m.*
role of bradykinin and arachidonic acid (abst) ... 253
renal *m.*
and chemically-induced cell carcinoma (abst) ... 275
Metaclopramide
effects on renal plasma flow in humans (abst) ... 296
Metalloprotease
activation of prokallikrein ... 630
Metals, heavy
lysosomes (abst) ... 39
Metenkephalin
uremia (abst) ... 95
Metronidazole
hemodialysis clearance of *m.* (abst) ... 165
MHC product expression
mechanism of changes in mouse (abst) ... 212
Microalbuminuria
in obese Zucker rat (abst) ... 297
Microcirculation
of glomerular capillaries (abst) ... 17
Microdissection
of rabbit arterioles to measure renin ... 762
Microelectrode techniques
to study proximal tubule reabsorption (abst) ... 330
Microperfusion
to compare distal convoluted and cortical collecting tubules (abst) ... 317
Microscopy, electron
electrical properties of collecting duct (abst) ... 309
Microspheres
distribution in cat kidney (abst) ... 300
Microvessels
biosynthesis of PGI_2 and PGE_2 (abst) ... 259
Microvillus membrane
fucosylation of glycoprotein after ischemia (abst) ... 236
Na-coupled Cl transport in dog (abst) ... 312
Mineralocorticoid
amiloride and Na transport (abst) ... 263
effects on sodium reabsorption and potassium secretion 886
potassium excretion, Editorial Review on ... 379
m. escape
site of calcium rejection (abst) ... 116
Minimal change lesion
paucity in young children (abst) ... 149
Mitochondria
hydrogen peroxide induced by gentamicin (abst) ... 238
respiratory enzyme integrity during gentamicin (abst) ... 227
two types in cortical collecting tubules (abst) ... 288
MK-421
effects on renal blood flow (abst) ... 297
Molecular structure
of diuretics (abst) ... 327
Monocyte
chemiluminescence (abst) ... 594
cryoglobulinemia-associated glomerulonephritis (abst) ... 93
intraglomerular *m.*
proliferative glomerulonephritis (abst) ... 94
Mononuclear phagocyte system
in idiopathic glomerulonephritis (abst) ... 93
Muckle and Wells syndrome
cause of renal amyloidosis (abst) ... 829
Muscle metabolism
insulin-mediated in acute renal failure (abst) ... 229
Muscle tissue
measurement of K by NMR (abst) ... 313
Myelinolysis
in rabbits following rapid correction of hyponatremia (abst) ... 141
Myeloma, multiple
anion gap, Nephrology Forum on ... 472
light-chain nephropathy, Nephrology Forum on ... 582
Myoglobin
and post-traumatic renal insufficiency (abst) ... 235

NADPH
PTH (abst) ... 401
Naloxane
uremia (abst) ... 95
Naproxen
prostaglandins (abst) ... 66
prostaglandins (abst) ... 512
Natriuresis
effect of carbohydrate intake (abst) ... 143
induced by atriopeptin, dependent on renal vasodilation (abst) ... 294
pressure dependence in 2-k, 1-c Goldblatt rat ... 731
tolerance to atrial natriuretic peptide (abst) ... 268
Natriuretic factors
and Na transport in tubules (abst) ... 263
Natriuretic hormone
marker for in HD patients (abst) ... 186
Necrosis, aseptic
in renal transplant recipients (abst) ... 340
renal transplantation (abst) ... 597
Neotetrazolium chloride
NADPH (abst) ... 401
Nephrectomy
effect of acute potassium load in rat ... 919
graded volume repletion (abst) ... 305
native *n.* improves rat renal isografts (abst) ... 339

potassium secretion after *n.* 636
uremia (abst) 523
nephrectomy 5/6
effect of eicosapetaenoic acid on PGE synthesis in mesangial cells (abst) 264
effect of protein intake 739
Nephrectomy, unilateral
effects on glomerular solute transport in humans (abst). 251
enhanced Na-H antiport in proximal tubule cells (abst). 249
in childhood (abst) 600
Nephritis, antiglomerular basement membrane (anti-GBM)
heterologous 643
influence of immune reaction site 938
role of terminal complement pathway 643
soluble immune response suppressor in *n.* urine (abst) . 222
transfer of plasma anti-GBM auto-antibodies in sheep (abst) 223
hereditary *n.*
clinical spectrum, Nephrology Forum on 83
Heymann *n.*
absence of glycoprotein in human kidney (abst) 211
antigen in rat serum that cross reacts (abst) 223
effects of cyclosporin (abst) 207
pathogenic autoantibody specificities (abst) 213
role of impaired organic ion transport (abst) 248
terminal complement complex (abst) 388
idiopathic interstitial *n.*
leucocyte interstitial infiltrate (abst) 225
IgA *n.*
spontaneous glomerular IgA deposition in ddY mice . 756
immune complex *n.*
role of terminal complement components (abst) 209
interstitial *n.*
caused by nitrofurans, activated by prostaglandin H (abst) 239
lupus *n.*
immunosuppressive therapy (abst) 204
prognosis (abst) 142
murine lupus *n.*
increased thromboxane production 214
role of anti-DNA antibodies (abst) 211
nephrotoxic *n.*
procoagulant activity in urine and glomeruli (abst)... 226
nephrotoxic serum *n.*
eicosanoid production by glomeruli (abst) 211
treatment with antihypertensive therapy (abst) 248
passive Heymann *n.*
colchicine reduces proteinuria (abst) 218
proteinuria (abst) 600
serum sickness *n.*
poly C9 and proteinuria and loss of anion sites (abst) 219
streptococcus mutans-induced *n.*
longitudinal studies in the rabbit (abst) 204
tubulo-interstitial *n.*
cell-mediated autoimmune, in Lewis rat (abst) 205
$L3R4^+$ helper T cells induce $Lyt\ 2^+$ effector T cells (abst) 217
suppressor T cell inhibits αTBM disease (abst) 219
role of dietary protein in development of immune-mediated TBM disease (abst) 240
Nephritogenicity
IgA molecular form-*n.* correlates with immune complex (abst) 221
Nephrocalcinosis
calcium metabolism 774
Nephrology Forum
clinical spectrum of hereditary nephritis 83
disorders associated with an altered anion gap 472
light-chain nephropathy 582
primary acquired hypoaldosteronism 690
renal vasculitis 954
renal vascular hypertension 811
Nephron
α2-adrenoceptor and cAMP levels in isolated single segment (abst) 269
bicarbonate secretion during metabolism alkalosis (abst) 281
handling of acid during acidosis (abst) 278
handling of potassium and sodium in acute glomerulonephritis (abst) 250
Na-K-ATPase (abst) 94
Na-K-ATPase following uninephrectomey (abst) 274
potassium excretion, Editorial Review on 379
amphibian *n.*
transport of bicarbonate (abst) 291
juxtamedullary *n.*
phosphate reabsorption in 879
n. loss
adaptations in chronic renal disease (abst) 242
n. loss adaptation
gain amplification in CRD (abst) 246
single *n.*
proximal tubule morphology after obstruction (abst) . 231
superficial *n.*
phosphate reabsorption 879
Nephropathy
lithium-induced, a 3-yr prospective study (abst) 141
protein/albumin excretion (abst) 94
de novo membranous *n.*
variability of course (abst) 343
diabetic *n.*
response to protein loading (abst) 241
with diabetes mellitus (abst) 138
experimental *n.*
Heymann nephritis (abst) 388
IgA *n.*
environmental antigens (abst) 210
light-chain *n.*
similarities to membranoproliferative glomerulonephritis (abst) 223
Nephrology Forum on (abst) 582
membranous *n.*
GBM changes with heparan sulfate (abst) 212
non-diabetic *n.*
with diabetes mellitus 138
primary IgA *n.*
charge restriction of mesangial IgA (abst) 218
sickle cell *n.*
insights into its pathophysiology, Editorial Review on 711
Nephrosis
effects of dietary protein intake (abst) 352
podocalyxin in puromycin aminonucleoside-induced *n.* (abst) 215
aminonucleoside *n.*
mesangial function and glomerular sclerosis (abst)... 405
role of oxygen free radicals 230
congenital *n.*
laminin and type IV collagen 662

puromycin aminonucleoside *n.*
application of monoclonal antibodies (abst) 219
Nephrotic serum, human
transferrin restores for IgG synthesis (abst) 225
Nephrotic syndrome
altered GBM anionic sites (abst) 217
edema (abst) 706
intestinal absorption (abst) 98
plasma volume and renin activity (abst) 706
primary renal amyloidosis presenting as *n.s.* (abst) 132
puromycin aminonucleoside glomerular neuaminidase activity in (abst) 205
scanning electron microscopy of acellular glomeruli ... 678
study of 48 infants (abst) 544
vasopressin (abst) 598
idiopathic *n.*
children (abst) 442
evaluation of renal vein thrombosis (abst) 352
variant of malignant focal segmental hyalinosis (abst) 155
Nephrotoxicity
Bence Jones protein nephrotoxicity (abst) 46
cyclosporin A-induced (abst) 593
effect of PTX (abst) 230
radiocontrast *n.*
a prospective audit (abst) 153
Nerve, renal
effect on $NaHCO_3$ and NaCl reabsorption (abst) 279
trophic effects of efferent *r.n.* (abst) 313
stimulation *r.n.*
role of calcium in renin secretion (abst) 254
sympathetic *r.n.*
mediate hypoperfusion in circulatory impairment (abst) 232
Nervous system, sympathetic
captopril and nifedipine (abst) 97
Netilmicin
compared with tobramycin (abst) 146
Neutrophil
decreased destruction during HD (abst) 172
Nicotinamide
effect on renal transport (abst) 118
Nifedipine
antihypertensive effect (abst) 97
effects on excretion of saline load in patients (abst).... 199
in hypertension: non-invasive Doppler cardiac output (abst) 188
Nitrofurans
cause interstitial nephritis (abst) 239
Nitrogen
chronic renal failure (abst) 58
effect of low serum triiodothyronine on metabolism in CRF (abst) 246
hemofiltration (abst) 97
measured (abst) 58
N^1-methylnicotinamide
transport in snake proximal tubule (abst) 325
Non-cyclooxygenase
archidonic acid and renal hemodynamics in dog (abst) . 299
Non-hypotensive sepsis
ARF produced in large animal model (abst) 233
Norepinephrine
free and conjugated plasma *n.* in HD (abst) 167
plasma *n.* levels in adolescent hypertension (abst)..... 192
response in pregnant rat (abst) 294
role of PTX and PG in CRF (abst) 242
Nuclear magnetic resonance (NMR)
bilirubin (abst) 51
measure of intracellular Na^+ (abst) 314
measure of K in muscle and kidney (abst) 313
study of immobile renal tubules (abst) 276
to measure Na^+ and K^+ fluxes (abst) 302
to study tissue heterogeneity (abst) 270
Nucleotide
coupling with glomerular angiotensin II receptor (abst). 253
Nutrition
total parenteral *n.*, Editorial Review on 489

Obesity, genetic
effects on renal function in rat (abst) 245
o. in rat
and glomerular hyperfiltration (abst) 297
protects the obstructed kidney from gentamicin (abst) 234
Octanol
effect on enzyme and transport systems (abst) 324
Ocular defects
Alport syndrome, Nephrology Forum on 83
Ontogency
role of extra renal renin (abst) 258
Opioids, endogenous
uremia (abst) 95
Organ culture
serum-free metanephric, and cyst formation (abst) 205
Organic ion transport
role of impaired mechanism in Heyman nephritis (abst) 248
Orthoclone OKT*3
treatment of allograft rejection (abst) 341
Osmolality
drop reduces solute transport (abst) 336
Osmotic fragility
effect of hyperparathyroidism (abst) 115
Osteoblasts
effect of PTH levels in bone (abst) 122
Osteoclast activity
end-stage renal disease (abst) 599
o. enlargement
end-stage renal disease (abst) 574
Osteodystrophy
desferrioxamine therapy in aluminum-related *o.* (abst) . 148
in children, effects of dialysis modalities (abst) 181
renal *o.*
differential response in CAPD and HD patients (abst) 127
Osteomalacia
and osteopenia caused by aluminum (abst) 161
effects of desferrioxamine on aluminum-induced *o.* (abst) 165
role of aluminum intoxication (abst) 114
Osteopenia
and osteomalacia caused by aluminum (abst) 161
Ouabain
influence on Na transport in uremia (abst) 243
role in potassium secretion 886
to regulate Na-K-ATPase activity (abst) 318
Oxalosis
a rat model (abst) 206
Oxygen
LLC-PK, cells and direct exposure and ammoniagenesis (abst) 271
o. consumption
and Na reabsorption and ATP synthesis (abst) 273

o. free radicals
role in aminonucleoside nephrosis (abst) ... 230
o. radical
cause of proteinuria following complement activation (abst) ... 220
involvement in arachidonic acid metabolism (abst) .. 232
involvement in tubular cell injury (abst) ... 232
phorbol myristate acetate induced glomerular injury (abst) ... 503
platelet activator stimulates release in mesangium (abst) ... 222
o. uptake
effects of amino acid infusion (abst) ... 272
Oxytocin
prostaglandin-*o.* interaction in dehydrated rat (abst) ... 326

Pancreas
effect of CRF on structure and function (abst) ... 245
Pancreatitis, acute
in renal failure, immune complex deposits during (abst) 131
Papilla, rat
two X-ray comparison techniques (abst) ... 304
Para-aminohippurate extraction
effects of hypertonic radio contrast medium (abst) ... 146
Para-aminohippurate hormone (PAH)
and urate excretion in anesthetized rabbit (abst) ... 325
p. secretion
inhibition by serum proteins in proximal tubules (abst) ... 336
p. transport
study of influx and efflux in proximal tubules (abst).. 331
Parathyroid
autografts, growth and function (abst) ... 118
hypertension (abst) ... 96
p. glands
enlargement in HD patients (abst) ... 125
Parathyroidectomy
effect on gentamicin, nephrotoxicity, and calciuria (abst) ... 230
hemodialysis (abst) ... 426
subtotal *p.*
increased bone aluminum deposition in HD patients . 785
Pars recta
NADPH ... 401
Pediatric nephrology
Alport syndrome, Nephrology Forum on ... 83
CAPD and CCPD in 82 children (abst) ... 558
crescentic glomerulonephritis in 50 children (abst) ... 450
focal segment glomerulosclerosis (abst) ... 442
long-term follow-up of unilateral nephrectomy (abst)... 600
nephrotic syndrome (abst) ... 98
pre-natal diagnosis of kidney disorders by ultrasound (abst) ... 600
study of 48 infants with nephrotic syndrome (abst) 544
nitrogen balance/growth (abst) ... 97
Pelvis, renal
electrolyte flux in rat (abst) ... 302
Peptide
hypertensogenic, derived from pro-opiocortin (abst) ... 191
atrial natriuretic *p.*
determined by radioimmunoassay ... 260
tolerance to (abst) ... 268
intestinal *p.*
vaso-action effects on renal function (abst) ... 310
Perfusion
action of sodium orthovanadate and potassium (abst) .. 301
calcium entry modulation and sodium excretion (abst) . 307
cold storage vs. machine *p.* in cadaveric kidneys (abst) 342
effect of wheat germ agglutinin (abst) ... 213
effects of verapamil after warm ischemia (abs. ... 229
flow rate and tubule adaptation (abst) ... 311
intrarenal effects of atriopeptin II (abst) ... 311
of isolated and perfused macula densa (abst) ... 303
role of fibrinogen in glomerular permeability ... 808
sodium delivery in proximal tubules (abst) ... 309
urinary PAH and urate excretion (abst) ... 325
p. pressure
chemoreceptor activation (abst) ... 187
Peritoneal transport
effects of time, diabetes, and hypertension (abst) ... 179
Peritoneum
fat absorption (abst) ... 183
Peritonitis
and decreased fibronectin secretion in CAPD (abst) ... 179
bacterial, Tenckhoff removal not necessary for treatment (abst) ... 186
CAPD and CCPD in 82 children (abst) ... 558
reduction using a patient assist device (abst) ... 180
sclerosing *p.* on CAPD, acetate vs. lactate (abst) ... 183
Peritubular activity
and proximal fluid reabsorption (abst) ... 311
Pertussis toxin
blunts PGE_2 inhibition of ADH-stimulated Ve in thick ascending limb (abst) ... 255
effects on renin secretion (abst) ... 262
reverses PGE_2 inhibition of arginine vasopressin and forskolin (abst) ... 252
pH
chronic hypercapnia (abst) ... 538
cellular *pH*
regulation in toad bladder (abst) ... 324
two types of mitochondria rich cells, determined by *c. pH* (abst) ... 288
pH dependency
of amiloride-sensitive Na-H antiporter in LLC-PK1, (abst) ... 285
intracellular pH
ATP-dependence, in medullary collecting duct (abst). 291
basolateral HCO-3 transport in tubules (abst) ... 286
change of luminal pH, P_{CO_2} and HCO_3 (abst) ... 287
CO_2 stimulation of H^+ secretion (abst) ... 280
effect of respiratory acidosis (abst) ... 290
optical measurements, Cl-HCO_3 exchange (abst) 279
luminal pH
change in P_{CO_2} and HCO_3 on intracellular pH (abst) . 287
urinary pH
Bence Jones protein nephrotoxicity (abst) ... 46
Phenotype
of leucocytes in the human kidney (abst) ... 209
p. identification
of intraepithelial lymphocytes in allograph rejection (abst) ... 206
Phenytoin
p. disposition and protein binding during CAPD (abst) . 178
Pheochromocytoma
conflicting results of diagnostic imaging (abst) ... 201
Phloretin
luminal site by autoradiographic techniques ... 726
Phlorizin
effect on fluorescence of BBM (abst) ... 329

receptor in BBM (abst) 334
Phorbol myristate acetate
oxygen radicals (abst) 503
role in exocytosis, endocytosis, and hydroosmosis in toad bladder (abst) 330
Phosphate
disturbed homeostatis (abst) 703
effects of vitamin D 864
p. binder
calcium carbonate in children on dialysis (abst) 185
p. deficiency
total parenteral nutrition, Editorial Review on 489
p. depletion
arrests progression of CRF (abst) 246
p. excretion
effects of acute phosphate loading (abst) 113
p. reabsorption
during hypocapnia (abst) 109
in proximal tubule in dog 879
influence of volume flux (abst) 117
tubular capacity in superficial and deep nephrons (abst) 117
p. restriction
and proteinuria in rats (abst) 251
effect on vitamin D metabolites in ERF (abst) 128
p. transport
effect of acute acidosis (abst) 121
effect of nicotinamide (abst) 118
in proximal tubule in dog 879
inhibition by PTH in opossum kidney (abst) 111
Na^+ independence in basolateral membrane (abst) ... 126
some unusual features (abst) 120
p. uptake
role of trifluoperazin (abst) 118
p. wasting
in renal transplant recipients (abst) 349
Phosphatidylcholine transfer
effect of vitamin D (abst) 119
Phosphaturia
correlation of cytosolic pH and phosphate 112
role of volume expansion-induced *p.* in proximal straight tubule (abst) 123
variability of effects by PTH (abst) 124
Phospholipids
influence of PTH (abst) 122
with vasopressin cAMP, and prostaglandins in toad bladder (abst) 264
Phosphorus
effect of amino acid on reabsorption 951
p. metabolism
effects of dialysis modalities, in children (abst) 181
plasma *p.*
effects of racemic and levo lactic acid (abst) 286
Phosphorus ion
^{31}P NMR
to measure renal pH (abst) 277
Physical fitness
dialysis (abst) 601
PK_1 cells
optical measurement, $Cl\text{-}HCO_3$ exchange (abst) 279
Plasma
effect of potassium depletion and acidosis (abst) 290
levels and PTH (abst) 401
vasopressin (abst) 597
p. flow rate
increased by captopril in hypertensives (abst) 339
renal *p.* flow
effects of metaclopramide (abst) 296
p. oxalate
measurement by gas chromatography and mass spectrometry (abst) 126
Plasmapheresis
follow-up of treatment in children (abst) 347
Plasma, uremic
impaired small ligand binding (abst) 244
Plasmin
activation of prokallikrein 630
Plasminogen
lipoproteins balance production in endothelial cells (abst) 213
Platelet activating factor
after immune complex (abst) 206
effect on prostaglandin release (abst) 269
stimulates oxygen radical release (abst) 222
stimulation of PGE_2 and TXB_2 in mesangium (abst) ... 267
Pneumonia, *Legionella pneumophila*
outbreak after immunosuppressive injections (abst) 830
PO_4 transport
abnormalities in SHR (abst) 123
Podocalyxin
in puromycin aminonucleoside-induced nephrosis (abst) 215
Poly C9
association with proteinuria and anionic sites (abst) ... 219
Polyclonal B cell
modulation of clearance of immune complexes (abst) .. 207
Polycystic kidney disease
abnormal epithelia grown in vitro (abst) 226
autosomal dominant, in children (abst) 153
CAPD in patients with *p.k.d.* (abst) 183
Polycythemia
following renal transplantation (abst) 342
Polyethyleneimine
movement across glomerular wall (abst) 292
Polyuronic acid
a non-aluminum phosphate binder (abst) 147
Polyvinyl alcohol
localization and thickness of glomerular basement membrane 751
Postprandial
effects on renal hemodynamics (abst) 291
Potassium
"delayed rectifier" in K channel in neuroblastoma cells (abst) 316
effect in kidney perfusion (abst) 301
effect of acute load on reabsorption 919
effect of prostaglandin inhibition (abst) 312
effects in Blacks with hypertension (abst) 194
effects of high K diet and circadian K excretion (abst) . 318
extrarenal role of aldosterone (abst) 258
hormonal control, Editorial Review on 379
measurement by NMR in muscle and kidney (abst) 313
nephron handling in acute glomerulonephritis (abst) ... 250
p.-aldosterone axis in dogs with chronic renal insufficiency (abst) 242
prevents stroke death without lowering blood pressure (abst) 201
role of renal regulation in *p.* and sodium balance, Editorial Review on 837
two-tiered control system (abst) 250
Potassium chloride transport

in basolateral membrane vesicles (abst) 307
Potassium deficiency
decreases vasopressin stimulation of adenylate cyclase (abst) 327
p. depletion
acidosis changes in plasma (abst) 290
effects of cAMP, forskolin, and isobutyl methyl xanthine (abst) 332
effects of depletion in SHR (abst) 195
induces hypereninemia in rat (abst) 264
measurement of renal pH by ^{31}P NMR (abst) 277
dietary *p.*
effect of restriction on bicarbonate reabsorption (abst) 279
effect on ^{22}Na rate efflux coefficient (abst) 322
p. disposal
calcium channel blockers enhance (abst) 320
p. excretion
adaptation to high K diet (abst) 318
effect of aldosterone and corticosterone (abst) 323
p. loading
effects on Henle's loop electrolyte transport (abst) .. 317
p. metabolism
adrenergic modulation during exercise (abst) 136
p. pathways
DOCA regulation in tubule (abst) 319
p. permeability
in distal convoluted tubule (abst) 322
plasma *p.*
and acidosis related to volume expansion (abst) 285
p. secretion
after nephrectomy 636
effects of amiloride, ouabain, and luminal sodium ... 886
serum *p.*
renal renin response (abst) 260
side effect of cyclosporine (abst) 349
p. transport
effects of vasopressin and bradykinin (abst) 321
transport (abst) 103
p. uptake
effects of anoxia in thick ascending limb (abst) 271
Potassium ion
p.i. channels
Ba^{++} sensitive, Ca^{++} activated (abst) 309
p.i. depletion
paradoxical, an extrarenal adaptation (abst) 320
p.i. flux
NMR measurement in proximal tubule (abst) 302
p.i. loading
and paradoxical K^+ depletion (abst) 320
p.i. permeability
effects of cell swelling in toad bladder (abst) 305
p.i. restriction
adaptation of K^+ transport in colon (abst) 321
p.i. secretion
chemical maturity in cortical collecting tubule (abst) . 319
p.i. transport
adaptation by colon to K^+ dietary restriction (abst) .. 321
Potential difference (PD)
positive transepithelial *p.d.* in early distal segments ... 622
transepithelial, effect of cisplatin 842
Prazosin
putative central effects of urapidyl (abst) 201
Pre-hypertension
prostaglandin alterations in *p.* Dahl rats (abst) 268
Predilution
effect during continuous AV hemofiltration (abst) 164
Prednisolone
effect of prolonged alternate day therapy on mesangiocapillary glomerulonephritis patients (abst) . 130
effect on lymphocytes (abst) 349
pharmacokinetics in cushingoid/non-cushingoid kidney transplant patients (abst) 459
Prednisone
idiopathic membranous glomerulonephritis (abst) 600
reversal of renal insufficiency in sarcoid nephritis (abst) 136
Pre-eclampsia
and lead excretion (abst) 139
Pregnancy
changes in angiotension II receptors (abst) 254
chronic renal failure (abst) 95
renal allograft recipients (abst) 74
p. in rat
effect of ANF (abst) 314
effects of indomethacin on single nephron hemodynamics (abst) 294
tubulo-glomerular feedback (abst) 292
vascular response to vasoconstrictors (abst) 294
Pressure, arterial
long-term effects of vasopressin (abst) 326
Pressure dependence
of exaggerated natriuresis in Goldblatt rat 731
Pressure regulation
proteinuria after protamine sulfate perfused kidney (abst) 293
Pressure, vasa recta
role in pressure diuresis response (abst) 298
Procainamide
transport action by BBM vesicles (abst) 330
Procoagulant activity
in urine and glomeruli in rabbit with nephritis (abst) ... 226
Prognosis
renal allograft biopsy (abst) 597
Prokallikrein, renal
activation by serine and metalloprotease 630
Pro-opiocortin
gamma MSH, a hypertensive peptide derived from *p.* (abst) 191
Prostaglandin
alteration in pre-hypertensive Dahl rats (abst) 268
biosynthesis inhibition effect of furosemide on chloride transport (abst) 259
dependence of blood flow during converting enzyme inhibition (abst) 297
effect of calcium antagonist in mesangium (abst) 259
effect of inhibition on K homeostasis (abst) 312
effect of inhibition of non-loop diuretics (abst) 261
effect of platelet activating factor (abst) 269
effects of complement depletion and thromboxane (abst) 216
effects of imidazole on production 892
ibuprofen, naproxen, and sulindac (abst) 66
inhibits ADH-stimulated chloride absorption (abst) 316
inhibits ammoniagenesis intracellularly (abst) 283
long-term effects of vasopressin on excretion (abst) ... 326
modulates GFR in rat on high protein diet (abst) 267
oxytocin-*p.* interaction in dehydrated rat (abst) 326
reversal of vasoconstriction by diltiazem (abst) 296
role in macrophage binding 855
role with norepinephrine in CRF (abst) 242

vasopressin-stimulated water flow (abst) 512
with vasopressin cAMP, and phospholipids in toad bladder (abst) 264
PGD_2
stimulates vasopressin secretion in vitro (abst)..... 255
PGE
effect of eicosapentaenoic acid in 5/6 NX rat (abst).. 264
PGE_2
action in perfused rabbit cortical collecting tubule (abst)..... 331
action on vasopressin in cortical collecting tubule (abst)..... 332
angiotensin II affects synthesis (abst) 256
biosynthesis in microvessels (abst) 259
control by rat inner medullary collecting tubule (abst)..... 253
effects on vasopressin-induced water flow in toad bladder (abst) 329
in dogs with chronic low cardiac output (abst)..... 293
influence on humoral and cellular immune response in treatment (abst) 217
inhibited by indomethacin (abst)..... 233
inhibits chloride transport in medullary thick ascending limb (abst)..... 260
mediates fluid reabsorption in proximal tubule (abst). 321
mediates Na-H antiport by angiotensin II (abst)..... 254
modulator of Na-H antiport in tubule (abst)..... 257
pertussis toxin in thick ascending limb (abst)..... 255
pertussis toxin reverses effects in rabbit epithelium (abst)..... 252
production in mesangium by platelet activating factor (abst)..... 267
release in single perfused glomerulus (abst) 297
role in cAMP synthesis (abst) 335
serotonin stimulates production in rat mesangium (abst)..... 252
16,16-dimethyl nephrotoxicity (abst)..... 593
stimulates mouse mesangial proliferation (abst) 216
stimulates vasopressin secretion in vitro (abst)..... 255
synthesis and degradation in rat (abst) 261
PGI_2
biosynthesis in microvessels 259
biosynthesis in SHR (abst)..... 256
functional interaction with angiotensin II (abst) 270
role in gentamicin-treated rats (abst)..... 235
PGH synthase
activates nitrofurans and causes nephritis (abst)..... 239
Protamine sulfate
effect on established glomerular immune deposits (abst) 206
proteinuria after pressure regulation, perfusion in rat (abst)..... 293
Protein
aldosterone-induced *p.* by chromatography 306
basolateral endocytosis (abst) 39
CAPD improves synthesis (abst)..... 182
excretion (abst) 94
excretion in acute hypertension (abst) 31
lipid stores and *p.* modulation in stressed uremic rats.. 251
modulates NaCl absorption (abst)..... 303
nitrogen (abst) 58
renal *p.* changes in hydronephrosis (abst)..... 274
restriction in diet and renal failure (abst) 553
urinary *p.* (abst)..... 705
Bence Jones *p.*
hypercalcemia increases nephrotoxicity (abst) 238
p. binding
phenytoin disposition during CAPD (abst) 178
p. degradation
indomethacin does not decrese muscle *p.d.* (abst) ... 233
dietary *p.*
effect on tubulo-glomerular feedback (abst) 299
p. intake
and GFR in growth hormone-deficient adult (abst)... 296
effects on experimental nephrosis (abst)..... 352
role on phosphate depletion in CRF (abst) 246
p. kinase C
inhibits vasopressin-induced water flow in toad bladder (abst)..... 334
light-chain *p.*
light-chain nephropathy, Nephrology Forum on..... 582
p. loading
effect on vascular reactivity (abst)..... 245
prostaglandins modulate GFR (abst)..... 267
reponse in diabetic nephropathy (abst) 241
plasma *p.*
and sampling techniques (abst) 295
carbamoylation in CAPD and HD (abst)..... 181
platelet cationic *p.*
following immune complex-induced platelet activation (abst) 206
p. restriction
and proteinuria in rat (abst)..... 251
effect on renal function in partial nephrectomy 739
effect on vitamin D metabolites in ERF (abst) 128
in chronic renal insufficiency (abst)..... 137
role after established renal injury (abst) 248
role in α-TBM disease and nephritis (abst)..... 240
role in salt-induced hypertension glomerular damage (abst)..... 249
serum *p.*
control of proximal tubule PAH secretion (abst) 336
p. turnover
effect of metabolic acidosis (abst) 274
Proteinase
elimination of a metallo *p.* during HD (abst) 175
p. activity
effect of age in proximal tubule (abst)..... 331
p. inhibitor
effect of dialyzer on (abst)..... 171
Proteinuria
aminonucleaside nephrosis (abst) 405
antibody-induced experimental glomerulonephritis (abst)..... 530
caused by antibodies to heparan sulfate proteoglycans (abst)..... 218
colchicine (abst)..... 600
colchicine reduces *p.* in passive Heymann nephritis (abst)..... 218
following renal donation (abst) 137
48 infants with nephrotic syndrome (abst) 544
Heymann nephritis (abst) 388
idiopathic Bence Jones *p.* and light-chain nephropathy, Nephrology Forum on 582
in protamine sulfate-perfused kidney (abst) 293
membranoproliferative glomulonephritis (abst)..... 436
monocytes (abst) 93
nephrotic *p.* in hypertension (abst)..... 200
ova excretion in..... 667
oxygen radical-induced *p.* following complement (abst). 220
oxygen radicals (abst) 503

poly C9 and loss of anionic sites in GMB in nephritis (abst) ... 219
post transplantation ... 800
pregnancy (abst) ... 74
proliferative glomerulonephritis (abst) ... 94
protein and phosphate restriction (abst) ... 251
role of fibrinogen in perfused kidney ... 808
light-chain *p.*
light-chain nephropathy, Nephrology Forum on ... 582
malignant *p.*
a new, life-threatening syndrome (abst) ... 132
Proton pump
partial resolution of clathrin-coated vesicle (abst) ... 289
Proton secretion
cyclic AMP (abst) ... 25
Proximal fluid reabsorption
peritubular factors and inhibition of carbonic anhydrase (abst) ... 311
Pseudemys scripta
acidification (abst) ... 25
Pseudoangina
in dialysis patients (abst) ... 177
Pseudohyperaldosteronism, acquired
as a complication of glomerulonephritis (abst) ... 146
Puromycin aminonucleoside
nephrosis ... 405
Pyrimidine nucleotide
metabolism in rat mesangial cell glomeruli (abst) ... 274
Pyruvate
vasorelaxant effects (abst) ... 159

Quality of life
recipients of living, related-donor renal donations (abst) ... 341
Quinidine
effect on Na-H exchange (abst) ... 316
effects on sodium uptake (abst) ... 285
Quinine
protective effect against cisplatin (abst) ... 228

Rabbit, newborn
K^+ secretion in cortical collecting tubule (abst) ... 319
Radiocontrast medium
calcium, Technical Note on ... 465
theophylline attenuates intrarenal vasoconstriction (abst) ... 227
Radioimmunoassay
to determine atrial natriuretic peptide (abst) ... 260
to determine effects of ischemia (abst) ... 262
Rats, Brattleboro, dehydrated
oxytocin and prostaglandin interactions (abst) ... 326
Receptor cells
Fc and C3b mediated binding of immunoglobulin (abst) 218
Receptors
dopamine *r.* in sheep (abst) ... 297
Recombinant interleukin-2
activation of alloimmune memory cells (abst) ... 350
Reflex responses
trophic effects of efferent renal nerve activity (abst) ... 313
Regional citrate anticoagulation
for hemodialysis (abst) ... 152
Rejection, allograft
T cells, Technical Note on ... 469
Renal ablation
control of hypertension retards glomerular injury (abst) 247
Renal action
of pure atrial natriuretic factor (abst) ... 258
Renal artery stenosis
predictive value of renal vein renin ratios (abst) ... 203
Renal blood flow
effects of imidazole and indomethacin ... 892
Renal concentrating defect
with gastric alkalosis (abst) ... 284
Renal disease, chronic
nephron loss adaptations (abst) ... 242
role of gain amplification (abst) ... 246
end-stage *r.d.* (ESRD)
cloning of T lymphocytes in ESRD kidneys (abst) ... 210
four-year study in Saudi Arabia (abst) ... 173
osteoclast activity (abst) ... 599
osteoclast enlargement (abst) ... 574
psychosocial outcome (abst) ... 600
racial differences in genetic epidemiology (abst) ... 144
serum electrolyte patterns ... 283
trends in the United States (abst) ... 151
polycystic *r.d.*
hemodialysis-induced (abst) ... 601
Renal failure
abnormalities of platelet and coagulation functions (abst) ... 101
analysis of progression (abst) ... 244
course of *r.f.* in primary chronic glomerulonephritis (abst) ... 246
hemotological problems (abst) ... 100
protein-restricted diet (abst) ... 553
acute *r.f.*
accelerated valine oxidation (abst) ... 273
backleaks of furosemide prevents urinary excretion (abst) ... 239
contribution of vascular decongestion (abst) ... 234
due to rhabdomyolysis, vitamin D, and hypercalcemia (abst) ... 226
effect of vitamin D-induced hypercalcemia (abst) ... 230
electron spectroscopic imaging of (abst) ... 239
etiology, treatment, and outcome (abst) ... 133
evaluation of calcium in post-ischemic ARF (abst) ... 234
glomerular dynamics, increased capillary resistance (abst) ... 240
in Saudi Arabia (abst) ... 152
lysine-induced (abst) ... 517
normal cortical cell amino acid concentration (abst) ... 232
pathophysiology of impaired recovery (abst) ... 235
post-receptor defects in muscle metabolism (abst) ... 229
potassium dichromate-induced role of renal Na-K-ATPase ... 229
prediction of outcome (abst) ... 135
produced by non-hypotensive sepsis in model (abst) ... 233
prognosis ... 928
protection by calcium channel blockers (abst) ... 233
resolving stage ... 928
role of calcium antagonists in dogs (abst) ... 235
study of a model of creatinine kinetics ... 928
thyroxine protection in gentamicin-induced ARF (abst) ... 230
total parenteral nutrition, Editorial Review on ... 489
unloading with furosemide reversed P_{O_2} depression (abst) ... 228
urinary sediment (abst) ... 601
value of intensive dialysis (abst) ... 162
post-transplant *a.r.f.*

effects of hypotension, renal insufficiency, and diabetes insipidus (abst) ... 344
chronic *r.f.*
altered lipoprotein metabolism (abst) ... 250
branched chain amino acid metabolism ... 249
calcium metabolism and effects of verapamil ... 774
cardiac risks with (abst) ... 163
case mix index for patients (abst) ... 160
dimethylnitrosamine and ethanol inhibition in liver (abst) ... 245
effect of acute potassium load ... 919
effect of phosphate and calcium metabolism (abst) ... 123
effect of protein intake in 5/6 nephrectomy ... 739
effects of valine and tyrosine (abst) ... 249
effects on structure and function of pancreas (abst) ... 245
in transplant recipients (abst) ... 340
iron overload in HD patients (abst) ... 171
nitrogen (abst) ... 58
pancreatic enzymes in (abst) ... 180
pregnancy (abst) ... 95
progression, influence of clinical follow-ups (abst) ... 240
protein-restricted diet (abst) ... 553
role of low serum triiodothyronine and nitrogen metabolism (abst) ... 246
role of phosphate depletion and protein intake (abst) ... 246
role of PTX, PG, and norepinephrine (abst) ... 242
triglyceride-rich lipoproteins (abst) ... 420
early *r.f.*
altered divalent ion metabolism (abst) ... 565
ischemic *r.f.*
sodium bicarbonate preloading is protective (abst) ... 227
post-transplant oliguric *r.f.*
dopamine and furosemide infusions (abst) ... 339
Renal function
effect of amino acid and low-dose dopamine (abst) ... 300
effect of protein intake ... 739
effect of vaso-active intestinal peptide (abst) ... 310
effects of atrial natriuretic factor (abst) ... 305
effects of genetic obesity in rat (abst) ... 245
effects of intermittent diet on conscious rats (abst) ... 295
in uni-nephrectomized rats (abst) ... 242
linoleic acid improves *r.f.* in rat (abst) ... 244
long-term effects of vasopressin (abst) ... 326
Renal injury
role of protein restriction after established *r.i.* (abst) ... 248
Renal innervation
in the SHR (abst) ... 191
Renal insufficiency, chronic
potassium-aldosterone axis in dog (abst) ... 242
post-traumatic *r.i.*
role of myoglobin and hemorrhage (abst) ... 235
Renal lesions
in diabetic patients with nephrotic syndrome (abst) ... 156
Renal mass, reduction
functional and morphological consequences in dog (abst) ... 241
Renal scanning techniques
comparison of two isotopic *r.s.t.* (abst) ... 191
Renal transport
culture of proximal tubule cells (abst) ... 314
effect of insulin (abst) ... 314
Renal vascular resistance (RVR)
metabolic control ... 848
Renal vasculitis
Nephrology Forum on ... 954
Renal vein renin ratios
predictive value in renal artery stenosis (abst) ... 203
Renin
effects of beta-1 receptor antagonism (abst) ... 188
r. activity
increased *r.a.* and catecholamines in CAPD (abst) ... 181
r. content
in rabbit afferent arterioles ... 762
extrarenal *r.*
during ontogeny in mouse (abst) ... 258
r. level
Nephrology Forum on renovascular hypertension ... 811
r. release
effects of adrenalectomy (abst) ... 322
effects of atrial natriuretic factor (abst) ... 305
renal *r.* response
alteration of serum potassium (abst) ... 260
r. secretion
de novo formation of angiotensin II (abst) ... 263
effects of pertussis toxin (abst) ... 262
in isolated rabbit afferent arterioles ... 762
role of calcium and renal nerve stimulation ... 254
Renin-aldosterone
effects of ANF (abst) ... 316
Renin-angiotensin blockade
and acute renal dysfunction (abst) ... 198
Renovascular hypertension
Nephrology Forum on ... 811
Response, contractile
angiotensin II affects *c.r.* in glomeruli in vitro (abst) ... 256
Rhabdomyolysis
and renal insufficiency with decompression sickness (abst) ... 145
cause of acute renal failure, use of vitamin D (abst) ... 226
Rifampin
induces sunset dialysate (abst) ... 177
Ritodrine
induced hypokalemia and pulmonary edema (abst) ... 304
RNA-INA dot blot hybridization
localization of angiotensinogen (abst) ... 266
Rubidium
effect of restriction and salt loading (abst) ... 198
vasopressin stimulates secretion (abst) ... 320

S3 tubule segment
transport-dependent cell injury (abst) ... 238
Salicylate reabsorption
in the proximal tubule (abst) ... 333
Saline
infra-aortic clamping and renal function (abst) ... 598
Salmon calcitonin
role in magnesium transport (abst) ... 125
Salt sensitivity
determination by interstitial cells determine in hypertension (abst) ... 198
Sampling techniques
variations in efferent arteriolar plasma protein (abst) ... 295
Saralasin
infusion in dogs with thoracic inferior vena cava constriction (abst) ... 312
Sarcoidosis
extra-renal synthesis of vitamin D (abst) ... 119
Schistosomiasis, urinary
circadian variation of ova excretion ... 667
Schizophrenia, chronic

anion gap, Nephrology Forum on 472
Schwartzman reaction
changes induced by cyclosporine (abst) 220
Sclerosis, glomerular
aminonucleoside nephrosis (abst) 405
Sediment, peritoneal
CAPD (abst) 602
urinary *s.*
acute renal failure (abst) 601
Segment, distal
DCCD-sensitive ATPase activity (abst) 285
proximal *s.*
DCCD-sensitive ATPase activity (abst) 285
Serine protease
activation of prokallikrein 630
Serotonin
proximal tubule (abst) 3
stimulates PGE_2 in rat mesangium (abst) 252
Serum insulin
uremia (abst) 420
Serum, noncurrent
renal transplantation (abst) 596
Serum, uremic
supersaturation with calcium oxalate monohydrate (abst) 251
Shark
fluid secretion in proximal tubules (abst) 319
Sickle cell
new insights into *s.c.* nephropathy, Editorial Review on 711
Single nephron obstruction
and proximal tubular morphology (abst) 231
SITS effect
differential time course in proximal straight tubule in rabbit (abst) 277
Snake
N^1-methylnicotinamide and tetraethylammonium in tubules (abst) 325
Sodium
abnormal handling in hypertension (abst) 189
delivery from tubules in perfusion (abst) 309
dietary intake vs. excretion (abst) 497
effect of changes on blood pressure and renin (abst) ... 197
effects on blood pressure (abst) 200
essential hypertension (abst) 97
nephron handling in acute glomerulonephritis (abst) ... 250
role of renal regulation in *s.* and potassium balance, Editorial Review on 837
sensitivity and hypertension (abst) 199
s. bicarbonate
cardiac homotransplantation (abst) 593
pre-loading protective in ischemic renal failure (abst) 227
s. calcium exchange
calcium permeability of proximal tubular cells (abst) . 334
s. chloride
anion gap, Nephrology Forum on 472
s.c. absorption
protein modulates in proximal tubules (abst) 303
s.c. concentration
estimate of proximal tubule interspace (abst) 318
s.c. transport
and magnesium transport (abst) 306
s.c. reabsorption
effect of renal membrane activity (abst) 279
s.-coupled chloride transport
in microvillus membrane in dog (abst) 312
dietary *s.*
effect on ^{22}Na rate efflux coefficient (abst) 322
s. excretion
calcium entry modulation in perfusion (abst) 307
dopamine receptors in denervated kidney (abst) 311
effect of aldosterone and corticosterone (abst) 323
effect of clonidine in SHR (abst) 194
effects of leukotrienes D4 and B4 (abst) 263
s.-glucose cotransport
amiloride inhibits in BBM (abst) 310
s. handling
increased binding of furosemide in diabetics (abst) .. 307
s. loading
asymmetrical responses (abst) 304
s. orthovanadate
action in kidney perfusion (abst) 301
s. pathways
DOCA regulation in tubule (abst) 319
s.-potassium pump
inhibition of activity in adapted goldfish (abst) 195
s. pump
inhibition in healthy subjects (abst) 194
s. reabsorption
and oxygen consumption and ATP synthesis (abst) .. 273
arachidonic acid affects in dog (abst) 299
s. restriction
and antihypertensive drugs: effects on renal function (abst) 193
and converting enzyme inhibition in rat (abst) 298
asymmetrical response (abst) 304
s. retention
role of angiotensin II and aldosterone (abst) 318
s. solute reabsorption
ANF inhibits in proximal tubules (abst) 306
s. transport
amiloride, effect of corticoid stimulation (abst) 263
bilirubin (abst) 51
cyclic AMP (abst) 25
effect of vasopressin and bradykinin (abst) 321
inhibition by amiloride, ouabain, and luminal sodium 886
natriuretic factors in isolated tubules (abst) 263
role of PTH and cAMP (abst) 113
role of thiazides in turtle bladder (abst) 125
sensitivity to ouabain in uremia (abst) 243
s. uptake
effects of lithium, amiloride, and quinidine (abst) 285
urinary *s.*
effects of verapamil and hypaque (abst) 326
Sodium bicarbonate reabsorption
effect of renal membrane activity 279
s.b. therapy
in lactic acidosis in dogs (abst) 139
Sodium-hydrogen antiport
and PTH, cAMP mediated effect 287
angiotension II stimulation mediated by PGE_2 (abst) ... 254
at BBM, interaction with individual antiporter (abst) ... 281
chronic hypercapnia enchances V-max (abst) 289
enhanced activity in proximal tubule (abst) 249
enhanced by α2-adrenergic agonist (abst) 317
induces hypertrophy in proximal tubule (abst) 241
PGE_2 as modulator in tubule cell (abst) 257
pH dependency in LLC-PK, cells (abst) 285
Sodium-hydrogen exchange
effect of quinidine, amiloride, and lithium (abst) 316

Sodium ion
NMR measures intracellular Na^+ (abst) 314
s.i. flux
NMR measurement in proximal tubule (abst) 302
s.i. loading
in 2-k, 1-c Goldblatt rat 731
^{22}Na rate efflux coefficient
in medullary collecting tubule (abst) 322
^{23}Na-NMR
to measure Na^+ and K^+ fluxes (abst) 302
s.i. reabsorption
effects of amino acid infusion (abst) 272
s.i. transport
corticosterone metabolite (abst) 269
s.i.-H exchange
in LLC-PK1 cells (abst) 305
s.i.-K^+-ATPase
studies with monoclonal antibody (abst) 303
s.i.-PAH cotransport
in rat basolateral membrane (abst) 328
Sodium-potassium-ATPase
along rat nephron after uninephrectomy 274
effects of amiloride, ouabain, and luminal sodium 886
in potassium dichromate-induced ARF (abst) 229
modulation by dietary K^+ in absence of aldosterone (abst) 308
regulation by ouabain (abst) 318
three inhibitors in human plasma (abst) 193
Solute clearance
and ultrafiltration with varying dialysate temperatures (abst) 170
s. concentration
and state of hydration in medulla (abst) 306
s. flux
across tight junction in proximal tubule (abst) 307
s. loading
and impaired urinary concentration mechanism 792
s. transport
autoradiographic studies in toad bladder 726
drop of osmolality in proximal tubules (abst) 336
effect of unilateral nephrectomy in humans (abst) ... 251
Sorbent
recycling of ultrafiltrate in humans (abst) 172
Sperker technique
glomerular filtration marker (abst) 9
Spontaneously hypertensive rat (SHR)
biosynthesis of PGI_2 (abst) 256
Staphylococcus aureus
in hemodialysis patients (abst) 160
Star vessel pressure
intra-animal coefficients for variation 871
Steroid
rejection treatment with cyclosporine (abst) 338
adrenal *s.*
effect on ammoniagenesis (abst) 271
dialysance during CAPD (abst) 185
Stop flow pressure
and filtration rate in loop of Henle (abst) 293
Streptococcus
s.-induced nephritis in rabbit (abst) 204
Streptokinase
renal vein thrombosis (abst) 599
treatment for thrombosed AV fistulae (abst) 159
Stroke death
potassium prevents without lowering BP (abst) 201
Subepithelial space
effects of antibodies in rat 938
Substrates, organic
proximal tubule PAH secretion (abst) 336
Succinate dehydrogenase
bicarbonate inhibition and glutamate metabolism (abst). 275
Sulfamethoxazole
interaction with cyclosporin by chromatography (abst) . 343
Sulindac
accentuates renal ischemia during hemorrhage (abst) .. 295
prostaglandins (abst) 66
Suppressor cells
donor-specific studies in allograft recipients (abst) 345
Suppressor T cells
nature of cyclosporine-induced tolerance (abst) 347
Systemic lupus erythematosis (SLE)
SLE overview (abst) 703

α-TBM disease
role of dietary protein restriction (abst) 240
T cell
hepatitis-B antigen and antibody (abst) 150
Lyt 2^+ effector *t.c.*, L3T4$^+$ helper *t.c.*, and nephritis (abst) 217
mediates ontologic tolerance to antigen (abst) 215
phenotype in cytomegalovirus, allograft (abst) 224
receptor in humans (abst) 106
suppressor inhibits α-TBM nephritis in mice (abst) 219
T c. subset
heart grafts (abst) 594
T lymphocyte
antibody-induced experimental glomerulonephritis (abst) 530
cytotoxicity (abst) 593
isolation and cloning in ESRD kidneys 210
Tachyphylaxis
on a vessel strip preparation 164
Technetium-99M tin colloid
diagnostic value in renal transplantation (abst) 351
Tegretol
interaction with cyclosporine (abst) 344
Terbutaline
induced hypokalemia and pulmonary edema (abst) 304
Terminal complement components
role in immune complex nephritis (abst) 209
t.c. pathway
role in anti-GMB nephritis 643
Tetraethylammonium
transport in snake proximal tubule (abst) 325
update in proximal tubule (abst) 335
Thallium
hyperkalemia causes low thyroid uptake (abst) 166
Theophylline
attenuates intrarenal vasoconstriction (abst) 227
cyclic AMP (abst) 25
Thermolysin
activation of prokallikrein 630
Thiazides
disassociation between *t.* and ionizable plasma Ca (abst) 202
role in calcium reabsorption and sodium transport in turtle bladder (abst) 125
3,3',5' Triiodothyronine
uremia (abst) 95
Thrombosis, renal vein

evaluation in idiopathic nephrotic syndrome (abst) 352
streptokinase (abst) 599
Thromboxane
activation of platelet synthetase by human glomeruli... 266
as indicator of allograft rejection (abst) 257
causal role in allograft rejection (abst) 257
effects of complement depletion (abst) 216
in pulmonary hypertension (abst) 158
increased production in murine lupus nephritis (abst) .. 214
inhibitors ameliorate hypertension in SHR (abst)..... 198
Thromboxane A_2
antagonism and endotoxin-induced renal ischemia (abst)..... 227
glomerular function in gentamicin-treated rats (abst)... 235
unmasking of 892
Thromboxane B_2
increase formation by glomeruli in immune complex glomerulonephritis (abst) 267
prostaglandins (abst) 66
stimulation in mesangium by platelet activating factor (abst)..... 267
Thrombus, glomerular
associated with cyclosporin therapy (abst)..... 345
Thymocyte sodium content
^{22}Na efflux in rats (abst) 190
Thyroparathyroidectomy (TPTX)
effects of vitamin D in TPTX hamster 864
Thyroxine
protection in gentamicin-induced ARF (abst)..... 230
Ticarcillin
reduces tobramycin nephrotoxicity (abst)..... 231
Tissue typing, HLA-DR
in cadaveric kidneys (abst) 345
Tobramycin
compared with netilmicin in ESRD (abst)..... 146
nephrotoxicity reduced in ticarcillin (abst)..... 231
"Trade off" hypothesis
in secondary hyperparathyroidism in uremia (abst) 114
Transepithelial transport
bilirubin (abst) 51
Transferrin
restores nephrotic serum in IgG synthesis (abst)..... 225
Transfusion, blood, donor-specific
induction of immune alterations (abst) 338
Transmission electron microscopy
of urinary sediment in aminoglycoside therapy (abst) .. 233
Transplantation, cardiac
cyclosporin (abst)..... 595
rejection (abst)..... 593
Transplantation, liver
new Canadian program (abst) 595
outcome for patients with cirrhosis (abst)..... 338
Transplantation, pancreas
p. duct anastomosis (abst)..... 595
Transplantation, renal
abnormal catechol production in recipients (abst) 203
as treatment for amyloidosis (abst)..... 828
aseptic necrosis (abst) 597
aseptic necrosis (abst) 340
cadaveric *r.t.*, cyclosporin immunosuppression (abst).. 597
cadaveric *r.t.*, psychosocial outcome (abst) 600
carcinoembryonic antigen levels (abst)..... 352
chemiluminescence (abst) 594
course of CRF (abst)..... 340
cushingoid and non-cushingoid (abst)..... 459
cyclosporine to treat rejection (abst)..... 342
cytomegiovirus infection (abst) 596
donor matching and cellular immune response (abst)... 220
donor-specific T cell reactivity (abst) 596
dopamine (abst) 96
effect on psychomotor development in infancy (abst) .. 348
erythrocytosis (abst) 96
focal segmental glomerulosclerosis in children (abst)... 442
from living, related-donor and quality of life (abst) 341
HLA-D matching and outcome (abst)..... 348
hypertension and decreased graft survival (abst) 188
immune alterations with donor-specific blood transfusion (abst) 338
in children, cyclosporine as sole therapy (abst) 350
living, related-donors and quality of life (abst)..... 341
low-dose cyclosporine maintenance treatment (abst)... 342
magnetic resonance imaging post *t.* (abst) 340
Minnesota antilymphoblast globulin (abst) 596
morphological changes in allograft 800
outcome in peritoneal dialysis patients (abst)..... 339
prednisolone pharmacokinetics (abst)..... 459
risk factors and outcome (abst)..... 347
role of fibrinogen in perfused kidney 808
transfer of cytomegalovirus infection (abst) 705
treatment with cyclosporine and azathiaprine (abst) ... 341
treatment with recombinant interferon-a (abst) 337
tubular function after living donor *r.t.* (abst) 346
use of cyclosporin (abst) 704
Transplantation, spleen
suppressor cells (abst) 595
Transport mechanisms
morphological insights (abst)..... 102
Transport systems
effects of benzyl alcohol and octanol (abst) 324
Transtubular transport
mediates proximal tubular cyst formation (abst) 205
Trifluoperazin
role in phosphate update (abst)..... 118
Triiodothyronine (T3)
effect on brush border membrane in cortex (abst)..... 277
role in nitrogen metabolism in CRF (abst) 246
Trypsin
as activator of prokallikrein..... 630
effect on 3H-phenamil binding to toad bladder (abst)... 308
TSH
response to TRH stimulation on CAPD (abst)..... 182
Tubular obstruction
acute renal failure (abst) 517
Tubule
biochemistry during alkalosis in dog..... 908
chloride transport and bicarbonate absorption (abst)... 304
differences in hypoxic and ischemic injury (abst)..... 231
effects of Pichinde virus infection (abst)..... 301
Na-H antiport angiotensin II stimulation mediated by PGE_2 (abst)..... 254
natriuretic factors in Na transport (abst) 263
NMR spectography in immobile *t.* (abst) 276
sodium delivery in perfusion (abst)..... 309
collecting *t.*
after nephrectomy 636
bicarbonate reabsorption with obstructed kidneys (abst)..... 284
effect of calcium ion and cAMP concentration (abst). 335
intercalated cells..... 636
principal cells 636

cortical collecting *t.*
bradykinin inhibits ADH-induced fluid absorption in rabbit (abst) ... 264
cAMP stimulated bicarbonate secretion (abst) ... 288
comparison by microperfusion (abst) ... 317
effects of cAMP, forskolin, and isobutyl methyl xanthine (abst) ... 332
effects of vasopressin and bradykinin (abst) ... 321
flow rate and hydraulic conductivity with arginine vasopressin (abst) ... 325
hormone regulation of chloride transport (abst) ... 321
interaction of PGE_2 and vasopressin (abst) ... 332
interactions of cholera toxin, forskolin, and PGE_2 (abst) ... 331
K deficiency, vasopressin, and adenylate cyclase (abst) ... 327
K^+ secretion in newborn rabbit (abst) ... 319
potassium secretion ... 886
purinergic regulation of conductivity (abst) ... 325
role of HCO_3 and P_{CO_2} on acidification ... 278
two types of mitochondria-rich cells ... 288
vasopressin stimulates rubidium secretion (abst) ... 320
distal *t.*
action of vasopressin and forskolin on adehylate cyclase (abst) ... 333
bicarbonate reabsorption, effect of low K diet (abst) ... 279
effects of acid loading and amiloride (abst) ... 284
effects of cisplatin ... 842
culture of isolated renal *t.* in rabbit (abst) ... 267
potential difference in early *d.t.* in rat ... 622
distal convoluted *t.*
comparison by microperfusion ... 317
K and Cl permeability (abst) ... 322
Malphigian *t.*
endoplasmic reticulum as transcellular route (abst) ... 323
medullary collecting *t.*
cAMP and control of PGE_2 (abst) ... 253
effects of dietary Na and K (abst) ... 322
role of Ca and PGE_2 in cAMP synthesis (abst) ... 335
papillary collecting *t.*
bradykinin increases release of inositol polyphosphates (abst) ... 265
differences in PGE_2 synthetic capacity in Dahl rats (abst) ... 199
proximal *t.*
albumin activities (abst) ... 331
α2-adrenergic agonist enhances Na-H antiport (abst) ... 317
ammonia production, effect of metababolic acidosis (abst) ... 286
ANF inhibits Na-coupled solute reabsorption (abst) ... 306
anoxic injury (abst) ... 106
basolateral endocytosis of protein (abst) ... 39
β-catecholamine cAMP system (abst) ... 261
cell injury in short-term anoxia ... 275
cell volume maintenance (abst) ... 328
change of luminal pH, P_{CO_2} and HCO_3 (abst) ... 287
citrate reabsorption (abst) ... 270
comparison of mesonephric and metanephric *p.t.* (abst) ... 322
control of PAH secretion (abst) ... 336
culture of cells and renal transport (abst) ... 314
dopamine histofluorescence (abst) ... 3
drop in osmolality reduces solute transport (abst) ... 336
effect of age on lysosome absorption and proteinase activity (abst) ... 331
effect of α2-adrenergic inhibition (abst) ... 333
effect of gramicidin on cytosolic ion activity (abst) ... 315
effect of respiratory acidosis on intracellular pH (abst) ... 290
electrical heterogeneity of amphiuma *p.t.* (abst) ... 309
energy sources for reabsorption ... 848
enhanced Na-H antiport after unilateral nephrectomy (abst) ... 249
flow rate and adaptation in perfusion (abst) ... 311
fluid reabsorption mediated by PGE_2 (abst) ... 321
fluid secretion by shark (abst) ... 319
flux across fibre matrix tight junction (abst) ... 307
H^+/OH^- permeability (abst) ... 283
interspace NaCl concentration (abst) ... 318
intracellular alkalinization in tiger salamander (abst) ... 288
morphology after single nephron obstruction ... 231
Na-Ca exchange inhibitors (abst) ... 334
Na-H antiport induces hypertrophy in renal patient (abst) ... 241
Na^+ and K^+ fluxes in rabbit (abst) ... 302
NADPH (abst) ... 401
NMR measurement of Na^+ (abst) ... 314
N^1-methylnicotinamide and tetraethylammonium transport (abst) ... 325
organic base transport in BBM vesicles (abst) ... 330
PGE_2 as modulator of Na-H antiport (abst) ... 257
phosphate transport in superficial and juxtamedullary nephrons ... 879
protein modulates NaCl absorption (abst) ... 303
receptors for insulin-like growth factors (abst) ... 272
role of cell membranes and diffusion barriers in water flow (abst) ... 332
salicylate reabsorption (abst) ... 333
study by voltammetric microelectrode (abst) ... 330
study of PAH transport (abst) ... 331
tetraethylammonium uptake (abst) ... 335
thyroid hormones (abst) ... 94
time course of SITS effect (abst) ... 277
transcellular chloride absorption (abst) ... 302
transport-dependent cell injury (abst) ... 238
utilization of fatty acids (abst) ... 275
X-ray analysis (abst) ... 319
proximal straight *t.*
intracellular pH regulation (abst) ... 286
renal *t.*
cellular action of arginine vasopressin (abst) ... 328
site of adenosine receptors (abst) ... 255
Tubulo-glomerular feedback
defective control in Milan hypertensive rat (abst) ... 292
effect of dietary protein (abst) ... 299
in hypertensive Milan strain rat (abst) ... 298
in pregnant rat (abst) ... 292
Tyrosine
effects on CRF (abst) ... 249

U937 cells
binding of immunoglobulin aggregates (abst) ... 218
Ultrafiltrate
sorbent recycling in humans (abst) ... 172
Ultrafiltration
impairment with acetate solutions from France (abst) ... 182
peritoneal *u.* increased by amphotericin B (abst) ... 182
solute clearance with varying dialysate temperatures (abst) ... 170
spectrum and pathogenesis of *u.* failure among CAPD

(abst) ... 181
whole body *u.*, implications for Na and U modeling (abst) ... 162
with hyponatremia and reduced peripheral resistance (abst) ... 170
u. barrier
influence of albumin concentration (abst) ... 294
Ultrasonography
pre-natal diagnosis of kidney disorders (abst) ... 600
renal biopsy, Technical Note on ... 80
Ultrasound-duplex scanning
to diagnose AV vascular access complications (abst) ... 177
Uninephrectomy
Na-K-ATPase along the rat nephon (abst) ... 274
study of renal function and morphology in UNX rats (abst) ... 242
Unilateral renal artery stenosis
99mTc-DTPA flow studies with CEI (abst) ... 196
Urapidyl
putative central effects of *u.* and prazosine in rats (abst) ... 201
Urate excretion
and urinary PAH in anesthetized rabbit (abst) ... 325
Urea
permeability (abst) ... 411
time average concentration predicts morbidity (abst) ... 166
u. kinetics
not a single pool in hemodialysis (abst) ... 165
u. mass transfer
implications for Na and U modeling (abst) ... 162
u. permeability
bilirubin (abst) ... 51
u. transport
analysis of *u.t.* and brush border water (abst) ... 336
bilirubin (abst) ... 51
Uremia
adrenergic dysfunction (abst) ... 247
carbohydrate metabolic control (abst) ... 95
dialysis (abst) ... 97
effect of verapamil on calcium metabolism ... 774
glycolytic activity in erythrocytes and glucose intolerance (abst) ... 243
indomethacine inhibits prostaglandin E2 (abst) ... 233
influence of ouabain on Na transport (abst) ... 243
lipid stores and protein modulation in rat (abst) ... 251
postbinding defects of insulin action ... 780
serum triglyceride-rich lipoproteins (abst) ... 420
"trade off" hypothesis in secondary hyperparathyroidism (abst) ... 114
treatment with ketoanalogs of amino acids (abst) ... 829
chronic *u.*
cell-mediated immunity in mice (abst) ... 211
cerebral mitochondrial calcium concentrations (abst) ... 523
effect of cyclophosphamide on skin hypersensitivity (abst) ... 210
heart rate (abst) ... 95
Uremic toxins
removal by biliary diversion (abst) ... 243
Ureter obstruction, unilateral
effect of platelet activating factor on prostaglandin (abst) ... 269
Ureteral ligation
effects of imidazole and indomethacin ... 892
u. obstruction
effects of angiotensin converting enzyme inhibitor (abst) ... 293
Urinary albumin
role insulin-dependent diabetes mellitus (abst) ... 135
Urinary assay
to detect proximal tubular injury (abst) ... 151
Urinary concentrating mechanism
defective in chronic glomerulonephritis ... 792
Urinary NAG
response to two osmotic diuretics in dog (abst) ... 151
Urinary sediment
by TEM in aminoglycoside therapy (abst) ... 233
Urinary tract
infections in post-menopausal women ... 150
Urine
blood P_{CO_2} gradients, negative levels (abst) ... 283
calcium excretion (abst) ... 96
isolation of epoxyeicosatrienoic acid (abst) ... 268
ova excretion in ... 667
potassium excretion, Editorial Review on ... 389
protein/albumin excretion (abst) ... 94
u. creatinine
ratio with urine protein to assess proteinuria (abst) ... 130
u. oxalate
measurement by gas chromatography and mass spectrometry (abst) ... 126
u. protein
ratio with urine creatinine to assess proteinuria (abst) ... 130
Uropathy, obstruction
acidification defect ... 187

Valine
accelerated oxidation in ARF (abst) ... 273
effects on CRF (abst) ... 249
Vanadate
potentiates gentamicin nephrotoxicity (abst) ... 231
Vancomycin
absorption in HD patients with colitis (abst) ... 163
Vascular function, renal
α-adrenoceptor effects (abst) ... 301
Vascular reactivity
effect of protein loading (abst) ... 245
Vascular response
to vasoconstrictors during pregnancy in rat (abst) ... 294
Vasculature, renal
effect of dopamine-4-sulfate (abst) ... 292
Vasculitis, renal
Nephrology Forum on ... 954
Vasoconstriction
reversal by diltiazem (abst) ... 296
theophylline attenuates intrarenal *v.* (abst) ... 227
Vasoconstrictor
effects on TXA_2 by imidazole ... 892
vascular response in pregnant rat (abst) ... 294
Vasodilation, renal
depends on atriopeptin-induced natriuresis (abst) ... 294
Vasopressin
action of PGE_2 in cortical collecting tubule (abst) ... 332
action on adenylate cyclase in distal tubules (abst) ... 333
and cAMP synthesis in medullary collecting tubule (abst) ... 335
antibody (abst) ... 597
bilirubin ... 51
effect of calcium ion in cAMP concentration (abst) ... 335
effect of protein kinase C in toad bladder (abst) ... 334

effect on Ca^{2+} levels in mesangium (abst) 323
effect on Na and K transport (abst) 321
effects of K deficiency and adenylate cyclase (abst) ... 327
effects of water flow and inhibition of PGE_2 (abst) 329
effects of water flow and luminal membrane and cytosol (abst) 324
effects on water flow and maleic acid (abst)..... 328
interaction with monoclonal antibodies (abst) 336
long-term effects on renal function (abst)..... 326
nephrotic patients (abst) 598
role in diuresis in hypertension (abst)..... 202
role of increased renal arterial pressure (abst)..... 192
stimulates rubidium secretion in tubule (abst) 320
use in rats with congestive heart failure (abst)..... 337
water flow (abst) 512
with cAMP, prostaglandins, and phospholipids in toad bladder (abst) 264
plasma *v.*
role in abnormal water excretion in congestive heart failure (abst) 133
platelet *v.*
role in abnormal water excretion in congestive heart failure (abst) 133
v. secretion
stimulated in vitro PGE_2, PGD_2, and arachidonic acid (abst) 255
v. tannate
untreated severe hyponatremia (abst) 323
Vasopressinase
effects with diabetes insipidus (abst)..... 326
Vein, basilic
elevated *b.v.* AV fistula instead of PTFE graft (abst) .. 164
Velocity of circumferential fiber shortening
differences in acetate or bicarbonate HD (abst)..... 768
Vena cava constriction
infusion of sarcosin in dog (abst) 312
Ventricular f[illegible]ieft
effects of acetate and bicarbonate HD 768
fractional shortening in HD..... 768
Verapamil
blocks PTH-induced decrease in cAMP (abst)..... 127
effect after warm ischemia in perfused kidney (abst)... 229
effects of myocardial energy metabolism 718
effects on calcium metabolism in CRF 774
effects on urinary sodium and hypaque (abst) 326
exaggerated glomerular response by SHR (abst) 200
protective effects with ischemia (abst) 348
renal function during cisplatin treatment (abst) 236
Verotoxin-producing *E. coli*
association with idiopathic hemolytic uremic syndrome (abst)..... 131
Vessel strip
tachyphylaxis in preparation of *v.s.* (abst) 164
VIP
messenger for cAMP-dependent luminal alkalinization (abst)..... 278
Virus infection, Pichinde
effect on guinea pig hemodynamics (abst) 301
insensible water loss and water balance (abst)..... 333
role of adrenal glands and electrolyte imbalance (abst) . 314
Vitamin
v.-induced hypercalcemia and acute renal failure (abst). 230
Vitamin D ($1,25(OH)_2D_3$)
aluminum (abst)..... 599
and hypercalcemia and ARF-rhabdomyolysis (abst) ... 226
early renal failure (abst)..... 565
effect of aluminum on calcium absorption (abst) 120
effect on phospatidylcholine transfer (abst) 119
effects on calcium, magnesium, and phosphate in hamster 864
extrarenal synthesis in sarcoidosis (abst) 119
interrelationship with bone GLA-protein and PTH in renal failure (abst) 137
renal compensatory hypertrophy (abst) 598
uremia (abst) 97
v. D metabolism
role in spontaneous hypercalciuria (abst) 128
v. D metabolites
effect of long-term phosphate and protein restriction (abst)..... 128
v. D receptor
role of phospholipids and fatty acids (abst)..... 112
v. D synthesis
effect of chronic metabolic acidosis (abst) 120
V-max
chronic hypercapnia enchances NA-H antiporter..... 289
Voltage conductance
in neuroblastoma cells (abst)..... 316
Voltage regulation
of carbonic anhydrase acidification (abst)..... 287
Volume expansion
effect on proximal straight tubule reabsorption rates (abst)..... 123
in hyporenin/hypoaldosteronism (abst)..... 285
in sodium-restricted rat (abst)..... 298
v. flux
across tight junction in proximal tubule (abst) 307
v. regulation
calcium and K^+ permeability in toad bladder (abst).. 305
dependence on ADH in thick ascending limb (abst).. 327
v. repletion
effects after nephrectomy (abst) 305

Water balance
and insensible water loss in Pichinde virus (abst) 333
Water content
and cell volume regulation in rats (abst)..... 190
Water excretion, impaired
in nephrotic syndrome (abst)..... 154
nephrotic patients (abst) 598
Water flow
effects of PGE_2 and vasopressin (abst)..... 329
effects of vasopressin and maleic acid (abst) 328
effects of vasopressin on luminal membrane and cytosol (abst) 324
prostaglandins and kinins (abst) 512
role of cell membranes and diffusion barriers (abst).... 332
role of protein kinase C in toad bladder (abst)..... 333
Water immersion
renal response in non-excretor cirrhotic patients (abst). 148
Water permeability
of basolateral membrane (abst)..... 334
Water transport
bilirubin (abst) 51
morphological insights (abst)..... 102
Wegener granulomatosis
ACPA as a marker (abst)..... 704
antibodies to granulocyte cytoplasm marker (abst) 224
with severe glomerulonephritis (abst)..... 156
WR-2721

effects on hypocalcemia, inhibition of PTH secretion, and vitamin D-induced hypercalcemia (abst) 129

X-ray
two techniques for rat papilla comparison (abst) 304
X-ray analysis
for proximal tubule cell measurement (abst)..... 319
Xenoantigen
cytotoxicity (abst) 593

Zeiotic knobs
peritoneal permeability (abst) 411
Zinc metabolism
in cyclosporine or azathioprine treatments (abst)..... 345
Zinc, serum
in non-uremic patients (abst)..... 140